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Summary
CD8+ cytolytic T lymphocytes (CTL) are the main effector cells of the adaptive immune
system against infection and tumors. The recent identification of molecularly defined
human tumor Ags recognized by autologous CTL has opened new opportunities for the
development of Ag-specific cancer vaccines. Despite extensive work, however, the
number of CTL-defined tumor Ags that are suitable targets for the vaccination of cancer
patients is still limited, especially because of the laborious and time consuming nature of
the procedures currently used for their identification. The use of combinatorial peptide
libraries in positional scanning format (Positional Scanning Synthetic Combinatorial
Libraries, PS-SCL) has recently been proposed as an alternative approach for the
identification of these epitopes. To validate this approach, we analyzed in detail the
recognition of PS-SCL by tumor-reactive CTL clones specific for multiple well-defined
tumor-associated Ags (TAA) as well as by tumor-reactive CTL clones of unknown
specificity. The results of these analyses revealed that for all the TAA-specific clones
studied most of the amino acids composing the native antigenic peptide sequences
could be identified through the use of PS-SCL. Based on the data obtained from the
screening of PS-SCL, we could design peptide analogs of increased antigenicity as well
as cross-reactive analog peptides containing multiple amino acid substitutions. In
addition, the results of PS-SCL-screening combined with a recently developed biometric
data analysis (PS-SCL-based biometric database analysis) allowed the identification of
the native peptides in public protein databases among the 30 most active sequences,
and this was the case for all the TAA studied. More importantly, the screening of PS-
SCL with a tumor-reactive CTL clone of unknown specificity resulted in the identification
of the actual epitope. Overall, these data encourage the use of PS-SCL not only for the
identification and optimization of tumor-associated CTL epitopes, but also for the
analysis of degeneracy in T lymphocyte receptor (TCR) recognition of tumor Ags.
Résumé Rubio-Godoy
6
Résumé
Les cellules CD8+ T cytolytiques (CTL) sont les principaux effecteurs du système
immunitaire adaptatif contre les infections et les tumeurs. La récente identification
d’antigènes tumoraux humains reconnus par des cellules T cytolytiques est la base pour
le développement des vaccins antigène spécifiques contre le cancer. Le nombre
d’antigènes tumoraux reconnus par des CTL que puisse être utilisé comme cible pour la
vaccination des patients atteints du cancer est encore limité. Une nouvelle technique,
simple et rapide, vient d’être proposée pour l’identification d’antigènes reconnus par des
CTL. Elle se base sur l’utilisation de librairies combinatoriales de peptides arrangées en
un format de “scanning” ou balayage par position (PS-SCL). La première partie de cette
étude a consisté à valider cette nouvelle technique par une analyse détaillée de la
reconnaissance des PS-SCL par différents clones de CTL spécifiques pour des
antigènes associés à la tumeur (TAA) connus ainsi que par des clones de spécificité
inconnue. Les résultats de ces analyses révèlent que pour tous les clones, la plupart
des acides aminés qui composent la séquence du peptide antigénique naturel ont été
identifiés par l’utilisation des PS-SCL. Les résultats obtenus ont permis d’identifier des
peptides analogues ayant une antigènicité augmentée par rapport au peptide naturel,
ainsi que des peptides comportant de multiples modifications de séquence, mais
présentant la même réactivité que le peptide naturel. La deuxième partie de cette étude
a consisté à effectuer des analyses biométriques des résultats complexes générés par
la PS-SCL. Cette approche a permis l’identification des séquences correspondant aux
épitopes naturels à partir de bases de données de peptides publiques. Parmi des
milliers de peptides, les séquences naturelles se trouvent comprises dans les 30
séquences ayant les scores potentiels de stimulation les plus élevés pour chaque TAA
étudié. Mais plus important encore, l’utilisation des PS-SCL avec un clone réactif contre
des cellules tumorales mais de spécificité inconnue nous a permis d’identifier l’epitope
reconnu par ce clone. Les données présentées ici encouragent l’utilisation des PS-SCL
pour l’identification et l’optimisation d’épitopes pour des CTL réactifs anti-tumoraux, ainsi
que pour l’étude de la reconnaissance dégénérée d’antigènes par les CTL.
Résumé pour un large public Rubio-Godoy
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Résumé pour un large public
Les cellules T CD8+ cytolytiques font partie des globules blancs du sang et sont les
principales responsables de la lutte contre les infections et les tumeurs. Les
immunologistes cherchent depuis des années à identifier des molécules exprimées et
présentées à la surface des tumeurs qui puissent être reconnues par des cellules T
CD8+ cytolytiques capables ensuite de tuer ces tumeurs de façon spécifique. Ce type de
molécules représente la base pour le développement de vaccins contre le cancer
puisqu'elles pourraient être injectées aux patients afin d'induire une réponse anti-
tumorale. A présent, il y a très peu de molécules capables de stimuler le système
immunitaire contre les tumeurs qui sont connues parce que les techniques développées
à ce jour pour leur identification sont complexes et longues. Une nouvelle technique
vient d’être proposée pour l’identification de ce type de molécules qui se base sur
l’utilisation de librairies de peptides. Ces librairies représentent toutes les combinaisons
possibles des composants de base des molécules recherchées. La première partie de
cette étude a consisté à valider cette nouvelle technique en utilisant des cellules T CD8+
cytolytiques capables de tuer des cellules tumorales en reconnaissant une molécule
connue présente à leur surface. On a démontré que l’utilisation des librairies permet
d’identifier la plupart des composants de base de la molécule reconnue par les cellules
T CD8+ cytolytiques utilisées. La deuxième partie de cette étude a consisté à effectuer
une recherche des molécules potentiellement actives dans des protéines présentes
dans des bases des données en utilisant un programme informatique qui permet de
classer les molécules sur la base de leur activité biologique. Parmi des milliers de
molécules de la base de données, celles reconnues par nos cellules T CD8+
cytolytiques ont été trouvées parmi les plus actives. Plus intéressant encore, la
combinaison de ces deux techniques nous a permis d’identifier la molécule reconnue
par une population de cellules T CD8+ cytolytiques ayant une activité anti-tumorale,
mais pour laquelle on ne connaissait pas la spécificité. Nos résultats encouragent
l’utilisation des librairies pour trouver et optimiser des molécules reconnues
spécifiquement par des cellules T CD8+ cytolytiques capables de tuer des tumeurs.
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Abbreviations
Ab Antibody
Ag Antigen
AICD Activation induced cell death
APC Antigen presenting cell
β2m Beta-2-microglobulin
BCR B cell receptor
BSA Bovine serum albumin
CD Cluster of differentiation
CDK4 Cyclin-dependent kinase 4
CDR Complementary determining
region
CMP Common myeloid precursor
CLP Common lymphoid precursor
CTL Cytolytic T lymphocyte
DNA Deoxyribonucleic acid
DC Dendritic cell
DOPA 3, 4-dihydroxyphenylalanine
EBV Ebstein barr virus
ER Endoplasmic reticulum
FACS Fluorescence-activated cell
sorting
FITC Fluorescein isothiocyanate
FCS Fetal calf serum
FluMA Influenza Matrix
GM-CSF Granulocyte-macrophage
colony-stimulating factor
GMP Granulocyte/monocyte
progenitor
HC heavy chain
HCV Hepatitis C virus
HIV Human immunodeficiency
virus
HLA Human leukocyte antigen
HPLC High-pressure liquid chroma-
tography
HPV Human papiloma virus
hr Human recombinant
HS Human serum
HSC Hematopoietic stem cell
ICAM Intercellular adhesion
molecule
ICOS Inducible costimulator
IFN Interferon
Ig Immunoglobulin
IL Interleukin
LCMV Lymphocytic choriomeningitis
virus
LFA-1 Leukocyte function-
associated antigen 1
L/T ratio Lymphocyte to target cell ratio
MAA Melanoma associated antigen
mAb Monoclonal antibody
MAGE Melanoma antigen
MART-1 Melanoma antigen recog-
nized by T lymphocytes-1
MBP Myelin basic protein
Melan-A MART-1/Melan-A
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MEP Megakariocyte/erythrocyte
progenitor
MHC Major histocompatibility
complex
MPP Multipotent progenitor
MUC-1 Mucin 1
MUM-1 Melanoma-ubiquitous
mutated
Multimer peptide/MHC multimeric
complexes
NaN2 Sodium azide
NK Natural killer
ORF Open reading frame
PBMC Peripheral blood mononuclear
cell
PBS Phosphate-buffered saline
PCC Pigeon cytochrome C
PE Phycoerythrin
PHA Phytohemagglutinin
pMHC peptide/MHC complex
PS-SCL Positional scanning synthetic
combinatorial library
RT-PCR Real time polymerase chain
reaction
SCL Synthetic combinatorial library
SD Standard deviation
SEREX Serological identification of
tumor Ag by recombinant
expression cloning
SMPS simultaneous multiple peptide
synthesis
SSX Synovial sarcoma X
translocation
TAA Tumor associated antigen
TAP Transporter associated with
antigen processing
TCR T cell receptor
TGN Trans Golgi network
TIL Tumor infiltrating lymphocyte
TILN Tumor infiltrated lymph node
TNF Tumor necrosis factor
TRP Tyrosinase related protein
TREC TCR excision circles
Treg Regulatory T lymphocytes
Tyro Tyrosinase
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Amino acids:
A Alanine
C Cysteine
D Aspartic acid
E Glutamic acid
F Phenylalanine
G Glycine
H Hystidine
I Isoleucine
K Lysine
L Leucine
M Methionine
N Asparagine
P Proline
Q Glutamine
R Arginine
S Serine
T Threonine
V Valine
W Tryptophan
Y Tyrosine
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Introduction
General introduction to immunology
Innate and adaptive immunity
The immune system plays a crucial role in the immune surveillance against infections
and numerous diseases including cancer. The innate immunity is present from birth and
protects the host from infection without previous contact with the infectious agent.
Macrophages and granulocytes for example, the mediators of the innate immunity are
essential for the control of a wide range of bacterial infections. The adaptive immunity, in
contrast to the innate immunity, is characterized by specific immune responses, such as
the production of antibodies (Ab) to a particular pathogen, and in some cases, it confers
life-long protective immunity to re-infection with the same pathogen. Both the innate
immunity and the adaptive immunity responses are mediated by the white blood cells,
also called leukocytes. All blood cells, including the leukocytes, derive from a common
progenitor cell called hematopoietic stem cell (HSC) that originates in the bone marrow
and then seeds the thymus [1]. The process of HSC differentiation involves the loss of
self-renewal capacity and functionally irreversible maturation steps (Figure 1).
Multipotent progenitors (MPP), which arise from the HSC, differentiate into the
oligolineage progenitors known as common myeloid progenitor (CMP) and common
lymphoid progenitor (CLP). CMP give rise to erythrocytes, or red blood cells and
platelets, as well as granulocytes and macrophages. CLP will originate lymphocytes (B-
and T lymphocytes) and natural killer (NK) cells. Lymphocytes will differentiate into B- or
T lymphocytes depending on the organ to which they home. B lymphocytes mature in
the bone marrow and fetal liver (in chicken, they mature in an equivalent lymphoid organ
called bursa of Fabricius, from which their name was derived). Efficient and specific
recognition of antigens (Ag) by T and B lymphocytes is achieve through the generation
of a large repertoire of clonally expressed T- and B-cell receptors (TCR and BCR). Prior
to contact with Ag, T naive (Ag-inexperienced) lymphocytes migrate continuously
through the secondary lymphoid tissues (spleen and lymph nodes) allowing them to
make rapid contact with Ag released by pathogens and captured by antigen presenting
cells (APC) at the site of infection. When Ag-loaded APC enter the T-cell zones in the
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lymphoid tissues, specifically reactive T lymphocytes recognize the peptide/major
histocompatibility complex (MHC) complexes (pMHC) expressed on the cell surface of
APC and within minutes are immobilized in an Ag-specific manner. This immobilization
leads to T lymphocyte activation and rapid clonal expansion followed by differentiation
into effector lymphocytes that causes the rapid elimination of the infectious agent. The
enormous number of effector lymphocytes is then reduced either by death or by
transformation into long-lived memory cells [2], providing in this way an immunological
memory.
Figure 1. Model of hematopoietic stem cell differentiation. Adapted from Lagasse et al. 2001. Long-
term hematopoietic stem cells (LT-HSC) are perpetually self-renewing cells that ultimately originate all
mature blood cells. Self-renewal as well as other maturation capacities are lost along the process of
differentiation (i.e. multipotent progenitors (MPP) do not self-renew and common lymphoid progenitors
(CLP) are committed to the lymphoid lineage). ST-HSC: short-term HSC; CMP: common myeloid
progenitor; MEP: megakariocyte/erythrocyte progenitor; GMP: granulocyte/monocyte progenitor; DC:
dendritic cell; NK: natural killer cell; CTP: common T lymphocyte precursor.
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Figure 2. Schematic representation and crystal structure of IgG molecule. Igs are made up of two
light chains (CL and VL) and two heavy chains (CH1, CH2, CH3 and VH), each of which has a variable (V,
shown in yellow in (A)) region at its amino-terminus, which correspond to the antigen-binding site, and a
constant region (C, shown in green in (A)). The constant region of the heavy chain, that is the CH2 and
CH3 domains, determines the isotype and functional properties of the antibody. (A) Adapted from Janeway
and Travers, 1997. (B) Adapted from Saphire et al., 2001.
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B lymphocytes can recognize foreign proteins in their native conformation through
receptors for Ag expressed on their cell surface, the antibodies, also called
immunoglobulins (Ig) or BCR (Figure 2) [3,4]. Each lymphocyte carries a unique BCR,
and this is the consequence of a phenomenon called allelic exclusion.
Igs are made up of two light chains and two heavy chains, each of which has a variable
region at its amino-terminus, which correspond to the antigen-binding site, and a
constant region. The constant region of the heavy chain determines the isotype and
functional properties of the antibody. A very vast diversity in Ab repertoire is required in
order to assure an adequate immune response against pathogens, and this diversity,
similarly to TCR (detailed below), is achieved by numerous gene rearrangement
mechanisms. Upon encounter with Ag and helper T lymphocytes in the T-cell areas of
lymphoid tissue, B lymphocytes are activated to proliferate, giving rise to Ab-secreting
plasma cells, but also to progeny lymphocytes that will migrate and form a germinal
center in a nearby follicle. Here they proliferate vigorously and undergo somatic
hypermutation of the rearranged Ig. These cells will either differentiate into Ab-secreting
plasma cells or long-lived memory cells [5].
As mentioned above, the adaptive immunity is mainly mediated by T lymphocytes
expressing TCR (Figure 3A and 3B) [3,6,7], which are composed of disulfide linked α-
and β-chains, both of which span the cell membrane. The generation of a vast TCR
repertoire is achieved by rearrangement of the genes encoding for α- and β-chains. The
production of α-chain involves recombinations of variable (V) and junctional (J) gene
elements, whereas β-chain is formed by recombinations of V, J and diversity (D) gene
elements. The ligand binding site of TCR is composed of two Vα- and two Vβ-encoded
complementary determining region (CDR) loops (CDR1α, CDR2α, CDR1β and CDR2β)
as well as two junctional CDR3 loops (CDR3α and CDR3β). These last two are highly
polymorphic because not only they are encoded by recombinations of numerous gene
elements, but also diversity is further increased by the insertion of palindromic (P)- and
non-template-encoded (N)-nucleotides between the V, D and J gene segments [3,5,8].
Introduction Rubio-Godoy
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Figure 3. Schematic representation and crystal structure of TCR and MHC class I molecule. The
T cell receptor (TCR) heterodimer is composed of two chains (α, shown yellow in (A) and β , shown
green). The TCR resembles immunoglobulins in that they also have variable (Vα and Vβ) and constant
(Cα and Cβ) regions (A) Adapted from Janeway and Travers, 1997 (B) Crystal structure adapted from
Garcia et al., 1998. The 3 CDR loops are shown for each V region with the corresponding color. (C) The
MHC class I heterodimer is composed of a membrane-spanning α chain non-covalently associated with
β2 microglobulin. The α chain folds into 3 domains, α1, α2 and α3. The folding of α1 and α2 creates a
single structure consisting of two segmented α helices lying on a sheet of antiparallel β-strands, giving rise
to the peptide binding cleft. Adapted from Janeway and Travers, 1997. (D) Crystal structure of an MHC
class I molecule. A peptide (red) is “buried” inside the binding cleft.
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Thus, TCR genes rearrange in a similar way to BCR rearrangement, but with the added
complication that precursor cells can develop into lymphocytes bearing either γδ
receptors or αβ receptors. γδ lymphocytes predominate in ontogeny, but after birth more
than 90% of the thymocytes express αβ receptors. Both lymphocyte lineages home to
different tissues where they perform different functions. Relatively little is known about
the function of γδ lymphocytes, on the other hand, αβ lymphocytes are the primary
mediators of the adaptive immune response. As a general rule, each T lymphocyte that
has undergone TCR gene rearrangement and all the T lymphocytes derived from it (T
lymphocyte clones), bear a unique TCR. Mature αβ lymphocytes express either cluster
of differentiation (CD) 4 or CD8 as coreceptor molecule. CD4+ T lymphocytes have a
helper function (Th lymphocytes) and recognize antigenic peptides in the context of
MHC class II molecules, and CD8+ T lymphocytes, which are mainly CTL and exert
direct effector functions after recognizing peptides presented by MHC class I molecules.
The anatomy of T lymphocyte specificity: Ag recognition
Both CD4+ and CD8+ T lymphocytes recognize self- or non-self-Ag in a self-MHC-
restricted manner. CD8+ T lymphocytes recognize peptides of 8 to 10 amino acids in
length derived from intracellular cytoplasmic proteins either from self- (defective
proteins) or non-self origin (viral proteins) that have been digested by proteasomes.
Once generated in the cytosol, these peptides are translocated by the transporter
associated with antigen processing (TAP) into the lumen of the endoplasmic reticulum
(ER) where they will bind to the class I peptide loading complex to give rise to a
peptide/MHC class I (pMHC) complex (Figure 3C and 3D). As shown in Figure 4A [9],
inside the ER a nascent MHC class I heavy chain (HC) is stabilized through interactions
with the chaperone calnexin. Then, β2-microglobulin (β2m) associates with the class I
HC and this complex binds another chaperone, calreticulin, leading to the recruitment of
two additional chaperones into the loading complex, tapasin and ERp57. ERp57 is
thought to be involved in inducing a particular conformation of the class I binding cleft to
assist in peptide binding, whereas tapasin physically bridges class I-β2m dimers to TAP,
placing in this way the class I molecules close to the peptide source [10-12]. Tapasin is
also implicated in increasing TAP levels and peptide binding to TAP, it is therefore
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involved in increasing the overall peptide supply to ER [13]. The so newly formed pMHC
complex is routed to the cell surface via the secretory pathway as shown in Figure 4B,
where they will be recognized by CD8+ T lymphocytes. In the case of CD4+ T
lymphocytes, the source of Ags are 10 to 15 amino acid long peptides, arising generally
from engulfed extracellular proteins mostly from non-self origin that are processed to
peptides in intracellular endosomes. They will be presented to CD4+ T lymphocytes in
association to MHC class II molecules.
Thymocyte development and shaping of T lymphocyte repertoire involves two steps of
selection: positive selection and negative selection. The positive selection provides a
survival signal to T lymphocytes that recognize with a low affinity self-MHC/self-peptide
complexes expressed by thymic cortical epithelial cells, and ensures that all mature T
lymphocytes will respond to foreign Ags presented by self-MHC molecules expressed on
APC (MHC-restriction). Negative selection, on the contrary, ensures the elimination of
self-reactive T lymphocytes that recognize self-MHC/self-peptide complexes with high
affinity expressed by DC and macrophages and that would trigger an autoimmune
response in the periphery [14-23]. It has recently been described that the type of APC
recognized by the developing T lymphocyte can alter its fate. Indeed, T lymphocytes that
recognize self-peptides with very high affinity on bone marrow-derived APC, and that
should be deleted, can alternatively develop into immunoregulatory CD4+ CD25+ T
lymphocytes if the self-peptide is presented by thymic epithelium [24].
The specificity of T lymphocyte recognition is determined not only by the sequence of
the antigenic peptide, but also by the particular MHC allele the peptides are bound to.
Although T lymphocyte recognition of pMHC complexes is very specific, it was originally
thought to be very selective too, in the sense that it was believed that there was a single
receptor for each epitope. This idea was supported by the fact that a very large number
of clonotypically unique TCR can be generated by rearrangement and addition of P- and
N-nucleotides, so that the immune system would be capable of generating unique
receptors for every immunogenic peptide.
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Figure 4. Schematic representation of the MHC class I peptide processing pathway. (A) The source of peptides for MHC class I
molecules is the degradation of proteins in the cytosol by the proteasome complex. Peptide fragments are then transported into the lumen of
the ER by the TAP transporter. Inside the ER, MHC class I α chains associate to calnexin. β2m binds to this complex with the aid of the
ERp57 chaperone. The partially folded MHC class I molecule is released from calnexin and bound to the TAP transporter by interacting with
tapasin. The TAP-transported peptides bind to this complex, the newly created pMHC complex is transported by the Golgi complex to the cell
surface. (B) Adapted from Klein and Sato, 2000.
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Nevertheless, this high degree of selectivity would give rise to an inadequate T
lymphocyte repertoire and would require a very larger number of T lymphocytes. In
order to generate a useful repertoire, several things have to be taken into consideration.
First of all, the MHC molecules must be capable of presenting a great number of
peptides to the T cells composing the actual repertoire so that all pathogenic peptides
are recognized by the immune system. Also, the frequency of T lymphocytes that can
recognize peptides from pathogen origin has to be large enough to assure an efficient
and rapid response. And more importantly, the T lymphocyte repertoire available must
be able to discriminate between the self and the non-self. Over the last years it has been
demonstrated that TCR have an inherent dual specificity. In other words, T lymphocytes
must be able to recognize self-Ags in association with self-MHC molecules in the
thymus so to be positively selected, but they also have to be able to discriminate
between self- and foreign-Ags in the periphery in order to avoid autoimmunity.
Therefore, T lymphocytes have the capacity to interact with a great number of different
pMHC complexes and this phenomenon is known as degeneracy of Ag recognition [25-
33]. The use of synthetic soluble peptide combinatoral libraries, arranged in a positional-
scanning format has been very successful to demonstrate degeneracy of antigen
recognition by alloreactive CD8+ T lymphocytes [34], for the identification of ligands of
MHC class I and class II molecules [35], and to identify cross-reactive ligands for a auto-
reactive CD4+ T lymphocyte clone [36]. The ability of T lymphocytes to recognize
several peptides assures that no infectious agent will go unrecognized. Although it is
evident that the recognition of T lymphocytes for a given pMHC complex (a given
pathogen) is highly specific, TCR are capable of recognizing a number of different
peptides with poorly related sequences, indicating that TCR recognition is also highly
cross-reactive [37]. This phenomenon of degeneracy in TCR recognition is important for
both, T lymphocyte selection in the thymus and survival in the periphery, as well as for
the eradication of infections [38]. The determination of the TCR/pMHC structure by
crystallography [6,7,39-43], together with the identification of peptide binding motifs [44-
50], have constituted an insight into how peptides are bound to MHC class I or class II
molecules and how TCR recognize pMHC complexes. The peptide-binding grooves of
MHC class I and class II molecules have several structural pockets to which the side
chains of antigenic peptides will bind (binding pockets). The polymorphism in amino acid
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composition of these pockets, which is characteristic for the different MHC alleles,
determines the specificity of peptide binding. Based on this, allele-specific peptide motifs
have been determined for some of the common MHC class I and class II molecules.
The available crystal structures for several TCR/pMHC complexes suggest that the
overall affinity of the TCR for the pMHC complex depends on direct contacts between
the TCR and the MHC molecule. Indeed, the TCR interacts with the pMHC complex
through a large molecular interface formed by the MHC molecule itself and the peptide;
two thirds of the contacts are between TCR and the MHC molecule. Contacts with the
peptide are thought to “modulate” the pre-existing affinity of the TCR for the MHC
molecule by increasing this affinity and allowing the threshold required for a productive T
lymphocyte response to be exceeded [25,51,52]. Wu et al. [53] proposed a two-step
binding mechanism for TCR recognition of pMHC complexes where MHC contacts will
dictate the initial association with TCR, docking it in a peptide-independent way. Peptide
contacts in contrast, impart specificity by stabilizing the interaction and modulating the
duration of binding. In agreement with this, major differences in potency have been
observed among different pMHC complexes recognized by the same TCR. In other
words, the binding affinity of the peptides to the MHC molecule, the affinity of the TCR
for the resulting pMHC complex, as well as the off-rate of the pMHC complex from the
TCR contribute to the stimulatory potency of antigenic peptides [54-56]. TCR adjust to
different peptides (agonists, partial agonists or antagonists) by making subtle
conformational changes in their complementary-determining regions (CDR), which
constitute the Ag-binding site. This structural plasticity in the TCR/pMHC interface has
allowed the understanding of the degenerate specificity of TCR/pMHC interactions
[57,58]. (Figure 5).
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Figure 5. Example of TCR interaction with a peptide/MHC class I complex. Crystal structure of the
mouse 2C TCR complexed with MHC class I molecule H-2Kb bound to the murine self-peptide dEV8
(EQYKFYSV). (A) Overall backbone structure of a TCR/pMHC complex. TCR: α chain pink, β chain light
blue, CDR1α magenta, CDR2α purple, CDR3α light yellow, CDR1β cyan, CDR2β dark blue, CDR3β gray,
HV4 orange. pMHC: MHC heavy chain green, β2m dark green, peptide yellow. (B) pMHC combining site.
All pMHC residues involved in contact with the TCR are shown and labelled. MHC residues contacting the
TCR α chain are pink and those contacting the TCR β chain blue. (C) TCR/pMHC interface showing all
side chains involved in the intermolecular contact. Hydrogen bounds are indicated. Adapted from Garcia
et al., 1996.
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The physiology of T lymphocyte activation
The initial interaction between T lymphocytes and APC leads to the formation of
synapses at the T lymphocyte/APC contact site [59]. Synapse formation is associated
with the rapid clustering of TCR molecules bound to pMHC complexes expressed on
APC, together with the local accumulation of intracellular signaling molecules such as
Lck, LAT and PCKθ [60-62]. These signaling molecules, together with many other
intracellular molecules, will in turn associate with the TCR/CD3 complexes in lipid rafts
and initiate the signaling cascade that induces mature T lymphocytes to proliferate,
secrete cytokines, and differentiate into effector T lymphocytes. Full activation of T
lymphocytes requires two signals; signal 1 is the recognition of Ag through the TCR,
which ensures the specificity of the response, and signal 2 is contributed by
costimulatory molecules. Indeed, a number of other molecules expressed on T
lymphocytes are required for the full activation of T lymphocytes, such as the
coreceptors CD8 and CD4 as well as CD28, LFA-1, CD40L, ICOS, CD2, and CD27,
among others, which all bind to complementary molecules on APC [63,64].
CD8 and CD4 coreceptors bind to the same MHC molecules as the TCR without
affecting the specificity of TCR/pMHC interaction. They increase the overall avidity of the
MHC molecule for the TCR, stabilizing the interaction, and facilitate TCR signaling
through the Lck kinase associated to their cytoplasmic tails [65-68]. CD28 is required for
interleukin (IL)-2 production (through the activation of the jun kinase JNK), expression of
the IL-2 receptor and progression through the cell cycle. It has also been suggested that
costimulation through CD28 may play a role in receptor orientation and/or aggregation
[60,61,69,70]. The leukocyte function-associated antigen 1 (LFA-1, αLβ2) is an adhesion
molecule that facilitates interaction with target cells (APC). This molecule and its ligands
(Intracellular adhesion molecule (ICAM)-1, -2, -3) are involved in lymphocyte homing to
most tissues. Studies by Bachmann et al. and Wülfing et al. using transgenic TCR
specific for lymphocytic choriomeningitis virus (LCMV) of LFA-1-/- or CD28-/- mice
demonstrated that LCMV-specific activation of T lymphocytes was independent of CD28
costimulation for strong peptide ligands, but this was not the case when weak peptide
ligands were used. In the absence of LFA-1, in contrast, a higher concentration of
peptide Ag was required to achieve stimulation with both, strong and weak peptide
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ligands [60,63,71-73]. CD40L or CD154 is a tumor necrosis factor (TNF) family member.
Its interaction with CD40 is crucial for primary and secondary thymus-dependent
humoral immune responses, as well as for the maturation of B lymphocytes towards
memory cells. CD40L is also implicated in the regulation of B lymphocyte growth and
differentiation [64]. The inducible costimulator (ICOS), which is expressed only on
activated T lymphocytes, induces their effector functions by increasing the secretion of
IL-4, IL-5, IL-10, interferon γ (IFNγ), TNFα and granulocyte-macrophage colony-
stimulating factor (GM-CSF). It also enhances the T lymphocyte-dependent B
lymphocyte help by upregulating the expression of CD40L [63,69,70]. CD2, as LFA-1,
promotes physical interaction with APC [60,68]. CD27 is expressed on T lymphocytes
and in a subset of B lymphocytes. It is upregulated upon activation and it has been
shown to enhance T lymphocyte proliferation and production of TNFα. CD27 and its
ligand CD70 are both expressed on activated T lymphocytes, and since CD70 is not
expressed on DC, it has been proposed that the CD27-CD70 interaction between T
lymphocytes promotes their expansion after initial activation by CD28 [63].
Depending on the affinity of the TCR for the pMHC complexes, different outcomes are
observed [74,75]: (1) high affinity recognition of non-self pMHC complexes leads to full
T lymphocyte activation, assuring the clearance of the pathogen, whereas high affinity
recognition of self pMHC complexes leads to autoimmune diseases. However, recent
thymic emigrants, but not mature T lymphocytes, develop into functional regulatory T
lymphocytes (Treg) upon recognition of self pMHC complexes in the periphery. (2)
Intermediate to low affinity recognition of non-self pMHC complexes leads to partial
activation, which may result in an inadequate immune response such as the lack of
cytokine secretion. Nevertheless, low levels of stimulation (probably through interaction
with self pMHC complexes) are thought to be required for the survival of memory
lymphocytes. (3) Ag recognition by T lymphocytes without second signals leads to a
state of functional unresponsiveness called anergy. Finally, (4) activation of T
lymphocytes induces the co-expression of the death receptors Fas (CD95) and its
ligand, FasL, resulting in the activation induced cell death (AICD) of the same cell as
well as the neighboring cells.
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Immunity and cancer
Cancer is one of the three leading causes of death in the industrialized countries.
Figure 6. Schematic representation of the metastatic process. From McKinnell et al., 1998. A
transformed cell will originate a primary tumor, that is a mosaic of cells, some of which can give rise to
metastatic colonies. Metastatic subclones (gray cells) bind to the disrupted basement membrane on which
they rest. They invade the extracellular matrix, they bind and disrupt the basement membrane of a vessel
and intravasate. Once inside the vessel, metastatic subclones have to circulate (either alone or as en
embolus) until they arrest by adhesion to the basement membrane of the vessel at a distant site. Nascent
metastatic cells exit the vessel by extravasation at a site where they will form a metastasis.
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Cancers are caused by transformed cells that acquire the capacity to proliferate in an
unordered and uncontrolled manner. These cells, as illustrated in Figure 6, invade the
tissues around them forming primary tumors, and disseminate through the vascular or
lymphatic systems to other distant organs where they continue to proliferate as
secondary tumors or metastases [76]. Most cancers can be treated with surgery,
chemotherapy or radiotherapy. Nevertheless, tumors may be inaccessible to surgery if
they have disseminated to vital organs or spread throughout the body, and many tumors
develop a resistance to the current methods of therapy when the metastatic process has
started [77]. There is growing evidence that the immune system can play a crucial role
in the fight against cancers [78-81]. Over the past decade, it has been established that
tumor cells express antigenic peptides that can be recognized by tumor specific CTL in
humans. The source of these antigenic peptides is mostly self-proteins that, like viral
proteins, follow the classical MHC class I loading pathway to be presented to CTL.
Briefly, they are digested by the proteasome in the cytosol into peptides that are
transported into the ER by TAP, bound to MHC class I molecules, and presented at the
cell surface as pMHC complexes. In some cases, peptides that are encoded by tumor
associated viruses can also be recognized by tumor-specific CTL. The identification of
MHC class I-restricted tumor Ags from melanoma and other types of cancer recognized
by tumor-reactive CTL has implemented the development of new anticancer therapies
based on the stimulation of the organisms’ self defenses.
Tumor antigens recognized by MHC class I-restricted T lymphocytes
Several categories of tumor associated Ags recognized by CD8+ T lymphocytes have
been identified, and they can be subdivided into five main categories based on their
expression pattern and/or origin. The first group is formed by the differentiation Ags,
which are specific to the tissue type from which the tumor is derived. Although
differentiation Ags are often expressed in large amounts in tumor cells, they often exhibit
low affinity for cell-surface MHC molecules. This group of Ags has been first identified in
melanoma. Examples of differentiation Ags are Melan-A, gp100 and tyrosinase [82-90]
expressed in melanomas and in cells of the melanocytic lineage, but not in other normal
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cells. The first melanocyte differentiation Ag found to be recognized by tumor-specific
human leukocyte antigen (HLA)-A2-restricted CTL was tyrosinase [86]. Tyrosinase
(Tyro) is a melanosomal membrane protein essential for the synthesis of melanin. Two
HLA-A2-restricted CTL epitopes have been described for this protein, the peptides 1-9
(MLLAVLYCL) and 369-377 (YMDGTMSQV). Another differentiation Ag was identified in
1994 by two different groups [88,91], Melan-A, which is a small transmembrane protein
of unknown function widely distributed in melanomas, but absent in other tumors. Two
HLA-A2-restricted epitopes have been described so far, and the nonapeptide 27-35
(AAGIGILTV) was shown to be the immunodominant epitope [92]. Romero et al. [93]
demonstrated that the decapeptide 26-35 (EAAGIGILTV) was recognized more
efficiently than the nonapeptide 27-35. More recently Zarour et al. [94] identified the
peptide 51-73 as a MHC class II epitope restricted to HLA-DRB*0401. gp100 is a
glycoprotein containing a single transmembrane domain for which five HLA-A2-restricted
epitopes have been identified [89,90,95]. Two other proteins involved in the biosynthesis
of melanin, namely tyrosinase-related protein 1 (TRP-1) and tyrosinase-related protein 2
(TRP-2) were found to contain HLA-A31 -restricted epitopes. The peptide identified for
TRP-1 (MSLQRQFLR, [96,97]), is the product of an alternative open reading frame
(ORF3) of TRP-1. The sequence identified for TRP-2 (LLPGGRPYR [98]) corresponds
to residues 197-205.
The second group of Ags, called shared Ags, comprises non-mutated self Ag products
with highly restricted tissue distribution. They are expressed by a significant proportion
of tumors of different histological types but not by most somatic tissues, usually with the
exception of male germ-line cells in the testis and to a lesser extent placental
trophoblast cells, and they are therefore also called cancer/testis Ags [99]. Because of
the fact that germ-line and placental trophoblast cells do not express of surface HLA
class I molecules, specific CD8+ CTL responses to these Ags can be considered strictly
tumor-specific. The Ags of the melanoma antigen (MAGE) family, NY-ESO-1 and HOM-
MEL-40 (SSX-2) [78,100-112] belong to this group. For several MAGE family members,
CTL epitopes restricted to multiple HLA molecules have been described [113-118]. An
HLA-A2-restricted CTL epitope for HOM-MEL-40 (KASEKIFYV, 41-49) has recently
been identified by our group [119]. Several epitopes have been described for NY-ESO-
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1; three are HLA-A2-restricted (SLLMWITQC, 157-165; QLSLLMWIT, 155-163 and
SLLMWITQCFL, 157-167 [120]) and the last one HLA-A31-restricted (ASGPGGGAPR
[121]).
The third group of unique Ags comprises Ags with genetic mutations, leading to the
generation of unique antigenic determinants recognized by tumor-reactive CTL. Mutated
epitopes generally exhibit high affinity for MHC molecules, but they are often derived
from proteins that are poorly expressed by tumors. MUM-1 (melanoma-ubiquitous
mutated), cloned using an HLA-B44-restricted CTL clone, was found to have a point
mutation within the region encoding the T cell epitope EEKLIVVLF. The change in one
amino acid at position 5 of the peptide (serine to isoleucine) altered T cell recognition
but did not affect peptide binding to HLA-B44 [122]. Another mutated gene is the cyclin-
dependent kinase 4 (CDK4), an enzyme involved in cell cycle control. The T cell epitope
ACDPHSGHFV was recognized in an HLA-A2-restricted manner. The mutation, arginine
to cysteine at residue 24, was part of the epitope recognized by CTL and inactivated the
normal function of CDK4, thus playing an important role in the malignant transformation
ADDIN[123]. A mutated epitope (SYLDSGIHF, HLA-A24-restricted) ADDIN[124] was
also identified for β-catenin, a cytoplasmic protein that interacts with the cellular
adhesion molecule E-cadherin.
The fourth group of overexpressed Ags includes Ags expressed at low levels in normal
tissues but overexpressed in tumors. An example is the mucin MUC-1, a high molecular
weight glycoprotein expressed on breast and pancreatic adenocarcinomas but also in
some normal tissues such as epithelial cells, fibroblasts and B cells [125-127]. T cell
and B cell-mediated responses have been demonstrated for this Ag [128]. Another
example of proteins in this group is the proto-oncogene HER-2/neu that encodes a
tyrosine kinase protein overexpressed in 30% of breast and ovarian cancers [129-131].
The fifth group is the one comprising Ags encoded by tumor-associated viruses.
Infection with some viruses can result in the malignant transformation of the infected
cells. Consequently, recognition of CTL epitopes derived from viral proteins can in
certain cases also represent a tumor-specific response. Examples of such viruses and
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derived epitopes are human papilloma virus (HPV), Epstein barr virus (EBV) and T-cell
lymphotropic virus-1 [132-134].
Methods for the identification of tumor antigens
The Ags listed above and mentioned in Table 1 have been identified using several
approaches. The most broadly utilized are detailed below and reviewed in [135-139].
Genetic approach
In the genetic approach, cells expressing the appropriate MHC class I molecule are
transfected with recombinant cDNA libraries prepared from tumor cells and then
screened for their ability to stimulate tumor-reactive CTL clones obtained from cancer
Group Name Localization Sequence HLA-restriction Method used for the identification
Melan-A 27-35 A A G I G I L T V A2 Genetic approach
Melan-A 51-73 R N G Y R A L M D K S L H V G T Q C A L T R R DRB*0401 Genetic approach
gp100.1 154-162 K T WG Q Y WQ V A2
gp100.2 209-217 I T D Q V P F S V A2
gp100.3 280-288 Y L E P G P V T A A2
gp100.4 457-466 L L D G T A T L R L A2
gp100.5 476-485 V L Y R Y G S F S V A2
tyrosinase 1-9 M L L A V L Y C L A2 Genetic approach
tyrosinase 369-377 Y M D G T M S Q V A2 Genetic approach, peptide elution from tumor cells
tyrosinase 192-200 S E I WR D I D F B*4402 Genetic approach
tyrosinase 206-214 A F L P WH R L F A24 Genetic approach
tyrosinase 243-251 K C D I C T D E Y A1 Genetic approach
TRP-1 1-9 M S L Q R Q F L R A31 Genetic approach
TRP-2 197-205 L L P G G R P Y R A31 Genetic approach
MAGE-A1 230-238 S A Y G E P R K L Cw1601 Genetic approach
MAGE-A1 230-238 S A Y G E P R K L Cw3
MAGE-A1 96-104 S L F R A V I T K A3
MAGE-A1 222-231 E V Y D G R E H S A A28
MAGE-A1 258-266 D P A R Y E F L W B53
MAGE-A1 62-70 S A F P T T I N F Cw2
MAGE-A2 156-164 E Y L Q L V F G I A24 Synthesis of putative antigenic peptides
MAGE-A2 112-120 K M V E L V H F L A2
MAGE-A2 157-166 Y L Q L V F G I E V A2
MAGE-A3 271-279 F L WG P R A L V A2 Genetic approach
MAGE-A3 281-295 T S Y V K V L H H M V K I S G DR11 Synthesis of putative antigenic peptides
MAGE-A3 114-127 A E L V H F L L L K Y R A R DR13
MAGE-A3 121-134 L L K Y R A R E P V T K A E DR13
MAGE-A3 167-176 M E V D P I G H L Y B44 Synthesis of putative antigenic peptides
MAGE-A3 168-176 E V D P I G H L Y A1 Genetic approach
MAGE-A4 230-239 G V Y D G R E H T V A2 Genetic approach
MAGE-A10 254-262 G L Y D G M E H L A2 Genetic approach
NY-ESO-1 157-165 S L L M WI T Q C A2
NY-ESO-1 155-163 Q L S L L M WI T A2
NY-ESO-1 157-167 S L L M WI T Q C F L A2
NY-ESO-1 10-53 A S G P G G G A P R A31 Genetic approach
NY-ESO-1 121-138 V L L K E F T V S G N I L T I R L T DRB4
NY-ESO-1 139-156 A A D H R Q L Q L S I S S C L Q Q L DRB4
NY-ESO-1 121-130 V L L K E F T V S G DR4 Synthesis of putative antigenic peptides
NY-ESO-1 157-170 S L L M WI T Q C F L P V F DP4 Synthesis of putative antigenic peptides
NY-ESO-1 119-143 P G V L L K E F T V S G N I L T I R L T A A D H R DR4 Synthesis of putative antigenic peptides
SSX-2 41-49 K A S E K I F Y V A2 Synthesis of putative antigenic peptides, proteasomal degradation prediction
MUM-1 nt 782-808 E E K L I V V L F B44 Genetic approach
CDK4 23-32 A C D P H S G H F V A*0201 Genetic approach
b-catenin 29-37 S Y L D S G I H F A24 Genetic approach
MUC-1 9-17 S T A P P A H G V A1, A2, A3, A11 Synthesis of putative antigenic peptides
HER-2/neu 754-762 V L R E N T S P K A3
CEA 61-69 H L F G Y S WY K A3
CEA 268-277 Q Y S WF V N G T F A24
CEA 652-660 T Y A C F V S N L A24
Synthesis of putative antigenic peptides
Genetic approach
Genetic approach
Synthesis of putative antigenic peptides
Synthesis of putative antigenic
Synthesis of putative antigenic peptides
Synthesis of putative antigenic peptides
SEREX
Table 1. Compilation of the most relevant TAA antigens
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patients. This approach allows the identification of the gene encoding the protein of
interest. Transfection of smaller gene fragments allows a more precise localization of the
sequence encoding the peptide epitope. This deduced sequence is used to produce
synthetic peptides that are then tested for recognition by tumor reactive CTL [86,88].
Peptide elution from tumor cells
This strategy is based on the biochemical purification of peptides eluted from MHC class
I molecules of tumor cells. The eluted peptides are subsequently separated by high-
pressure liquid chromatography (HPLC). Peptide fractions are tested for their ability to
stimulate CTL when pulsed onto the MHC matched APC. Positive fractions are further
processed and the native tumor-specific peptide recognized by the CTL can be identified
after sequencing by Edman degradation or tandem mass spectrometry [82,95].
However, this approach is technically challenging and can be applied only rarely as it
requires a large amount of cells and only few tumor cell lines can be grown in vitro to a
sufficient number.
Predictive algorithms to identify candidate antigenic peptides
A third strategy involves the synthesis of putative antigenic peptides corresponding to
linear amino acid sequences of a known tumor Ag-associated protein and selected on
the basis of their ability to bind to a particular MHC class I molecule.
The synthetic peptides are then used to stimulate CD8+ T cells from either normal
individuals or from cancer patients. Peptide-specific CTL clones can be obtained from
this procedure and are tested to assess whether the antigenic peptide is processed by
tumor cells and presented at their surface. Nevertheless, it has been observed that the
majority of CTL clones derived in this way fail to recognize tumor cells that express the
protein of interest. This can be explained, at least in some cases, by inefficient
generation of the peptide by the processing machinery of the cell [139,140]. Thus, the
prediction power of this method can be enhanced by screening precursor peptides for
appropriate generation of the C-terminus of the putative antigenic peptide after in vitro
digestion with purified proteasomes [119,141].
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Serological identification of tumor antigens by recombinant expression cloning
(SEREX) approach
The SEREX approach allows the identification of tumor Ags able to stimulate specific
humoral responses in cancer patients. For this purpose, a cDNA library is constructed
from fresh tumor specimens, packaged into lambda-phage vectors and expressed in E.
coli. Recombinant proteins are transferred onto nitrocellulose membranes and possible
TAA are identified using IgG antibodies obtained from the sera of cancer patients [142].
This approach has allowed the identification of several tumor Ags both previously
identified with other methods such as Tyrosinase [109] and MAGE [109] or previously
unknown, such as NY-ESO-1 [102] and SSX-2 [143].
Despite the long list of TAA and derived epitopes listed above, it is of note that only a
very limited number of these sequences can be used for vaccination of cancer patients.
Indeed, only Ags expressed in a wide range of tumors of different histological type and
recognized by tumor-reactive CTL in association with commonly expressed HLA class I
alleles are relevant to this purpose. Thus, the use of epitopes derived from melanocyte
differentiation Ags would be for example only limited to melanoma patients, whereas
elicitation of CTL responses specific for shared Ags will be limited to those patients
expressing the Ag and the appropriate restricting MHC class I molecule on their tumor
lesions. In addition, the methodologies used so far for the identification of tumor Ag
derived peptides summarized above are lengthy, labor intensive and proceed at a much
slower rate than that of the corresponding encoding genes or proteins. Therefore, the
design of alternative methodologies allowing the rapid identification of additional tumor
Ags is still a major challenge for the development of cancer vaccines. A novel approach
recently proposed for the identification of such sequences consists in using tumor
reactive CTL clones of unknown specificity to screen positional scanning synthetic
combinatorial libraries. The molecular bases underlining this approach are detailed
below:
Positional Scanning of Synthetic Combinatorial Libraries approach
Antigenic peptides recognized by CTL are normally generated by the processing of
cellular proteins whose degradation products are endogenously loaded onto MHC class
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I molecules in the ER and transported to the cell surface as pMHC complexes. However,
antigenic MHC class-I peptide complexes mimicking the endogenously formed ones can
also be obtained by exogenously loading free class I heavy chains present at the cell
surface with synthetic peptide in the presence of β2m. Based on this concept, an
alternative approach for the identification of antigenic peptide sequences consists in
testing recognition of complex soluble synthetic peptide mixtures (libraries)
systematically arranged in such a way as to provide information on the sequence of the
antigenic peptides. The approach of synthetic combinatorial libraries (SCL) is an
extension of one previously described methodology for the identification of epitopes
and/or active compounds [103]. Indeed, the use of overlapping peptides composing the
entire sequence of the NY-ESO-1 protein permitted the identification of CD4+ T
lymphocyte epitopes. The positional scanning-SCL (PS-SCL) are tested in the same
way as the overlapping peptides, with the added complication that the peptides in PS-
SCL represent billions of potential candidates that could be virtually found in several
proteins. This approach has already been successfully used to study interactions such
as peptide-Ab interactions [144]. In contrast to B lymphocyte epitopes, where the tertiary
structure plays a crucial role in the epitope interaction with a given Ab, T lymphocyte
epitopes are linear. Therefore it is feasible to use PS-SCL for the study of T lymphocyte
specificity.
PS-SCL allow the simultaneous synthesis and screening of millions of compounds as
compared to the traditional approaches developed so far. Two strategies were
developed simultaneously in the early 90s by Lam et al. [145] and by Houghten et al.
[146]. These methods are based on Merrifield’s-developed solid-phase peptide
synthesis [147,148]. The one-bead compound-based library, developed in 1991 by Lam
et at. (split-and-mix synthesis [145] , also called divide-couple-recombine synthesis by
Houghten et al. [146]) is based on the synthesis of peptides on resin beads. MHC-
biased one-bead one-compound libraries, where DR1 anchor amino acids were
introduced at positions 1, 4 and 6, were used by Hiemstra et al. [149] to determine the
specificity of MHC class II restricted T lymphocytes using a sequential identification
process. For this purpose peptides were released from decreasing amounts of beads
until sequencing from individual beads revealed the sequence recognized. During the
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synthesis process of such libraries, protected amino acids are coupled to separate
portions of resin. All resin portions are combined and mixed before being divided again
for the next coupling step. Due to the physical separation of the resins prior to the
incorporation of individual amino acids, this process yields libraries containing an
individual, unique compound on each resin bead [150]. The identification of active
compounds takes place at the level of single beads, which are then retrieved manually
and microsequenced. The main limitation of this method is inherent in the physical
nature of mixing resins. Since each bead contains a single peptide, the number of beads
required at the beginning of the synthesis must exceed the number of sequences to be
obtained. Therefore, the synthesis of one-bead one-compound libraries longer than 5 to
6 amino acids long implies technical problems such as the amount of starting materials
needed for that purpose. To synthesize the 64 million possible peptides in a hexapeptide
library using the 20 natural amino acids (206) for example, tens of grams of resin would
be required. For a heptapeptide library kilograms of resins would be required and tons of
resin for the synthesis of a decapeptide library. This connotes that the amount of resin
required for the library synthesis increases with peptide length, thus it would be
impossible to represent all the expected peptide diversity in libraries exceeding 6 amino
acids in length.
The mixture-based libraries are collections of peptides that can be screened as
systematically arranged soluble mixtures [146,150,151]. These libraries have two
advantages; they contain all the possible sequences for a peptide of a given length and
all these peptides are in solution, which allows them to be tested at different
concentrations and/or independently. The most used methods for the identification of
individual compounds from mixture-based SCL are depicted in Figure 7. The first
method involves an iterative deconvolution approach, where following the identification
of active mixtures having defined positions, the remaining mixture positions are then
defined one diversity position at a time through several synthesis and selection
processes until individual compounds are identified (Figure 7A).
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Figure 7. Deconvolution methods for a C-terminal amidated hexapeptide SCL. ( A ) Iterative
process. For the first screening step, positions 1 and 2 are defined with all amino acids (as AA, AC, AD...
YW, YY). An additional position is be defined during each iterative step. The whole sequence is
determined after 9 iterative steps. (B) Positional scanning process. A number of sublibraries (as many
sublibraries as positions in the sequence) are screened at once. Sublibraries provide information about
the most relevant residues at the defined positions. Individual peptides representing all possible
combinations of the most active residues at each position are then synthesized and tested. O represents a
defined amino acid, X represent randomly added amino acids.
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1Selection 3,200,0003,200,000
YXXXXX
XMXXXX
1 3,200,0003,200,000
Selection
Selection
1
1Selection
3,200,000
3,200,000
3,200,000
3,200,000
XXDXXX
XXXGXX
XXXXMX
1 3,200,0003,200,000
Selection
Synthesis
1 3,200,0003,200,000XXXXXS
YMDGMS 1 112
A
B
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20 mixtures
1. XXAXXX
 3. XXDXXX
20. XXYXXX
 2. XXCXXX
This iterative approach has been successfully used in several studies for the
identification of active compounds ranging from ligands for receptors to Ab epitopes
([146] and reviewed in [150]). In the second deconvolution approach, called positional
scanning, each diversity position is individually addressed by separate sublibraries. For
deconvolution, the building blocks of the most active mixtures at each diversity position
are combined and the resulting individual compounds are synthesized and tested to
determine their activities. The advantage of this second deconvolution approach is that
iterations are not required, very frequently a single synthesis is sufficient to obtain
individual active compounds (Figure 7B, [151] and reviewed in [150]).
Positional scanning synthetic combinatorial libraries (PS-SCL) are composed of peptide
mixtures systematically arranged in sublibraries having one defined position and n
variable positions composed of mixtures of all 19 natural L-amino acids (cysteine (C)
excluded).
O1XXXXX
XO2XXXX
XXO3XXX
XXXO4XX
XXXXO5X
XXXXXO6
The sublibraries for each position represent the same diversity of peptides, they differ
only in the localization of the defined amino acid. For a peptide of six amino acids, for
example, the library consists of six separate positional SCL represented as shown
above, where O represents an individually defined amino acid at that given position, and
X represent positions occupied by variable, randomly added amino acids. When the 20
natural amino acids are included, the hexapeptide library consists of 120 different
mixtures, each composed of six amino acid-long peptides. ([151,152] and reviewed in
[150,153]).
Nr. of peptide mixtures : 20 X 6 = 120
Total nr. of peptides : 20 X 195 ≅ 50 X 106
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The screening of such a PS-SCL allows the identification of key residues at the different
diversity positions. The activity detected for a given mixture is due to active peptides
within the mixture and not to independent amino acids. In the example shown in Figure
8, we illustrate the arrangement of a PS-SCL composed of tripeptides incorporating four
different amino acids. The diversity of such a library results in 64 (43) individual peptides.
When arranged in the positional scanning format, only 12 peptide mixtures (4 amino
acids x 3 positions) are synthesized. Each peptide mixture is composed of 16 peptides
(4 x 4). In this example, make the assumption that the sequence RAT represents the
only active peptide. The tripeptide RAT (shown in boxes in Figure 8, [153,154]) is
present in all three sublibraries, and only the mixtures RXX, XAX and XXT, in which the
RAT sequence is comprised, will be active. These three amino acids in their respective
positions build up the sequence RAT, which can then be synthesized and tested for its
individual activity. It is important to note, however, that the activity observed for each of
the mixtures is due to the presence of the tripeptide RAT in all of the three mixtures, and
not to the individual contribution of the amino acids R, A and T that occupy the defined
positions. More than one mixture are usually found to be active at each diversity
position. The combination of all the defined amino acids in the most active mixtures
results in individual active peptides. Consequently, for the synthesis of individual
peptides, the selection of the building blocks is based on the activity of a given mixture
as well as on the chemical character of the defined amino acids. This concept has been
applied to libraries having more than one defined position [155,156]. The PS-SCL
approach has been successfully used for the determination of Ab determinants and
ligands of MHC class I and II molecules, such as microbial epitopes or candidate
autoantigens implicated in different autoimmune diseases. The determination of favored
and optimal amino acids for each position of putative TCR epitopes, or even of more
effective peptide epitope analogs without any apparent sequence homology has also
been possible using this approach [36,37,157-159]. In addition and more importantly,
this approach is easily applicable to CTL clones restricted to any HLA molecule simply
by using autologous cells as APC.
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Figure 8. Example of a tripeptide synthetic combinatorial library arranged in the positional
scanning format. (From Houghten, 2000) Four amino acids (A, R, T and W) are incorporated in three
diversity positions producing a diversity of 64 peptides (43). Arranged in the positional scanning format,
only 12 peptide mixtures are synthesized (4 separate mixtures for the 3 positions). The resulting positional
sublibraries, namely OXX, XOX and XXO, contain the same diversity of peptides, differing only in the
location of the defined position.
Individual peptides
1 A A A 17 R A A 33 T A A 49 W A A
2 A A R 18 R A R 34 T A R 50 W A R
3 A A T 19 R A T 35 T A T 51 W A T
4 A A W 20 R A W 36 T A W 52 W A W
5 A R A 21 R R A 37 T R A 53 W R A
6 A R R 22 R R R 38 T R R 54 W R R
7 A R T 23 R R T 39 T R T 55 W R T
8 A R W 24 R R W 40 T R W 56 W R W
9 A T A 25 R T A 41 T T A 57 W T A
10 A T R 26 R T R 42 T T R 58 W T R
11 A T T 27 R T T 43 T T T 59 W T T
12 A T W 28 R T W 44 T T W 60 W T W
13 A W A 29 R W A 45 T W A 61 W A W
14 A W R 30 R W R 46 T W R 62 W W R
15 A W T 31 R W T 47 T W T 63 W W T
16 A W W 32 R W W 48 T W W 64 W W W
Position 1 OXX Position 2 XOX Position 3 XXO
1 A X X 5 X A X 9 X X A
2 R X X 6 X R X 10 X X R
3 T X X 7 X T X 11 X X T
4 W X X 8 X W X 12 X X W
A X X R X X T X X W X X X A X X R X X T X X W X X X A X X R X X T X X W
A A A R A A T A A W A A A A A A R A A T A A W A A A A A A R A A T A A W
A A R R A R T A R W A R A A R A R R A T R A W R A R A A R R A R T A R W
A A T R A T T A T W A T A A T A R T A T T A W T A T A A T R A T T A T W
A A W R A W T A W W A W A A W A R W A T W A W W A W A A W R A W T A W W
A R A R R A T R A W R A R A A R R A R T A R W A R A A R A R R A T R A W
A R R R R R T R R W R R R A R R R R R T R R W R R R A R R R R R T R R W
A R T R R T T R T W R T R A T R R T R T T R W T R T A R T R R T T R T W
A R W R R W T R W W R W R A W R R W R T W R W W R W A R W R R W T R W W
A T A R T A T T A W T A T A A T R A T T A T W A T A A T A R T A T T A W
A T R R T R T T R W T R T A R T R R T T R T W R T R A T R R T R T T R W
A T T R T T T T T W T T T A T T R T T T T T W T T T A T T R T T T T T W
A T W R T W T T W W T W T A W T R W T T W T W W T W A T W R T W T T W W
A W A R W A T W A W A W W A A W R A W T A W W W W W A W W R W W T W W W
A W R R W R T W R W W R W A R W R R W T R W W R W R A W R R W R T W R W
A W T R W T T W T W W T W A T W R T W T T W W T W T A W T R W T T W T W
A W W R W W T W W W W W W A W W R W W T W W W W W W A W W R W W T W W W
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A flowchart depicting the steps to be taken for the use of PS-SCL is shown in Figure 9.
Figure 9. Steps to be taken for the identification and optimization of T lymphocyte ligands using PS-
SCL.
Screening of PS-SCL
Identification of T lymphocyte
ligands that do not necessarily
correspond to natural epitopes
Identification of T lymphocyte
ligands in protein databases
Few mixtures are
clearly active
Many mixtures show
similar activity
Synthesize all combi-
nations of defined amino
acids in the most active
mixtures
Make a biased
library with reduced
complexity based on
screening results:
Xn = amino acids in
most active mixtures
at position n
P S - S C L - b a s e d
biometric analysis
Test individual peptides for T 
lymphocyte recognition
Synthesize peptides 
from database
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It is important to note, however, that each mixture of the PS-SCL analyzed contains
billions of peptides each present at subfemtomolar concentration. Thus, it is clear that
Ag recognition measured under these test conditions, is due to the recognition of
multiple peptides (most likely hundreds of them). As mentioned before, the capacity of T
lymphocytes bearing a single clonotypic TCR to recognize multiple peptides is a
common phenomenon known as degeneracy in T lymphocyte recognition [26,29].
While the degeneracy of T lymphocyte recognition makes the PS-SCL approach
feasible, it also inherently implies a level of complexity that challenges the interpretation
of the data for several reasons. First of all, additional activities, besides the native amino
acid at each position, are to be expected, corresponding to amino acids whose presence
at that position favorably impact either peptide binding to the MHC molecule and/or T
lymphocyte recognition. In addition, although most cross-reactive peptides in the
mixtures can be expected to be closely related to the native sequence, exceptions to
this rule have already been described [157,159-162] and, at least in principle, peptides
fully cross-reactive with the native one but unrelated to the latter in terms of sequence,
could be identified.
Since the majority of the sequences designed with the deconvolution strategy do not
correspond to proteins, a novel strategy developed by Zhao et al. [163], the PS-SCL-
based biometric analysis, can be used to systematically compare the data generated
from PS-SCL screening with all the proteins contained in databases. The PS-SCL-based
biometric analysis is based on the independent and additive contribution of each amino
acid within the peptide to its T lymphocyte stimulatory activity or antigenicity. This
algorithm allows the searching of stimulatory peptides of the same length as the tested
PS-SCL in public protein databases. In brief, the complete and complex screening
information obtained with PS-SCL is incorporated to generate a quantitative scoring
matrix that will in turn assign a predicted T lymphocyte stimulatory score to peptides of
the relevant length (Figure 10A). The columns in the matrix represent the diversity
positions, and the rows represent the 20 native amino acids used in the PS-SCL (the
defined positions). The matrix entry for a given amino acid in a specific position
corresponds to the PS-SCL-screening results obtained for the mixture defined with that
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particular amino acid at the selected position. This matrix is then used to search for
predicted stimulatory peptides in public protein databases by creating a scoring window
of the appropriate length that will move across the protein sequence in one amino acid
increments (Figure 10B). Note that the drastic changes observed in the peptides shown
in the scoring windows in Figure 10B indicate that they do not have the correct amino
acids at both the TCR and MHC contact positions, which contribute to most of the
stimulatory activity of the peptide. Once all peptides found within the database have
been attributed a stimulatory score based on the matrix, the retrieved peptides can be
ranked according to this score, as shown for the tyrosinase peptide in Figure 10C, and
which is of great practical value.
Because of the above considerations and in order to implement this approach as a tool
for epitope identification, and for the study of degeneracy in peptide recognition, it is
important to test the recognition of PS-SCL first by CTL clones of known specificity, and
then by clones of unknown specificity. To this end, we analyzed in detail the recognition
of PS-SCL by three different Melan-A-specific CTL clones that differ in terms of avidity
and fine specificity of Ag recognition as detailed in chapter 1. We also performed the
recently developed PS-SCL-based biometric database analysis that allowed the
identification of the native epitope among the 25 most active sequences retrieved in
public protein databases. In addition, several of the retrieved peptides of self- and
pathogen-origin were fully cross-reactive with the native Melan-A26-35 peptide. As a next
step (chapter 2), we analyzed and compared the recognition of four PS-SCL differing in
length and C-terminus by a Tyrosinase-specific CTL clone. Here again, we applied the
PS-SCL-based biometric database analysis and this allowed the identification of the
native peptide as the most active sequence. Finally, as described in chapter 3, we used
PS-SCL and the biometric database analysis to determine the specificity of a tumor-
reactive CTL clone that was derived by limiting dilution cloning of a tumor infiltrated
lymph node cell culture (TILN) from a melanoma patient.
Introduction Rubio-Godoy
15.7 
6.7 5.7 
5.3 
7.5 
6.8 6.7 
8.0 
7.6 
SMHNALHIYMNGTMSQVQGSANDPIF 
Score Sequence 
SMHNALHIYMNGTMSQVQGSANDPIF 
61.77 
SMHNALHIYMNGTMSQVQGSANDPIF 
59.03 
SMHNALHIYMNGTMSQVQGSANDPIF 
108.31 
SMHNALHIYMNGTMSQVQGSANDPIF 
56.87 
SMHNALHIYMNGTMSQVQGSANDPIF 
58.61 
MATRIX Database analysis Position 
1 2 3 4 5 6 7 8 9 
A 
C 
D 
E 
F 
G 
H 
I 
K 
L 
M 
N 
P 
Q 
R 
S 
T 
V 
W 
Y 
5.3 7.3 6.7 6.7 6.7 6.0 6.8 
5.6 5.5 8.3 6.7 6.9 4.9 6.9 5.0 4.9 
5.2 5.2 6.1 7.4 5.5 7.6 4.9 6.7 5.9 
4.9 6.9 7.4 7.2 6.8 7.1 6.8 6.0 
7.3 3.6 7.3 4.5 6.7 7.1 6.9 6.8 6.5 
.9 7.2 5.5 5.9 5.1 9.0 5.9 
6.2 4.7 6.7 5.8 7.3 6.7 6.8 6.7 5.4 
6.8 5.9 6.7 5.1 6.7 7.7 6.8 
6.8 7.0 6.7 7.1 6.8 6.8 9.7 10.3 
7.3 6.9 5.3 4.0 6.7 5.9 7.1 6.8 7.4 
7.3 7.4 7.2 7.2 7.2 7.6 7.2 6.8 7.6 
5.0 6.0 14.7 7.0 7.3 7.3 4.5 6.8 6.7 
4.8 3.8 5.3 7.3 7.4 6.7 7.2 8.0 7.2 
6.2 7.4 7.3 6.1 7.3 6.0 5.1 7.6 7.9 
7.2 5.8 6.0 7.2 6.1 4.0 6.8 6.9 7.7 
6.2 5.7 7.3 6.9 6.7 4.0 7.0 7.5 7.4 
4.0 7.2 5.5 6.1 13.5 3.8 6.7 7.4 
6.0 7.3 6.8 5.0 7.3 6.7 7.6 7.7 20.1 
7.3 5.1 6.8 7.0 7.1 7.0 10.5 7.3 11.6 
14.9 5.8 6.8 6.7 6.8 7.1 7.3 6.7 7.4 
Tyrosinase369-377 Y M N G T M S Q V 
Score 
108.31 
Rank Score Sequence Protein ID Nr. Protein descroption 
1 108.31 YMNGTMSQV P14679 Homo sapiens Human mRNA for tyrosinase (EC 1.14.18.1) 
2 102.87 YKNGKLLSV AF077346 Homo sapiens interleukin-18 receptor accessory protein-like mRNA 
3 101.72 IMNGTDEGV AL035252 Homo sapiens Human DNA sequence from clone RP4-738P15 on chromosome 0p11.2-11.22 
4 101.44 YGNGPGYKV AB012643 Homo sapiens Homo sapiens mRNA for alkaline phosphatase 
5 101.26 YGNGDDIGV D14041 Homo sapiens mRNA for H-2K binding factor-2 
6 101.04 YLNGPFTVV M29474 Homo sapiens Human recombination activating protein (RAG-1) gene 
7 101.03 YGSGTLVLV X06180 Homo sapiens Human mRNA for CD7 antigen (gp40) 
8 101.03 YLHGTGHGV X95762 Homo sapiens mRNA for aminopeptidase P-like 
9 100.81 YKNGVNQGV AB020982 Homo sapiens Homo sapiens ASH2L mRNA, similar to Drosophila ash2 sequence 
10 100.76 YKNGFNTLV AF141021 Homo sapiens Homo sapiens oxygen-regulated protein 1 (RP1) mRNA 
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Figure 10. Matrix generation and PS-SCL-based database analysis. (A) Data from the screening of a 9-PS-SCL with a Tyro369-
377-specific clone were used to generate a scoring matrix. Numbers represent the % specific lysis of all 180 mixtures in the nonapeptide
PS-SCL (for the 20 amino acids designated by the single letter code and for the 9 positions of the nonapeptide, P1 to P9). A
stimulatory score is calculated for any nonapeptide by adding the values of the individual amino acids in the scoring matrix. Here, the
amino acids composing the peptide Tyro369-377 are shown on boxes. (B) The scoring matrix was used to score continuous nonapeptides
contained in all known protein sequences contained in public databases to find potential stimulatory peptides for this particular CTL
clone. A nonamer scoring window is created which moves in 1 amino acid increments along the protein sequences. In this example,
the matrix attributed the highest score to the peptide Tyro369-377, the native peptide as shown in (C).
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Materials and Methods
Libraries and synthetic peptides
Four different L-amino acid synthetic positional scanning peptide libraries having their N-
termini free and differing in length and C-termini were used. Two nonapeptide libraries,
one with an amidated C-terminus (PCL 97-3) and the other with a free C-terminus (TPI
921), and two decapeptide libraries, one with an amidated C-terminus (DCR 207) and
the other with a free C-terminus (TPI 1210). These libraries were prepared at Torrey
Pines Institute for Molecular Studies or at Mixture Sciences Incorporated (San Diego,
CA, USA) as described previously [144,151]. Briefly, peptide mixtures making up the
PS-SCL were synthesized using the simultaneous multiple peptide synthesis (SMPS)
method. Mixture positions were incorporated by coupling mixtures of side chain
protected Boc-amino acids in a predetermined molar ratio, which compensates for the
different coupling rates of the different amino acids (i.e. isoleucine (I) and valine (V)
incorporate slower than alanine (A) or glycine (G)). Cysteine (C) was omitted since its
presence in the mixture positions could either require the constant presence in the
assay of a reducing agent, or it could result in the presence of difficult-to-define disulfide
aggregates in the library. Peptide mixtures were deprotected and cleaved from the resin
using low-high hydrogen fluoride method. The nonapeptide libraries consist of 180
mixtures in the OX8 format where O represents one of the 20 natural L-amino acids in a
defined position and X represent all the natural amino acids, with the exception of C, at
each of the remaining positions. Each mixture in the library is composed of 1.6 x 1010
peptides and the total X9 library consists of 3.1 x 10
11 different nonamer peptides in
approximate equimolar concentration. Assuming an average Mr of 1080 and a
concentration of 100 µg/ml of the mixture, the concentration of individual peptides is of
5.5 x 10-15 M. Decapeptide libraries consist of 200 mixtures in the OX9 format. In DCR
207, X represent a mixture of 18 amino acids (C and tryptophan (W) are not included).
Each mixture is composed of 1.9 x 1011 peptides and the total X10 library consists of 4 x
1012 different peptides. Assuming an average Mr of 1200 and a concentration of 100
µg/ml of the mixture, the concentration of individual peptides is of 2.6 x 10-16 M.
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Individual peptides were synthesized at the Torrey Pines Institute for Molecular Studies
or Mixture Sciences Inc. (San Diego, CA, USA) by the simultaneous multiple peptide
synthesis method [144], and at the Institute of Biochemistry, University of Lausanne
(Epalinges, Switzerland) by Dr. Catherina Servis using standard solid phase F-moc
chemistry on a multiple peptide synthesizer (Applied Biosystems, Foster City, CA, USA).
Purity and identity of each peptide were characterized using an electrospray mass
spectrometer interfaced with a liquid chromatography system. All peptides were ≥90%
pure. Lyophilized peptides were dissolved in 100% DMSO at a concentration of 10
mg/ml and stored at –20°C until use.
T cell clones and tumor cell lines
Tumor samples and PBMCs used in this study were obtained from melanoma patients
with stage III-IV disease. Melanoma cell lines Me 275, Me 242 and Me 260 were
established in our laboratory by Dr. D. Rimoldi (Ludwig Institute for Cancer Research,
Lausanne Branch, Epalinges, Switzerland) from surgically excised melanoma
metastases and cultured in RPMI 1640 medium (Life Technologies, Basel, Switzerland)
supplemented with 10% fetal calf serum (FCS), 0.24 mM asparagine (N), 0.55 mM
arginine (R) and 1.5 mM glutamine (Q). Melanoma cell lines SK-Mel 37 and SK-Mel 23
were kindly provided by Dr Y. T. Chen (Ludwig Institute for Cancer Research, New York
Branch, New York, USA). The HLA-A2+ melanoma cell line NA8-MEL was a gift from Dr.
F. Jotereau (Institut Nationale de la Santé et de la Recherche Médicale, Nantes,
France). The HLA-A2+ human mutant cell line CEMx721.T2 (T2 hereafter) [164] used as
target in 51Chromium release assay, was cultured in RPMI containing 10% FCS.
Tumor infiltrated lymph node (TILN) cells and tumor infiltrating lymphocytes (TIL) were
obtained from HLA-A*0201 melanoma patients during surgery at the Centre
Pluridisciplinaire d’Oncologie, CHUV, Lausanne, Switzerland. Small fragments from the
lymph nodes were finely minced with needles to single cell suspensions and cultured in
24-well tissue culture plates (Costar, Cambridge, MA, USA) in 2 ml of CTL medium
(Iscove’s Dulbecco medium (Life Technologies, Basel, Switzerland) supplemented with
8% pooled human A+ serum (HS), 0.24 mM N, 0.55 mM R and 1.5 mM Q) in the
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presence of 100 U/ml human recombinant (hr) interleukin (IL)-2 (Glaxo, Geneva,
Switzerland, kindly provided by Dr. M. Nabholz, ISREC, Epalinges, Switzerland) and 10
ng/ml hr IL-7 (R&D Systems, Europe, Oxon, U.K.). After 2 or 3 weeks of culture, the cell
surface phenotype of these cells was determined by flow cytometry and they were
tested for cytolytic activity. The Melan-A specific CTL clones LAU 203/1.3, LAU 203/1.5
and LAU 203/17, the tyrosinase specific CTL clone LAU 156/34, and the CTL clone LAU
50/4D7 of unknown specificity, were derived either from TILN or from TIL of patients
LAU 203, LAU 156 and LAU 50 respectively. These cells were previously cultured
during 14 days in CTL medium containing hrIL-2 and hrIL-7 (100 U/ml and 10 ng/ml
respectively) as mentioned above, and cloned by limiting dilution culture in the presence
of allogeneic irradiated peripheral blood mononuclear cells (PBMC), Phytohemagglutinin
(PHA), and hrIL-2 as described previously [165]. Shortly, lymphocytes were diluted in
CTL medium containing 150 U/ml hrIL-2 at a concentration of 0.3 to 1 cell/well (200
µl/well) and plated into 96 wells plates (Costar, Cambridge, MA, USA) in the presence of
1 x 105 allogeneic irradiated (3,000 rad) PBMC (isolated by centrifugation in Ficoll-
Paque (Pharmacia, Uppsala, Sweden)) and 1 µg/ml PHA. After 24 hours, the
supernatant was removed and replaced with CTL medium containing 150 U/ml hrIL-2.
Further restimulations were performed every 10 to 15 days by adding CTL medium
containing 150 U/ml hrIL-2, 1 x 105 allogeneic irradiated PBMC and 1 µg/ml PHA.
Magnetic cell sorting
For peptide stimulation of PBMC (LAU 97, LAU 181 and LAU 203), CD8+ T lymphocytes
were positively selected by magnetic cell sorting from PBMC of HLA-A*0201 melanoma
patients using a MiniMACS device (Miltenyi Biotec GmbH, Sunnyvale, CA, USA). Cells
of the CD8- fraction were irradiated (3,000 rads) and used as autologous Ag presenting
cells (APC). CD8+ highly enriched lymphocytes (1 x 106/condition) were stimulated with
synthetic peptide (1 µg/ml) and irradiated autologous APC in 2 ml of CTL medium
containing hrIL-2 (10 U/ml) and hrIL-7 (10 ng/ml). Cells underwent two additional cycles
of weekly restimulation with peptide pulsed APC.
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(experimental – spontaneous release)
(total – spontaneous release)
Antigen recognition assay
Standard 4 hours 51Chromium release assays (CTL assay) were used to assess
functional T cell recognition of antigenic peptides. Target cells (HLA-A2+ and TAP
deficient T2 cells or tumor cells) were labeled with sodium chromate (Na2
51CrO4) as
described [165]. Shortly, 5 x 105 to 1 x 106 target cells were incubated in 50 to 100 µl of
Na2
51CrO4 for 1 hour at 37°C and washed 3 times with RPMI medium. Labeled target
cells (1,000 cells/well) were added to microtiter V-bottom plates in the presence or
absence of the peptide library mixtures (100 µg/ml final) or synthetic peptide serial
dilutions for the titration experiments, and incubated for 15 minutes at room temperature
before the addition of effector cells at the indicated lymphocyte to target cell (L/T) ratios.
51Chromium release was measured in supernatants harvested after 4 hours incubation
at 37°C. Percent specific lysis was calculated as:
% Specific lysis = 100 x
The total release was determined from 0.75 N HCl-lysed labeled target cells. The
spontaneous release was determined as the counts released by labeled target cells in
the absence of added CTL.
Scoring matrices and PS-SCL-based biometric database analysis
The algorithm designed by Zhao et al. [163] to perform the PS-SCL-based biometric
database analysis is based on the assumption of an independent and additive
contribution of each amino acid in the peptide ligand to recognition. To this purpose, the
percentage specific lysis values of every mixture defined with 1 of the 20 L-amino acids
in each position of the peptide libraries are used to generate a matrix. The information in
the matrix is in turn used to assign a value to each amino acid at each position of a
given sequence according to the individual contribution of the amino acids to
recognition, as determined in the functional screening assay. The PS-SCL-based
biometric database analysis uses the information in the matrix to score all sequences
registered in public protein databases. For this purpose, a scoring window of the length
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of the desired peptide will be created which will move along the sequence of all proteins
in the database by increments of one amino acid. Based on the matrix, a potential
stimulatory score will be calculated by adding the individual values of amino acids
composing all the window-long peptides in the GenPept databasea. This score can be
used to identify sequences with the predicted highest T lymphocyte stimulatory values
and to rank these peptides accordingly [161-163].
HLA-A*0201 binding assay
The peptide binding capacity to HLA-A*0201 was assessed in a functional competition
assay based on the inhibition of recognition of the native antigenic peptide Tyro368-376
(YMDGTMSQV) by the HLA-A*0201-restricted CTL clone LAU 156/34 as described
previously [165]. Briefly, T2 cells were 51Chromium-labeled in the presence of anti-class
I monoclonal Ab (mAb) W6/32. Grading concentrations of peptides were incubated with
the labeled target cells (1,000 cells/well) for 15 minutes at room temperature. A
suboptimal dose (1.5 to 3 nM) of the native antigenic peptide Tyro369-377 was then added
together with the specific CTL (10,000 cells/well). 51Chromium release was measured
after 4 hours incubation at 37°C. The concentration of each competitor peptide required
to achieve 50% inhibition (IC50) of target cell lysis was determined and is indicated as
[nM] 50%. To facilitate comparison, the relative competitor activity of each peptide was
calculated as the IC50 of the native peptides (Melan-A26-35 and Tyro369-377) divided by the
IC50 of the competitor peptide.
Peptide/MHC class I molecule multimers
Fluorescent multimeric complexes allow the visualization of Ag-specific CD8+ T
lymphocytes within lymphocyte populations. They were synthesized by Dr. P. Guillaume
(Ludwig Institute for Cancer Research, Lausanne Branch, Epalinges, Switzerland) as
detailed in [166,167]. Shortly, HC MHC class I molecule and β2m were expressed on a
prokaryotic expression system (pET R&D Systems, Inc. Minneapolis, MN, USA) and
purified. The transmembrane- and cytosolic domains of the HC were deleted and a BirA
                                                 
a Internet address : ftp://ftp.ncifcrf.gov/pub/genpept
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enzymatic biotinylation site was added at the C-terminus. β2m, HC and peptide were
refolded by dilution; the refolded product was purified by fast protein liquid
chromatography and biotinylated by BirA (Avidity, Denver, CO, USA) in the presence of
biotin, adenosine 5’-triphosphate and magnesium (Mg2+) (all three from Sigma Chemical
Co. St. Louis, MO, USA). Fluorochrome-labeled streptavidine (Phycoerytrin (PE)-
streptavidin) was added in a 1:4 ratio, leading to the formation of fluorescent multimeric
complexes of up to 4 pMHC complexes. Multimers of HLA-A*0201 were synthesized
using the peptides Melan-A26-35 A27L (ELAGIGILTV), PT178-187 (LLAGIGTVPI), PV454-463
(VIAGIGILAI), CT51-60 (MLSGIGIFFI) and Influenza Matrix Flu-MA58-66 (GILGFVFTL).
Multimers were concentrated to 0.3 to 1 mg/ml and their sensitivity and specificity were
tested on titration experiments using specific and non-specific CD8+ T lymphocytes.
Antibodies, multimer/Ab staining and cytometric immunofluorescence
analysis
Anti-CD8 mAb was purchased from Becton Dickinson (Mountain View, CA, USA). Anti-
Vβ mAb were purchased from Immunotech (Beckman-Coulter, Marseilles, France). mAb
CR11.351 (anti HLA-A*0201, ascites, [168]) was kindly provided by Dr A. Anichini,
Istituto Nazionale Tumori, Milan, Italy. For Fluorescent-activated cell sorting (FACS)
analysis, cells were stained with multimers in 20 µl of phosphate-buffered saline (PBS),
2% bovine serum albumin (BSA), 0.2% sodium azide (NaN3) for 1 hour at room
temperature and/or with fluorescein isothiocyanate (FITC)-conjugated mAb in 50 µl of
PBS, 2% BSA, 0.2% NaN3 for 30 min at 4°C, washed in the same buffer and analyzed
by flow cytometry on a FACScan or on a FACSVantage SE devise (Becton Dickinson,
Mountain View, CA, USA). Data analysis was performed using Cell quest® software.
Fluorescence-activated cell sorting
Cell sorting of multimer+ and multimer- cell fractions was performed on a FACSVantage
SE device (Becton Dickinson, Mountain View, CA, USA). For this purpose cells were
resuspended in 100 µl/1 x 106 cells PBS, 2% BSA, 50 µM EDTA and stained with the
indicated multimer at room temperature during 1 hour. Cells were then stained with an
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FITC-conjugated anti-CD8 mAb (1 µl mAb/50 µl buffer; Becton Dickinson, Mountain
View, CA, USA) for 20 minutes at 4°C, washed two times and passed through a cell-
strainer (Falcon, Becton Dickinson Labware Europe, Le Pont de Claix, France) to avoid
the formation of cell aggregates. Sorted populations were collected in CTL medium and
cells were subsequently put in culture, cloned by limiting dilution culture or stimulated as
bulk cultures in 96 round bottom plates in the presence of 1 x 104 allogeneic irradiated
PBMC in 200 µl/well of CTL medium containing 150 U/ml hrIL-2 and 1 µg/ml PHA.
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Results
Chapter I: Recognition of PS-SCL by Melan-A-specific CTL clones and
design of peptide analogs
Several strategies have been employed so far for the identification of MHC class I-
restricted tumor Ags, but most of them are time consuming and labor intensive. They
depend on the acquisition of great numbers of tumor-reactive CD8+ T lymphocytes and
tumor cells, but more important, on the knowledge of the protein, or the gene encoding
it, from which the relevant peptide is derived. The PS-SCL approach has been
successfully used to identify Ab determinants and T lymphocyte ligands restricted to
MHC class I and II molecules, such as microbial epitopes or candidate autoantigens
implicated in different autoimmune diseases. The use of this approach has permitted the
identification of putative CD4+ [155,159,169] and CD8+ [157,161] T lymphocyte epitopes
(reviewed in [25,152,170]). This technique can also be applicable to a large number of
HLA-restricting molecules by using autologous APC, the only requirement being to have
access to large numbers of monospecific CTL clones. The isolation of tumor-specific
CD8+ T lymphocytes from melanoma patients is a current procedure in our laboratory,
rendering the application of such a strategy possible.
From the previously described studies using PS-SCL it was evidenced that activity can
be detected for mixtures of a given complexity. Two explanations can be raised from this
observation; either very active peptides are present within the mixtures which are
responsible for the observed activity, or a number of peptides are active and the activity
observed is the sum of their individual activities. Based on this, and in order to explore
the use of PS-SCL as an approach for the identification of new CTL-defined tumor
antigens, we first wanted to validate it by analyzing the patterns of recognition of nona-
and decapeptide libraries by melanoma tumor-reactive CTL clones of well defined
antigen specificity. Therefore, we first decided to study the recognition of PS-SCL by
tumor-reactive CTL clones specific for the melanoma differentiation Ag Melan-A. For this
purpose we compared the recognition of two C-terminally amidated PS-SCL (a nona-
and a decapeptide libraries) by three Melan-A-specific CTL clones.
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The melanoma antigen recognized by T lymphocytes-1 (MART-1/Melan-A) gene product
is expressed by practically all fresh melanoma tumor samples [88,91] and it represents
a very frequently recognized melanoma associated Ag (MAA) by tumor-reactive CTL
derived from melanoma patients[171]. The immunodominant epitope was originally
mapped to the amino acid residues 27 to 35 corresponding to the sequence AAGIGILTV
[92]. Some years later, Romero et al. [93] demonstrated that the optimal
immunodominant peptide corresponds to the decapeptide EAAGIGILTV26-35. Although
both sequences are cross-recognized by Melan-A-specific CTL with different avidity and
fine specificity, the decapeptide Melan-A26-25 is very often better recognized than the
nonapeptide Melan-A27-35 [165]. We screened the two PS-SCL with the Melan-A-specific
CD8+ CTL clones LAU 203/1.3, LAU 203/1.5 and LAU 203/17, which have a quite
different avidity and fine specificity in the recognition of the native Melan-A nona- and
decapeptides (AAGIGILTV and EAAGIGILTV respectively). Superagonist and cross-
reactive peptides were identified using two approaches that will be discussed.
Tumor- and peptide recognition by the selected Melan-A-specific CTL clones
The Melan-A-specific CTL clones LAU 203/1.3, LAU 203/1.5 and LAU 203/17 were
previously derived from tumor infiltrated lymph node cells (TILN) of melanoma patient
LAU 203 by limiting dilution cloning as detailed in the methods section and as described
elsewhere [165]. The three clones are tumor-reactive and HLA-A*0201-restricted as
shown in Figure I.1A since they efficiently lysed the Melan-A+ autologous melanoma
cell line Me 290 but not the Melan-A+ but HLA-A*0201- melanoma cell line Me 242.
Although they were all tumor-reactive, Melan-A recognition of the native peptides by the
three selected Melan-A-specific CTL clones was significantly different in terms of avidity
and fine specificity, as determined with peptide titration experiments. The results
obtained are depicted in Figure I.1B. Clone LAU 203/1.5 recognized the decapeptide
Melan-A26-35 ten times better that the nonapeptide Melan-A27-35 (EC50; 0.01 nM and 0.1
nM respectively). Clone LAU 203/17 recognized both peptides with similar efficiency
(EC50; ~0.1 nM for both peptides). And finally, clone LAU 203/1.3 recognized the
nonapeptide Melan-A27-35 one hundred times better than the decapeptide Melan-A26-35
(EC50; 10 nM for Melan-A27-35 and 1 µM for Melan-A26-35). The overall affinity of this
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clone was significantly lower as compared to clones LAU 203/1.5 and LAU 203/17. The
PS-SCL used for the screening with these clones were composed of C-terminally
amidated peptides. Therefore, we also tested the recognition of the C-terminally
amidated native peptides Melan-A26-35 and Melan-A27-35 (Figure I.1B open symbols).
Figure I.1. Tumor lysis and fine specificity of peptide recognition of Melan-A specific CD8+ CTL
clones. Clones LAU 203/1.5, LAU 203/17 and LAU 203/1.3 were tested for antigen recognition in a 4 hr
51Chromium release assay (CTL assay) as detailed in Materials and Methods. (A) Lysis of 51Cr labeled
target cells was assessed at the indicated lymphocyte to target (L/T) cell ratio in the absence or presence
of peptide Melan-A26-35 (EAAGIGILTV). Me 290 (HLA-A*0201
+, Melan-A+) and Me 242 (HLA-A*0201-,
Melan-A+) are melanoma lines obtained in our laboratory from melanoma patients LAU 203 and LAU 92
respectively. (B) Lysis of T2 cells was assessed at a L/T ratio of 10/1 in the presence of serial dilutions of
the indicated peptides.
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These peptides were recognized two orders of magnitude less efficiently than their C-
terminal carboxyl-free counterparts, but the hierarchy of peptide recognition by the
selected clones was not altered. It is of note that the recognition of amidated peptides by
clone LAU 203/1.3 was minimal (only ~25% specific lysis with the nonapeptide Melan-
A27-35 at 1µM).
Recognition of PS-SCL by Melan-A-specific CTL clones
The selected clones were used to test the recognition of PS-SCL in a standard CTL
assay. We obtained very low levels of specific lysis (less than 10%) with clone LAU
203/1.3 using either the nonapeptide C-terminally amidated PS-SCL (9-PS-SCL-NH2,
PCL 97-3) or the decapeptide C-terminally amidated PS-SCL (10-PS-SCL-NH2, DCR
207). Table I.1 summarizes the results obtained for clones LAU 203/1.5 and LAU
203/17 with both libraries where the amino acids corresponding to the most active
mixtures are shown.
Clone LAU 203/1.5 Clone LAU 203/17
Decapeptide PS-SCL Decapeptide PS-SCL
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 10
R1 V2 T3 G4 I5 G6 I7 H8 P9 A1 L2 T3 G4 W5 G6 W7 W8 T9 W10
Y1 I2 A3 D4 L5 A6 L7 F8 T9 M1 V2 A3 W4 I5 W6 F7 L8 W9 V10
L2 S3 N4 L8 V1 I2 W3 A4 F5 H6 L7 I8 Y9 I10
M2 P3 F4 P8 T1 G2 G3 R4 L5 R8 S9 A10
L1 S3 Y4 A8 N9 T10
Nonapeptide PS-SCL Nonapeptide PS-SCL
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9
W1 V2 P3 I4 C5 I6 W7 L8 W9 L1 L2 M3 P4 W5 R6 W7 R8 W9
Y1 I2 Y3 A4 G5 M7 V8 I9 M1 M2 P3 W4 T5 W6 P7 P8 I9
L1 F2 W3 C4 R5 L7 K8 F9 I1 I2 L3 A4 M5 L6 Y7 G8 V9
R1 W2 F3 V4 I8 V1 V2 Y3 I5 H6 M7 W8 P9
D1 C2 N3 H4 A1 F5 M6 L7 F8 L9
Only those amino acids (see Materials and Methods) of mixtures giving percent specific lysis higher than 10%
are shown. Those giving percent specific lysis higher then 15% are underlined, and those giving percent
specific lysis higher than 30% are darkened. Amino acids in cases correspond to the ones found at the same
position in the native Melan-A peptide sequence.
Table I.1. Summary of the recognition of nonapeptide and 
decapeptide  PS-SCLs by Melan-A specific clones.
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The first observation that could be done from the screening of PS-SCL with the Melan-
A-specific CTL clones is that the levels of specific lysis obtained were equivalent to the
ones obtained with individual peptides. Due to the complexity of the mixtures composing
the PS-SCL, this observation led us to suggest that a number of the mixtures were
active, and that the profile that resulted from this screening would allow to differentiate
between active and non active mixtures. Figure I.2 shows the results obtained for the
screening of 10-PS-SCL-NH2 with clone LAU 203/1.5. Panels represents the percentage
specific lysis (Y-axes) obtained for all peptide mixtures defined with one amino acid (X-
axes, amino acids are named according to the single-letter code) at one particular
position (P1 to P10). At position 1, the mixture defined with the hydrophilic amino acid
arginine (R) was responsible for the highest activity detected. At position 2, we found
mixtures containing amino acids known to function as anchor residues for binding to
HLA-A*0201 among the most active ones (such as valine (V), isoleucine (I), leucine (L)
and methionine (M)). These results are in agreement with previous studies were it was
shown that the introduction of an anchor residue at position 2 of the Melan-A epitope
(the substitution A27L, [172]) results in a peptide with improved binding to HLA-A*0201
as well as improved recognition by Melan-A-specific CTL. From positions 3 to 7, the
mixtures defined with the amino acids composing the native Melan-A28-32 sequence
(AGIGI) were among the ones giving the highest lytic activity. Several mixtures,
including those defined with the amino acids in the native peptide, were active at the
remaining 3 positions. Thus, the screening results revealed that the defined amino acids
in the most active mixtures correspond to the amino acids in the native epitope: four of
the native amino acids identified (G4, I5, G6 and I7) correspond to the defined mixtures
giving the highest levels of specific lysis, whereas the remaining four mixtures defined
with the correct amino acid (A3, L8, T9 and V10) were among the most active ones.
The results obtained from the screening of 10-PS-SCL-NH2 with clone LAU 203/17
revealed that 7 out of the 10 amino acids corresponding to the native Melan-A sequence
were found among the most antigenic mixtures (Table I.1). At position 1, A was
identified among the most active mixtures. This substitution has already been described
as a favorable one in a previous study [165].
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Figure I.2. Recognition of decapeptide PS-SCL (DCR 207) by clone LAU 203/1.5. Recognition was
tested in a 4 hr CTL assay as detailed in the Materials and Methods section. Each panel shows the level
of specific lysis (Y-axes) obtained in the presence of individual sublibraries, each containing one of the 20
L-natural amino acids at the defined positions (X-axes). Thus, the panel designed P1, contains the
sublibraries with a defined amino acid at position 1 of the decapeptide. The amino acids are named
according to the single letter code. Open bars represent amino acid corresponding to the Melan-A26-35
native peptide sequence.
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Indeed, by testing single A-substituted Melan-A26-35 analogs for binding to HLA-A*0201
and recognition by a panel of Melan-A-specific CTL, the peptide variant having the E26A
substitution (AAAGIGILTV) showed increased antigenicity as compared to the native
peptide Melan-A26-35. This is most probably due to the detrimental effect on binding to
HLA-A*0201 of the negatively charged amino acid E in position 1, which is abolished
with the E26A substitution [173]. At position 2 known HLA-A*0201 anchor residues (L2,
V2 and I2) were again defined at the mixtures giving the highest levels of specific lysis.
The mixtures defined with T, A, the native amino acid at this position and tryptophan
(W), were the most active ones at position 3. The highest activities at positions 4, 6 and
9 were detected with the mixtures defined with the native amino acid (G4, G6 and T9).
The mixtures defined with W were very active in several positions (P4 to P10). In the
case of positions 4, 7, 8 and 10, we identified the native amino acids as the second most
active mixtures after the one defined with W.
The results obtained from the screening of 9-PS-SCL-NH2 with clones LAU203/1.5 and
LAU 203/17 are also shown in Table I.1, bottom panels. For clone LAU 203/1.5, only
very low levels of specific lysis were obtained with the nonapeptide library, which is in
agreement with the preference of this clone for the native decapeptide Melan-A26-35.
Despite this low lysis, the mixtures defined with the native amino acids at positions 4 to
7 (G4, I5, G6, and L7) were among the most active ones. As previously mentioned,
clone LAU 203/17 recognizes peptides Melan-A26-35 and Melan-A27-35 with similar
efficacy. As expected, when the 9-PS-SCL-NH2 was tested for recognition by this clone,
comparable levels of specific lysis were obtained as with the 10-PS-SCL-NH2, although
the amino acids defined at the most active mixtures did not correspond to the ones in
the native Melan-A sequence. The presence of W among the most active mixtures from
positions P4 to P7 was persistent. The screening of 10-PS-SCL-NH2 allowed us to
identify the majority of the amino acids composing the native Melan-A26-35 sequence.
Indeed, in the case of clone LAU 203/1.5, 8 out of 10 native amino acids were identified
and for clone LAU 203/17, 7 of the mixtures defined with the native amino acids were
among the most active mixtures. For both clones, the results obtained with the 9-PS-
SCL-NH2 were not as clear as the ones obtained with the decapeptide library.
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Figure I.3. Recognition of single or multisubstituted analogs deduced from the screening of
decapeptide PS-SCL by clone LAU203/1.5. (A) The relative antigenic activity of single or
multisubstituted analogs deduced from the decapeptide PS-SCL was assessed in a 4 hours CTL assay as
detailed in the Materials and Methods section. The peptide concentration required to obtain 50% of
maximal activity [EC50 (nM)] was determined for each peptide. Then, the relative antigenic activity was
calculated as the nanomolar concentration required to achieve 50% maximal lysis for the reference
peptide Melan-A26-35 divided by that of the corresponding peptide analog. (B) Peptide titrations are shown
for the native peptide Melan-A26-35 and for 5 analogs carrying a single substitution.
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Recognition of PS-SCL-deduced peptides by Melan-A-specific CTL clones
In order to determine if the data from the screening of the PS-SCL allows the generation
of peptides that are better recognized by the Melan-A-specific clones, a deconvolution
approach was used to design two series of peptides for clones LAU 203/1.5 and LAU
203/17. For this purpose, the amino acids defined in the mixtures giving the highest
activity in the screening of 10-PS-SCL-NH2 with both clones were selected. In other
words, the building blocks of the most active mixtures at each diversity position were
combined and the resulting individual peptides had either single (which is the case for
clone LAU 203/1.5, Figure I.3A) or multiple amino acid substitutions (for both clones). In
order to reduce the number of peptides to synthesize, the amino acids were selected
based, first of all and as mentioned above, on their activity, but also on their chemical
character. To facilitate comparison, the activity of each deduced peptide was calculated
relative to the native peptide Melan-A26-35 by dividing the nM concentration of the native
peptide required to achieve 50% specific lysis (EC50) by that of the newly designed
peptide. The results of the titration experiments done with clone LAU 203/1.5 are shown
in Figure I.3. One peptide, having V at position 2 as only substitution, was recognized
significantly better than the native peptide (Peptide N88-65: EVAGIGILTV, recognized
66 times better than Melan-A26-35). Another set of peptides having multiple substitutions
including V at position 2 (peptides N88-56: RVAGIGILTV, relative activity: 0.6; N88-74:
EVTGIGILTV, relative activity: 1.3; N88-76: EVAGIGIHTV, relative activity: 1.3; N88-77:
EVAGIGILPV, relative activity: 0.6; and N88-80: EVAGIGIHPV, relative activity: 0.4)
were recognized as efficiently as the native peptide. In contrast, peptides containing
single or multiple substitutions other than V at position 2 were poorly or not recognized
(relative activities between 0.1 and <0.02). The improved binding to HLA-A*0201 and
activity of the Melan-A26-35 peptide after the introduction of an anchor residue in position
2 has already been demonstrated [172]. Therefore, the substitution A27V could explain
the efficient or better recognition of some of the deduced peptides having V at position
2. Nevertheless, not all of the peptides having A27V were recognized, implicating that
there are other amino acids that have a detrimental effect in peptide recognition [37].
Indeed, none of the peptides having single substitutions (besides peptide N88-65
EVAGIGILTV) were recognized by clone LAU 203/1.5.
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Figure I.4. Recognition of single or multisubstituted analogs deduced from the screening of
decapeptide PS-SCL by clone LAU 203/17. (A) The relative antigenic activity of single or
multisubstituted analogs deduced from the decapeptide PS-SCL was assessed in a 4 hr CTL assay as
detailed in the Materials and Methods section. The peptide concentration required to obtain 50% of
maximal activity [EC50 (nM)] was determined for each peptide. The relative antigenic activity was
calculated as in Figure I.3. (B) Peptide titrations are shown for the native peptide Melan-A26-35 as well as
for selected analogs.
This suggests that the high levels of specific lysis seen in the 10-PS-SCL-NH2 screening
for R1, T3, F or H8 and P9 are due to the combined effect of additional amino acid
substitutions giving rise to peptides having one or all of these amino acids fixed at the
given positions. The peptides deduced for clone LAU 203/17 and the titration curves
done for a selection of them are shown in Figure I.4. Among these peptides, two were
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recognized much more efficiently than the native peptide Melan-A26-35 (peptides N88-81:
ALAGIGILTV, relative activity: 14000 and N88-89: ALTGIGILTV, relative activity: 4666).
Here again, the introduction of an anchor residue, added to the favorable substitution
E26A [165], could to some extend, explain the improved recognition of these peptides.
The presence of W within the peptide seems to have a strong negative effect on peptide
recognition. Indeed and with the exception of two peptides, N88-96: ALTGWWWLTV
and N88-100: ALWGIWWLTV having six and five substituted positions respectively,
which were recognized as efficiently as the native Melan-A26-35 peptide (relative
activities: 1.6 and 0.3, respectively), none of other peptides, including the ones having W
as a single substitution from position 3 to 8, were recognized by clone LAU 203/17.
The binding capacity to HLA-A*0201 of the deduced peptides recognized by either clone
LAU 203/1.5 or clone LAU 203/17 was determined in a functional competition assay
(Figure I.5A). For comparison, binding to HLA-A*0201 was calculated relative to the
native peptide Melan-A26-35 as the nM concentration of the latter peptide required to
achieve 50% inhibition in peptide Tyro369-377 recognition by the Tyrosinase-specific CTL
clone LAU 156/34 (IC50) divided by the IC50 [nM] of the deduced peptides. The peptide
Influenza matrix58-66 (FluMA), which has been shown to bind HLA-A*0201 with high
affinity [174], was used as control. As expected and as compared to Melan-A26-35, a
lower dose of the selected deduced peptides was required to achieve 50% inhibition in
target cell lysis by the Tyrosinase-specific CTL clone, confirming that they bind to the
HLA-A*0201 molecule with increased affinity. Nevertheless, the peptide recognition
results could again not be solely explained by the improved binding of these peptides to
HLA-A*0201 as compared to Melan-A26-35, since peptide N88-93: ALTGWGILTV, which
also exhibited improved binding (Figure I.5A and data not shown), was not recognized.
To determine if the observed enhanced peptide recognition was clone-specific or not,
two polyclonal Melan-A-specific cell lines derived from melanoma patients LAU 181 and
LAU 233 were used to test recognition of peptides N88-63: EAAGIGILTV, N88-65:
EVAGIGILTV, N88-81: ALAGIGILTV, N88-89: ALTGIGILTV and N88-96:
ALTGWWWLTV in a titration experiment as shown in Figure I.5B.
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Figure I.5. Binding to HLA-A*0201 and recognition of peptide analogs N88-65, N88-81, N88-89
and N88-96 by polyclonal Melan-A monospecific cell lines from melanoma patients LAU 181 and
LAU 233. (A) Competitor activity was measured on the basis of the inhibition of recognition (IC50) of
peptide Tyro369-377 by the specific CTL clone LAU 156/34 as detailed in the Materials and Methods section.
The relative competitor activity was calculated using the native peptide N88-63 EAAGIGILTV as the
reference peptide with an arbitrary competitor activity of 1. The antigenic peptide Influenza matrix FluMA58-
66, which has been shown to bind to HLA-A*0201 with high affinity was used as an internal standard. (B)
Peptide titrations are shown for the native peptide Melan-A26-35 as well as for peptides N88-65
EVAGIGILTV, N88-81 ALAGIGILTV, N88-89 ALTGIGILTV and N88-96 ALTGWWWLTV.
Although with different avidity, both polyclonal cell lines recognized the deduced
peptides with the same hierarchy. Since peptide N88-96: ALTGWWWLTV was
recognized at least as efficiently as the native Melan-A26-35 peptide and these two
peptides greatly differ in sequence homology, we decided to test if peptide N88-96:
ALTGWWWLTV was immunogenic and able to stimulate the expansion of Melan-A-
specific T cell precursors. After in vitro stimulation of highly enriched CD8+ T cells from
patient LAU 203 with this peptide, we were able to detect a significant number of Melan-
A-specific T lymphocytes by staining with multimers incorporating the peptide Melan-A26-
35 A27L (Figure I.6A). Previous studies in our laboratory demonstrated that peptides
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Melan-A26-35 and Melan-A26-35 A27L are perfectly interchangeable [171], but multimers
incorporating the modified A27L peptide are easier to synthesize because of the
increased affinity of this peptide for the HLA-A*0201 molecule. Remarkably, and as
shown in Figure I.6A, stimulation with peptide N88-96: ALTGWWWLTV was more
efficient than stimulation with the native decapeptide, but not as efficient as the
stimulation with peptide N88-81: ALAGIGILTV, which was recognized with increased
efficiency as compared to the native peptide. To have an insight into the degree of
cross-recognition of peptides Melan-A26-35 and N88-96: ALTGWWWLTV, we isolated the
CD8+ A2/Melan-A+ and CD8+ A2/Melan-A- cell fractions within the culture stimulated with
peptide N88-96: ALTGWWWLTV by multimer-guided cell sorting. Peptide recognition by
the CD8+ A2/Melan-A+ cell fraction was assessed in a titration experiment as shown in
Figure I.6B. As expected based on the previous peptide recognition experiments,
peptides Melan-A26-35 and N88-96: ALTGWWWLTV were recognized with the same
efficiency. The lytic activity of these cells was further studied on T2 cells and tumor cell
lines. The graph in Figure I.6C shows that the CD8+ A2/Melan-A+ cell fraction was able
to efficiently lyse T2 cells only in the presence of both exogenously added peptides. In
addition, two Melan-A-expressing melanoma cell lines were also efficiently lysed by this
cell fraction. The CD8+ A2/Melan-A- cell fraction in contrast, did not lyse the tumor cell
lines or the T2 cells when loaded with the native Melan-A26-35 peptide. Nevertheless,
lower but significant levels of specific lysis of T2 cells were obtained by the CD8+
A2/Melan-A- cell fraction in the presence of peptide N88-96: ALTGWWWLTV,
suggesting that there is a population within these cells which is not cross-reactive with
Melan-A.
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Figure I.6. Elicitation of a Melan-A specific CTL response by stimulation with a PS-SCL-deduced
peptide mimic. (A) Stimulatory capacity of native and analog Melan-A peptides. CD8+ T cells from patient
LAU 203 were stimulated with peptides N88-63 EAAGIGILTV, N88-81 ALAGIGILTV and N88-96
ALTGWWWLTV and stained 7 days after the third stimulation with A2/Melan-A A27L multimers. Multimer+
and multimer- cell fractions from peptide N88-96-stimulated culture were isolated by multimer-guided cell
sorting. (B) Efficiency of peptides N88-63 and N88-96 recognition was determined in a peptide titration
experiment. (C) Lytic activity of multimer+ and multimer- fractions was assessed on T2 cells alone or in the
presence of peptides N88-63 and N88-96 at 1 µg/ml. Tumor lysis was also assessed on tumor cell lines
Me 275 and Me 290.
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PS-SCL-based biometric database analysis and search of predicted stimulatory
sequences in public protein databases
Figure I.7. PS-SCL-based database analysis performed with the data obtained from the screening
of 10-PS-SCL-NH2 with the Melan-A-specific clone LAU 203/1.5. (A) A scoring matrix was generated
with the data obtained from the PS-SCL screening which was then used to calculate stimulatory scores for
all decapeptides in the public protein database GenPept by adding the values of individual amino acids.
The amino acids composing the native Melan-A sequence are shown in black boxes. (B) A 10 amino
acids long scoring window was used to determine the score of all decapeptides. (C) Summary of all the
sequences retrieved ranking higher than Melan-A26-35.
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The recently developed PS-SCL-based biometric database analysis was used to
evaluate the predictive potential of the PS-SCL approach and to search for other
potential stimulatory peptides as shown in Figure I.7. Table I.2 summarizes the scores
obtained for the native peptide Melan-A26-35 with clones LAU 203/1.5 and LAU 203/17.
The screening of 10-PS-SCL-NH2 with clone LAU 203/1.5 revealed that Melan-A26-35
was the 22nd most active peptide among more than 13 million decapeptides contained in
the GenPept protein database. When this same analysis was performed with the results
obtained from the screening of 10-PS-SCL-NH2 with clone LAU 203/17, the native
sequence ranked 4th.
Selection and recognition of potentially cross-reactive self- and pathogen-derived
peptides deduced from PS-SCL-based biometric database analyses
The matrix generated with the data for clone LAU 203/1.5 was used to search for
potential stimulatory and/or cross-reactive peptides in different databases ([175,176]).
25 peptides of viral origin had a higher score than the native Melan-A26-35 peptide. When
a database of bacterial proteins was searched, more than 280 peptides scored above
Melan-A, therefore, only the top 25 peptides were selected for further analyses. As listed
in Table I.3, the 21 peptides of self-origin and the 25 viral peptides ranking higher than
Melan-A, as well as the top 25 peptides of bacterial origin where synthesized (with
amidated C-termini, since the PS-SCL used for the initial screening was also amidated).
CTL clone Melan-A26-35 rank in database
Clone LAU 203/17
Clone LAU 203/1.5
4
22
43'795 proteins scored in H. sapiens GenPept database (13'879'822 decamer
peptides)
Table I.2 Rank of Melan-A26-35 among all deca-
peptides on Human database.
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Score Origin Protein Sequence Location
Human
1 161.45 Homo sapiens Epididymis-specific alpha-mannosidase R V T D E A G H P V 501-510 Q9Y2E5
2 159.82 Homo sapiens Multidrug resistance-associated protein 3 N V A D I G L H D V 1353-1362 O15438
3 159.79 Homo sapiens Hypothetical 32.2 kDa protein R I S G V C I H P R 150-159 Q9Y4U1
4 159.07 Homo sapiens Thioredoxin reductase GRIM-12 L D S T I G I H P V 465-474 Q9UES8
5 158.35 Homo sapiens SLC1A1 or EAAT3 or EAAC1 V L T G L A I H S I 289-298 P43005
6 156.17 Homo sapiens Adenylate kinase isoenzyme 2 R I T G R L I H P K 137-146 P54819
7 155.54 Homo sapiens Programmed cell death protein 8 R I S G L G L T P E 98-107 O95831
8 155.30 Homo sapiens Integrin alpha-11 R I Q N L G L F P I 991-1000 Q9UKX5
9 154.83 Homo sapiens P47 R I S D I R L F I V 317-326 Q9UNZ2
10 154.74 Homo sapiens Prostaglandin transporter L L A G I G T V P I 178-187 Q92959
11 154.54 Homo sapiens Multidrug resistance-associated protein 5 R I S D I G L A D L 1257-1266 O15440
12 154.41 Homo sapiens KIAA0735 L I S G I G I G G A 206-215 O94840
13 154.25 Homo sapiens Hypothetical 20 kDa protein R I S A I I L H P N 3-12 Q9Y432
14 154.11 Homo sapiens Endothelin-1 receptor R V Q G I G I P L V 192-201 P25101
15 153.82 Homo sapiens G-Protein coupled receptor RE2 R I T D L G L S P H 364-373 O75963
16 153.74 Homo sapiens Multidrug resistance-associated protein 3 N V A D I G L H D L 1353-1362 O15438
17 153.21 Homo sapiens Human Ig heavy chain mRNA, partial cds R L S E L A I F G V 103-112 M97804
18 152.61 Homo sapiens Monocarboxylate transporter 8 A V A F I G L H T S 253-262 P36021
19 152.15 Homo sapiens Phosphorylase B kinase alpha reg. chain M L A D I E I H S I 1136-1145 P46020
20 151.97 Homo sapiens Hypothetical protein KIAA0274 K M A D I G G H A I 115-124 Q92562
21 151.89 Homo sapiens Multidrug resistance-associated protein 3 N V A D I G F H D V 1353-1362 O15438
22 151.36 Homo sapiens Melan-A/MART-1 E A A G I G I L T V 26-35 Q16655
Viral
23 161.81 Herpes simplex virus Capsid protein P40 R Q A G I A G H T Y 235-244 P10210
24 161.06 Little cherry closterovirus Methyltransferase and helicase domains R V S N I A I A T G 1684-1693 O40959
25 160.47 Pseudorabies virus Glycoprotein GIII V I A G I G I L A I 454-463 P06024
26 159.52 Pseudrabies virus Glycoprotein C V I A G I A I L A I 462-471 Q9QQM9
27 158.40 Human rotavirus Outer capside protein VP4 R L S G I Y G L P A 443-452 Q08778
28 158.13 Human rotavirus Outer capside protein VP4 R M S G I Y G L P A 443-452 P39033
29 157.76 Canine calicivirus Capsid protein N T T D I G I H V V 439-448 O72120
30 156.07 Variola virus (XhoI-F, O, H, P, Q genome fragment) genes M I A G I G I S L I 272-281 Q89230
31 154.75 Bovine herpesvirus type 1 Capsid protein P40 R E A G I A G H T Y 242-251 P54817
32 154.58 Bovine herpesvirus 2 DNA-dependent DNA polymerase R L A G I G L T R A 608-617 Q9QEL0
33 154.36 Vaccinia virus Protein A49 R I A D I D I K Q V 136-145 P21068
34 154.35 Hepatitis E virus Non-structural polyprotein R V R G I G C H F V 255-264 Q03495
35 154.18 Tobacco necrosis virus RNA-directed RNA polymerase R Y S G I G G H L L 239-248 P22958
36 153.64 Gallid herpesvirus 1 UL22 product homolog R I S D L A L N F I 468-477 Q9QTC3
37 153.57 Puma lentivirus 14 GAG polyprotein R I T G I C F H F G 920-929 Q84809
38 152.86 Murine cytomegalovirus Helicase/primase complex protein R L A G I L D H T L 654-663 Q69153
39 152.75 Human cytomegalovirus Hypothetical protein HVLF2 R I A G L L L F Q I 47-56 P09717
40 152.68 Mumps virus Fusion glycoprotein R F A G I A I G I A 102-111 P19716
41 152.64 Human parainfluenza virus 1 L protein R V R G I G I P E V 1683-1692 Q9WFZ5
42 152.19 SINP virus Hypothetical 36.5 kDa protein C T S I I G I F P V 77-86 O73555
43 151.81 Rotavirus G8 Outer capsid protein VP4 R I S G L Y G L P A 443-452 O71293
44 151.74 Mouse cytomegalovirus 1 M83 protein L I P G L D I H P S 311-320 Q98330
45 151.59 TT virus Hypothetical 15.9 kDa protein R A P S I G I L P A 87-96 Q9QUE2
46 151.50 Human adenovirus type 12 DNA terminal protein R Q A D I P L P P L 579-588 P12541
47 151.49 Nilaparvata lugens reovirus 23.6 kDa putative non-structural protein N F A G I A I L F I 74-83 Q83866
Bacterial
48 180.19 Chlorobium tepidum Hypothetical 22.8 kDa protein R L S G H G I H P V 150-159 O68985
49 175.48 Bacillus subtilis YKOR R V A S I G L H P S 431-440 O34830
50 173.12 Bacillus subtilis Putative transporter V M A G I A I F P A 260-269 O34383
51 171.51 Deinococcus radiodurans Aminotransferase, class I R V A G L G G H P S 267-276 Q9RUD5
52 170.17 Bacillus subtilis Hypothetical protein yhdh L L A G L A I F P A 264-273 O07577
53 170.06 Rickettsia prowazekii Cell division protein FTSK homolog R L S L I G L F P I 190-199 Q9ZCD4
54 168.15 Propionigenium modestum ATP synthase beta-chain, sodium ion specific R I A S L G I Y P A 327-336 P29707
55 167.60 Aeromonas salmonicida EPSP synthase R V T G I G K H S I 262-271 Q03321
56 167.22 Chlamydia trachomatis Arginine/ornithine antiporter M L S G I G I F F I 51-60 O84379
57 166.51 Nostoc punctiforme Carboxyl-terminal protease T R A N I A I H P V 197-206 O30968
58 166.35 Strepomyces coelicolor Putative sectreted protein V L S S I G I F P I 669-678 Q9RIU7
59 166.16 Escherichia coli Hypothetical protein ypfI R V S R I A V H P A 457-466 P76562
60 165.62 Synechococcus sp. RepA protein R V T G I G L L T G 65-74 Q53576
61 164.87 Bacillus pumilus Anthranilate synthase component I R Y S F I G L H P F 59-68 P18267
62 164.77 Methylobacterium extorquens Hypothetical protein in phaC 3'region L V A G I A I G P F 37-46 P52071
63 163.99 Salmonella typhimurium LtkB homolog R I A D I P I F I I 180-189 O85327
64 163.22 Burkholderia cepacia Hypothetical 23.3 kDa protein S I A D I A I Y P W 158-167 Q45073
65 163.10 Aquifex aeolicus ATP synthase beta-chain R L A E L G I Y P A 339-348 O67828
66 163.07 Escherichia coli Colicin V secretion ATP-binding protein cvaB R I A D I A L H E K 465-474 P22520
67 162.94 Helicobacter pylori J99 Serine acetyltransferase F I T G I E I H P G 61-70 Q9ZK14
68 162.82 Escherichia coli ATP-dependant protease La V I A D L D I H P V 751-760 P08177
69 162.52 Azospirillum brasilense Glutamate synthase (NADPH) large chain R I S G I G L N G I 781-790 Q05755
70 162.36 Rhizobium meliloti Rhizobactin siderophore biosynthesis protein L I A G H G I H P C 143-152 Q9Z3R0
71 162.18 Rhizobium sp. Probable ABC transporter permease Y4FN R S A F I G I D P A 452-461 P55452
72 162.17 Escherichia coli K(+)/H(+) antiporter L L A G I A I G P W 36-45 P45522
MSI 44-
Accessioin 
number
a: Accesion number  for SWISS-PROT or NCBI
Table I.3. Description of Melan-A potentially cross-reactive peptides MSI 44 
peptides retrieved from public protein databases 
a
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Figure I.8. Recognition of Melan-A-related peptides retrieved different databases based on the
screening results of 10-PS-SCL-NH2 with clone LAU 203/1.5. Peptide recognition by clones LAU
203/1.5 and NM/55 was assessed in a CTL assay using T2 cells as targets as detailed in the Materials
and Methods section. Recognition was tested at a single peptide dose (1 µg/ml). (A) Recognition of
peptides retrieved from a human database. (B) Recognition of peptides retrieved from a viral database.
(C) Recognition of peptides retrieved from a bacterial database. (D) Summary of the peptides recognized
in each group by both clones and their percentage.
Recognition of all these retrieved peptides (called MSI 44 peptides hereafter) by clone
LAU 203/1.5, as well as by a clone specific for the influenza matrix peptide FluMA, clone
NM/55, was first tested in a CTL assay at a single peptide dose (1 µM). The results of
these experiments are shown in Figure I.8 for each group of peptides (A: human
peptides, B: viral peptides and C: bacterial peptides). In addition, a set of 100 unrelated
peptides, having scores between 27 and 89, was also tested for recognition by clone
LAU 203/1.5 (data not shown). The recognition of these peptides was negligible, since
less than 10% specific lysis was obtained for all of them.
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Therefore, only the MSI 44 peptides giving more than 10% specific lysis were
considered active. As illustrated in Figure I.8D, about 40% of the MSI 44 peptides were
recognized by clone LAU 203/1.5, being the percentage of peptides significantly
recognized greater among the peptides of bacterial origin (52%) than in the other two
groups (32% for both). To further analyze the recognition of MSI 44 peptides by clone
LAU 203/1.5, titration experiments were performed as illustrated in Figure I.9A and
summarized in Figure I.9B. From the 28 MSI 44 peptides that were recognized by this
clone, 4 were recognized significantly better (between 10 and 100 times better
recognized) than the native Melan-A26-35 peptide, 12 were recognized with similar
efficacy, and the remaining 12 were recognized at least 10 times less efficiently. We
compared the recognition of a selection of the most active peptides having amidated or
free C-termini by clone LAU 203/1.5. As depicted in Figure I.9C for some of the
peptides tested, peptides having free C-termini were in general equally well or better
recognized than amidated C-terminal peptides, although some exceptions were
observed.
Cross-recognition of the retrieved peptides is a general feature of Melan-A-
specific CTL
In order to determine whether the cross-recognition of the MSI 44 peptides observed
with clone LAU 203/1.5 was exclusive of this particular clone, or whether it could be
seen with other Melan-A-specific CTL, we tested their recognition with a panel of Melan-
A-monospecific CTL lines and clones. The results of these analyses are shown in Table
I.4 and summarized in Tables I.5 and I.6. The degree of cross-reactivity in peptide
recognition observed for the different CTL populations used varied from not detectable
to very high. Indeed, one clone (LAU 337/6C3) showed no recognition of any of the MSI
44 peptides, while some populations were able to recognize up to 68% of the MSI 44
peptides (i.e. polyclonal lines LAU 203/P and LAU 465 as well as clone LAU 337/2A5). It
should be noted that clones LAU 337/6C3 and LAU 337/2A5, which had contrasting
degrees of cross-recognition, were derived from the same melanoma patient LAU 337.
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Figure I.9. Recognition efficiency of retrieved peptides. (A) Efficiency of peptide recognition relative
to the native Melan-A26-35 peptide by clone LAU 203/1.5 was determined in the presence of grading
concentrations of a selection of peptides in a CTL assay as detailed in the Materials and Methods section.
(B) Summary of the results. Activity is shown relative to the native Melan-A26-35 decapeptide. The relative
antigenic activity was calculated as the nanomolar concentration required to achieve 50% maximal lysis
for the reference peptide (Melan-A26-35) divided by that of the corresponding deduced peptide. (C)
Recognition of a selection of C-terminally amidated peptides (MSI 44-10, -25, -54 and -65) and their free
C-terminal counterparts (MSI 62-1, -3, -8 and -11) was tested in a CTL assay.
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Human Human
1 - - - - - - - 0 1 - - - - - - - - - - - - - - - - 0
2 - - - - - - - 0 2 - - - - - - - - - ++ - - - - - - 1
3 - - - - - - - 0 3 - - - - - - - - - - - - - - - - 0
4 ++ - - - - - - 1 4 - - - - - - - - - - - - - - - - 0
5 - - - - - - + 1 5 - - + - - - - - + +++ - - + - - - 4
6 - - - - - - - 0 6 - - - - - - - - - + - - - - - - 1
7 - - - - - - - 0 7 - - - - - - - - - + - - - - - - 1
8 - - - - - - - 0 8 - - - - - - - - - + - - - - - - 1
9 +++ + +++ - - ++ ++ 5 9 - - + - ++ - - - + ++ - - + - - - 5
10 ++++ ++ ++++ ++ - ++ +++ 6 10 + - ++++ + +++ - +++ + +++ - - - + - + - 9
11 ++ - ++ - - ++ ++ 4 11 - - - - + - - - - - - - - - - - 1
12 +++ ++++ +++ - + ++ +++ 6 12 - + - - - - - - ++ ++ - - + - + - 5
13 - - - - + - - 1 13 - - - - - - - - - - - - - - - - 0
14 +++ - - - + - + 3 14 - - - - - - + - - ++ - - - - - - 2
15 - - - - - - - 0 15 - - ++ - - - - - - - - - - - - - 1
16 - - - - - - - 0 16 - - - - - - - - - - - - - - - - 0
17 - - - - + - + 2 17 - - - - - - - - - ++ - - + - - - 2
18 ++ + + - ++ + ++ 6 18 ++ - ++ - - - + - ++ +++ - - ++ - - - 6
19 - - - - ++ - + 2 19 - - - - - - - - - + - - + - - - 2
20 - - - - + - - 1 20 - - - - - - - - - - - - - - - - 0
21 - - + - + + ++ 4 21 +++ - - - - - - - - + - - - - - - 2
22 ++++ ++++ ++ +++ +++ ++++ +++ 7 22 ++++ ++ ++++ ++++ +++ ++++ +++ +++ ++++ ++++ ++++ ++++ +++ +++ + ++ 16
Viral Viral
23 - - - - ++ ++ ++ 3 23 + - + - - - ++ + ++ +++ - + + - - - 8
24 ++ - + - + + ++ 5 24 - - + - - - + - + +++ - - + - - - 5
25 ++++ ++++ ++ +++ +++ ++ ++++ 7 25 ++++ +++ ++++ ++ +++ +++ +++ +++ ++++ ++++ - - ++ + ++ - 13
26 ++ - - - + - ++ 3 26 + - + - - - - - + ++ - - + - - - 5
27 - + - - ++ - + 3 27 - - - - - - - - ++ ++ - - + - - - 3
28 + - - - ++ + + 4 28 - - + - - - - - + ++ - - + - - - 4
29 ++ ++++ ++ + ++ ++ +++ 7 29 + +++ - - ++ - ++ + +++ +++ - - ++ - - - 8
30 ++++ ++++ +++ - - +++ ++++ 5 30 ++++ - ++++ ++ +++ - - - ++ + - - - - + +++ 8
31 ++ - + - - + ++ 4 31 - - - - - - - - + ++ - - + - - - 3
32 ++ - + - - + ++ 4 32 - - + - - - - - + ++ - - ++ - - - 4
33 + ++ - - - + ++ 4 33 ++ - ++ - - - + - ++ +++ - - ++ - - - 6
34 - - - - - - + 1 34 - - - - - - - - + ++ - - + - - - 3
35 + + + - + + ++ 6 35 - - + - - - - - ++ ++ - - + - - - 4
36 ++++ - - - - - + 2 36 - - - - - - - - ++ ++ - - + - - - 3
37 ++ + - - - - + 3 37 + +++ ++ - ++ - + - ++ ++ - - ++ - - - 8
38 - - + - - - - 1 38 - - + - - - - - + ++ - - - - - - 3
39 + + - - - - + 3 39 + - ++ - - - - - ++ ++ - - + - - - 5
40 ++ + - - - + + 4 40 + + ++ - - - - - + ++ - - + - - - 6
41 ++ + - - - - + 3 41 + - + - - - - - ++ +++ - - ++ - - - 5
42 ++ + - - - - - 2 42 - - - - - - - - + ++ - - + + - - 4
43 - - - - - - - 0 43 - - - - - - - - - - - - - - - - 0
44 - - - - - - - 0 44 - - - - - - - - + - - - - - - - 1
45 ++ - - - - - - 1 45 + ++ - - + - - - - - - - - - - - 3
46 - - - - - - - 0 46 - - - - + - - - - - - - - - - - 1
47 ++ + - - + + ++ 5 47 - - ++ - - - - - ++ +++ - - + - - - 4
Bacterial Bacterial
48 +++ - - - - - + 2 48 ++ +++ + - - - - - - + - - - - - - 4
49 +++ - - - - - - 1 49 - - - - - - - - - - - - - - - - 0
50 ++++ - - - - ++ ++ 3 50 - - - - - - - - - - - - + - - - 1
51 + - - - - - + 2 51 - - - - - - - - - - - - - - - - 0
52 +++ - +++ - - ++ ++ 4 52 - - - - ++ - - - + + - - + - - - 4
53 ++++ - - - - + - 2 53 - - - - - - - - - - - - - - - - 0
54 ++++ - + - - - + 3 54 - ++++ ++ - - - - - - + - - - - - - 3
55 + - - - - + + 3 55 + - + - + - - - + ++ - - + - - - 6
56 ++++ - ++++ - + ++ +++ 5 56 ++++ ++ ++++ - +++ - - - - - - - - - + +++ 6
57 ++ + - - - + ++ 4 57 - - + - - - - - + ++ - - - - - - 3
58 ++++ ++ +++ - - ++ +++ 5 58 +++ - + ++ + - + - - - - - - - + - 6
59 ++ - - - - + - 2 59 - - - - - - - - - - - - - - - - 0
60 +++ +++ + + ++ + ++ 7 60 ++++ - + - - - ++ + + ++++ - - + - - - 7
61 ++ - - - - - - 1 61 - - - - - - - - - - - - - - - - 0
62 ++ ++ - - + ++ + 5 62 - - ++ - - - - - + ++ - - + - - - 4
63 + - - - - - + 2 63 - - + - - - - - - + - - - - - - 2
64 + - - - + - + 3 64 - - +++ - + - - - - ++ - - - - - - 3
65 +++ - - - - - - 1 65 - - - - + - - - - - - - - - - - 1
66 + + - - + - + 4 66 - - - - - - - - - - - - - - - - 0
67 - - - - + - - 1 67 - + - - - - - - - ++ - - - - - - 2
68 - + - - + - + 3 68 - - + - - - - - + ++ - - + - - - 4
69 ++ + - - + + ++ 5 69 - - + - - - - - - ++ - - + - - - 3
70 + + - - - + + 4 70 + - ++ - - - - - ++ +++ - - + - - - 5
71 +++ +++ - + ++ ++ ++ 6 71 ++++ - +++ - ++ + ++ ++ +++ ++++ - - ++ - - - 9
72 +++ +++ + + ++ ++ +++ 7 72 ++++ - +++ - + + ++ + +++ +++ - - ++ - - - 9
Nr. 
pos
LAU 
337/1B5
LAU 
455/37 
Monospecific monoclonal populations
LAU 
465/12A6
LAU 
465/10B8
LAU 
465/8D3
LAU 
455/29
LAU 
465/4E1MSI 44-
LAU 
203/P
HD 421 
2/4A12
HD 421 
2/7B12
LAU 
181/P
LAU 
552
LAU 
465
HD 
421/P
LAU 
455/P MSI 44-
Monospecific polyclonal populations
Nr. 
pos
LAU 
337/3A9
LAU 
337/P
LAU 
203/17
LAU 
337/6C3
LAU 
203/1.3
HD 421 
2/4G7
LAU 
337/2A5
LAU 
455/2
+ > 10% specific lysis, ++ > 20% specific lysis, +++ > 40% specific lysis, ++++ > 60% specific lysis
Table I.4. Recognition of MSI 44 peptides by Melan-A-monospecific CTL lines and clones 
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Human sequences Viral sequences Bacterial sequences
MSI 44 Score Sequence Lines Clones MSI 44 Score Sequence Lines Clones MSI 44 Score Sequence Lines Clones
1 161.5 R V T D E A G H P V 0 0 23 161.8 R Q A G I A G H T Y 3 8 48 180.2 R L S G H G I H P V 2 4
2 159.8 N V A D I G L H D V 0 1 24 161.1 R V S N I A I A T G 5 5 49 175.5 R V A S I G L H P S 1 0
3 159.8 R I S G V C I H P R 0 0 25 160.5 V I A G I G I L A I 7 13 50 173.1 V M A G I A I F P A 3 1
4 159.1 L D S T I G I H P V 1 0 26 159.5 V I A G I A I L A I 3 5 51 171.5 R V A G L G G H P S 2 0
5 158.4 V L T G L A I H S I 1 4 27 158.4 R L S G I Y G L P A 3 3 52 170.2 L L A G L A I F P A 4 4
6 156.2 R I T G R L I H P K 0 1 28 158.1 R M S G I Y G L P A 4 4 53 170.1 R L S L I G L F P I 2 0
7 155.5 R I S G L G L T P E 0 1 29 157.8 N T T D I G I H V V 7 8 54 168.2 R I A S L G I Y P A 3 3
8 155.3 R I Q N L G L F P I 0 1 30 156.1 M I A G I G I S L I 5 8 55 167.6 R V T G I G K H S I 3 6
9 154.8 R I S D I R L F I V 5 5 31 154.8 R E A G I A G H T Y 4 3 56 167.2 M L S G I G I F F I 5 6
10 154.7 L L A G I G T V P I 6 9 32 154.6 R L A G I G L T R A 4 4 57 166.5 T R A N I A I H P V 4 3
11 154.5 R I S D I G L A D L 4 1 33 154.4 R I A D I D I K Q V 4 6 58 166.4 V L S S I G I F P I 5 6
12 154.4 L I S G I G I G G A 6 5 34 154.4 R V R G I G C H F V 1 3 59 166.2 R V S R I A V H P A 2 0
13 154.3 R I S A I I L H P N 1 0 35 154.2 R Y S G I G G H L L 6 4 60 165.6 R V T G I G L L T G 7 7
14 154.1 R V Q G I G I P L V 3 2 36 153.6 R I S D L A L N F I 2 3 61 164.9 R Y S F I G L H P F 1 0
15 153.8 R I T D L G L S P H 0 1 37 153.6 R I T G I C F H F G 3 8 62 164.8 L V A G I A I G P F 5 4
16 153.7 N V A D I G L H D L 0 0 38 152.9 R L A G I L D H T L 1 3 63 164.0 R I A D I P I F I I 2 2
17 153.2 R L S E L A I F G V 2 2 39 152.8 R I A G L L L F Q I 3 5 64 163.2 S I A D I A I Y P W 3 3
18 152.6 A V A F I G L H T S 6 6 40 152.7 R F A G I A I G I A 4 6 65 163.1 R L A E L G I Y P A 1 1
19 152.2 M L A D I E I H S I 2 2 41 152.6 R V R G I G I P E V 3 5 66 163.1 R I A D I A L H E K 4 0
20 152.0 K M A D I G G H A I 1 0 42 152.2 C T S I I G I F P V 2 4 67 162.9 F I T G I E I H P G 1 2
21 151.9 N V A D I G F H D V 4 2 43 151.8 R I S G L Y G L P A 0 0 68 162.8 V I A D L D I H P V 3 4
22 151.4 E A A G I G I L T V 7 16 44 151.7 L I P G L D I H P S 0 1 69 162.5 R I S G I G L N G I 5 3
45 151.6 R A P S I G I L P A 1 3 70 162.4 L I A G H G I H P C 4 5
46 151.5 R Q A D I P L P P L 0 1 71 162.2 R S A F I G I D P A 6 9
47 151.5 N F A G I A I L F I 5 4 72 162.2 L L A G I A I G P W 7 9
a b
a : Number o f polyclonal monospecific cell lines recongizing the peptides. b : Number o f CTL clones recognizing the peptides. Gray boxes represent peptides that were
recognized by at least half of the CTL populations in each group. Selected peptides for each group are shown in bold.
Table I.5. Score, sequence and recognition of the MSI 44 peptides by Melan-A-monospecific CTL lines and clones
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In general, we observed an increased degree of cross-reactivity with the Melan-A-
monospecific CTL lines (Table I.6) as compared to the clones. Indeed, Melan-A-
monospecific CTL lines from patients LAU 203 and LAU 465 recognized both 68% of the
retrieved peptides, whereas clones derived from these two lines were able to recognize
between 4 to 51% of them (LAU 203/1.3: 15%, LAU 203/1.5: 39%, LAU 203/17: 32%,
LAU 465/10B8: 4%, LAU 465/8D3: 10% and LAU 465/4E1: 51%).
Immunogenicity of selected MSI 44 peptides
The studies of cross-reactivity discussed above were extended to the analysis of the
immunogenicity of some of these peptides. This was studied by stimulating PBMC-
derived CD8+ T lymphocytes from three melanoma patients with the three retrieved
peptides (one representative of each group) that were the most frequently recognized.
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Cell line Human Viral Bacterial Total %
LAU 203/P 8 18 23 49 68
LAU 181/P 5 12 10 27 38
HD 421/P 7 8 6 21 29
LAU 455/P 2 2 3 7 10
LAU 337/P 9 9 10 28 39
LAU 552 7 12 14 33 46
LAU 465 11 19 19 49 68
LAU 203/17 4 11 8 23 32
LAU 203/1.3 2 5 4 11 15
HD 421 2/4A12 6 15 15 36 50
HD 421 2/7B12 2 2 1 5 7
HD 421 2/4G7 4 6 8 18 25
LAU 455/2 1 1 2 4 6
LAU 455/29 4 6 4 14 19
LAU 455/37 2 3 3 8 11
LAU 337/1B5 6 22 9 37 51
LAU 337/2A5 13 21 15 49 68
LAU 337/6C3 1 0 0 1 1
LAU 337/3A9 1 1 0 2 3
LAU 465/4E1 8 19 10 37 51
LAU 465/10B8 1 2 0 3 4
LAU 465/8D3 3 2 2 7 10
LAU 465/12A6 1 1 1 3 4
a
a: Number of peptides recognized in each group. b: Percentage of peptides recognized by
each cell population.
b
Table I.6. Summary of MSI 44 peptide
recognition by Melan-A-monospecific CTL
lines and clones 
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These peptides are MSI 44-10, derived from the human prostaglandin transporter
(called PT178-187 hereafter) MSI 44-25, derived from the glycoprotein GIII precursor of
Pseudorabies virus (PV454-463 hereafter), and MSI 44-56, derived from the
arginine/ornithine antiporter of Chlamydia trachomatis (CT51-60 hereafter). Additionally,
as positive controls we stimulated PBMC from the same patients with the native peptide
Melan-A26-35, and with the enhanced analog Melan-A26-35 A27L. As a negative control we
cultured CD8+ T lymphocytes under the same conditions without adding any peptide.
After three weekly rounds of stimulation, we performed a flow cytometry analysis with
multimers incorporating the peptides used for the in vitro stimulation (autologous
multimers) to determine the number of elicited specific cells. As shown in Figure I.10A
for patient LAU 241 and summarized in Figure I.10B for all three patients, and as
expected, [172,177] stimulation with the enhanced analog Melan-A26-35 A27L elicited a
higher number of Melan-A-specific cells than the native Melan-A26-35 peptide.
Surprisingly, stimulation with the selected MSI 44 peptides elicited a stronger response
than the one evoked with the enhanced Melan-A analog Melan-A26-35 A27L and
therefore, clearly superior to the one evoked with the natural peptide Melan-A26-35. When
this analysis was performed using a multimer incorporating the enhanced analog Melan-
A26-35 A27L (A2/Melan-A multimer), a lower even though very significant proportion of
A2/Melan-A multimer+ cells were also detected in each of the cultures (Figure I.10B).
To further dissect the heterogeneity of the elicited responses, autologous multimer+ and
multimer- cell fractions from each culture were separated by multimer-guided cell sorting,
expanded in vitro with PHA and stained again with multimers incorporating either the
autologous peptide or peptide Melan-A26-35 A27L. Here again, the resulting populations
were homogeneously stained with the autologous multimers whereas only a fraction of
the lymphocytes were specifically stained with the multimer incorporating peptide Melan-
A26-35 A27L (as shown in Figure I.11A for patient LAU 241). Fine specificity of peptide
recognition by autologous multimer+ and multimer- cell fractions was assessed in a CTL
assay as shown in Figure I.11B and summarized in Figure I.11C.
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Figure I.10. In vitro immunogenicity of frequently recognized retrieved peptides. Highly enriched CD8+ T cells from three melanoma
patients were stimulated with peptides Melan-A26-35, Melan-A26-35 A27L, PT178-187, PV454-463 and CT51-60 and stained after the third stimulation
with A2/Melan-A multimers and with multimers incorporating the three retrieved peptides. The results obtained for patient LAU 241 are shown
in (A) and those for the three patients are summarized in (B).
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Figure I.11. Cytometric analysis of polyclonal monospecific populations of patients LAU 203 and LAU 241. Highly enriched CD8+ T
cells from patient LAU 203 and LAU 241 (A) followed 3 rounds of in vitro stimulation with peptides PT178-187, PV454-463 and CT51-60 and were
sorted with multimers incorporating those peptides. Sorted populations were then stained either with the multimer incorporating the peptide
used for the stimulation or with multimer incorporating the Melan-A26-35 A27L peptide.  (B) Multimer
+ and multimer- cell fractions were isolated
by multimer-guided cell sorting (The respective populations are indicated with the bold letters a, b and c in (A) and (B)) and their efficiency of
peptide recognition was assessed in a CTL assay at a lymphocyte to target cell ratio of 10/1. The results are summarized in (C).
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In all cases, the autologous peptides were efficiently recognized by both, the A2/Melan-
A multimer+ and the A2/Melan-A multimer- cell fractions. Efficient cross-recognition with
the Melan-A26-35 A27L peptide, however, was only observed with the A2/Melan-A
multimer+ cell fraction.
Conclusions to chapter I
In this first chapter we used three Melan-A-specific CTL clones for the screening and
deconvolution of PS-SCL. We obtained clear screening profiles for two of the three
clones analyzed, and in both cases most of the amino acids composing the Melan-A26-35
epitope were identified as the peptide mixtures eliciting the strongest responses at the
corresponding positions. Amino acids other than the native ones were also identified
within the most active peptide mixtures. The combination of these active building blocks
resulted in the synthesis of analog peptides that were tested individually for activity in a
functional assay. We identified three enhanced analogs (N88-65: EVAGIGILTV, N88-81:
ALAGIGILTV and N88-89: ALTGIGILTV) and several agonist peptides (N88-56:
RVAGIGILPV, N88-74: RAAGIGILPV, N88-76: EVAGIGIHTV, N88-77: EVAGIGILPV),
one of which had 6 substituted amino acids (N88-96: ALTGWWWLTV) as compared to
the native sequence. Thus, these results indicate that this approach not only allows the
identification of the native sequence, but also may lead to the identification of enhanced
analogs and of agonist peptides sharing little or no sequence homology at all that are
fully cross-reactive with the native peptide, simply by combining the amino acids defined
in the most active building blocks of the PS-SCL. Furthermore, we have demonstrated
that among the identified analogs, the fully cross-reactive peptide N88-96
(ALTGWWWLTV) sharing little sequence homology, and the enhanced analog N88-81
(ALAGIGILTV) were immunogenic and able to stimulate the expansion of Melan-A-
specific CTL precursors.
The three selected Melan-A-specific CTL clones recognized differently the PS-SCL
tested. This implies that the three different TCR involved in the recognition of the native
Melan-A26-35 peptide must interact with the pMHC complex differently, having each a
given preference for certain amino acids at the TCR contact positions. Thus, there is a
different extent of degeneracy of peptide recognition for each clone studied. This was
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also implied by the results obtained from the PS-SCL-based biometric database
analysis. We could even suggest that the recognition of the native peptide by clone LAU
203/1.5 is more degenerate than by clone LAU 203/17. Indeed, more potential
stimulatory peptides having higher stimulatory scores than that of the native peptide
were retrieved when the matrix generated with the screening results of clone LAU
203/1.5 was used for the analysis, suggesting that the interaction of this particular TCR
with pMHC complexes is more permissive. The fact that a higher degree of cross-
recognition was generally observed with Melan-A-monospecific CTL lines than with CTL
clones supports the above mentioned idea of variable extent of degeneracy for
individual TCR. Indeed, this augmented cross-recognition could be the consequence of
the combined activity of numerous clonal populations present in the CTL lines that
account for their total reactivity.
In general the results presented in this first chapter encourage the use of PS-SCL to
study the interactions of particular TCR with different peptides associated to different
HLA-restricting molecules, as well as the importance of individual amino acids to peptide
recognition. Two different strategies for the analysis of the data obtained from PS-SCL
screening were used. The deconvolution strategy allowed the identification of analog
peptides with equivalent or increased activity for the clones analyzed. Nevertheless, the
information obtained with this strategy would not have allowed the identification of the
native sequence if a degenerative search based on sequence homology had been
performed since several amino acids not corresponding to the native ones were found to
be more active at certain positions. More importantly, since these peptides were
designed by combining the amino acids defined at the most active mixtures, is it likely
that their sequence does not necessarily correspond to a known protein. On the other
hand, the PS-SCL-based biometric analysis used enabled the identification of the native
epitope, as well as of cross-reactive ligands among millions of peptides derived from
naturally occurring proteins. The stimulatory potency of the retrieved cross-reactive
peptides, which was higher than the predicted for the Melan-a peptide, was directly
related to the number of amino acids at each position of the ligand that matched the
library prediction. The elevated number of naturally occurring peptides retrieved
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suggests that the autoantigen Melan-A, which originally generated the CTL clones used,
represents a suboptimal epitope, and that more efficient ligands, some of which are
derived from foreign proteins, can be identified through the use of PS-SCL.
In conclusion, this approach has a high predictive value for the identification of epitopes
recognized by tumor-reactive CTL. In addition, when combined to the recently
developed biometric analysis, the PS-SCL approach enables the retrieval of highly
cross-reactive and immunogenic peptide sequences from self-and pathogen origin in
public protein databases.
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Chapter II: Recognition of several PS-SCL by a single Tyrosinase-
specific CTL clone and PS-SCL-based biometric database analysis
The cross-recognition phenomenon was well illustrated in the precedent chapter, where
we observed an important activity at several diversity positions with amino acids other
than the native ones. Moreover, several cross-reactive peptides could be identified using
a deconvolution approach that consists in combining the defined amino acids within the
PS-SCL that induced a strong cytolytic response by the Melan-A-specific CTL clones
studied. Therefore, and in order to further implement this approach for the identification
of epitopes recognized by tumor-reactive CTL, we decided to compare the recognition of
four PS-SCL of various lengths having different C-termini by a CTL clone specific for the
melanocyte differentiation Ag Tyro377-369.
CD8+ tyrosinase-specific T cell clone LAU 156/34: fine specificity of antigen
recognition and tumor-reactivity
The biosynthesis of the pigment melanin by melanocytes is the basis of the human
pigmentary system. The genes involved in the formation, transport and distribution of the
specialized melanosome organelle in which melanin accumulates are called
pigmentation genes. Melanin production is stimulated by the peptide hormones α-MSH
or ACTH, and the critical step in melanin biogenesis is the hydroxylation of L-tyrosine to
3, 4-dihydroxyphenylalanine (DOPA) and the oxidation of DOPA to DOPAquinone by the
enzyme tyrosinase [178,179]. The pheomelanosome produces light red/yellowish
melanin, whereas the eumelanosome produces darker melanins. Tyrosinase, like other
melanosomal proteins, is a glycoprotein that is folded and correctly assembled in the ER
through interaction with the chaperone calnexin. Tyrosinase is then accumulated in the
trans Golgi network (TGN) and transported to the melanosomal compartment. Boon and
collaborators [85] identified two nonapeptides derived from the tyrosinase protein which
were recognized by CTL of an HLA-A*0201 melanoma patient, peptides Tyro1-9
MLLAVLYCL and Tyro369-377 YMNGTMSQV. Engelhard and collaborators performed
mass spectrometry analyses on peptides eluted from melanoma cells. They found that
the naturally occurring HLA-A*0201-associated peptide corresponding to peptide 369-
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377 differed at residue 371 due to the posttranslational modification of a genetically
encoded asparagine residue (N) to aspartic acid (D).
Figure II.1. Fine specificity of peptide recognition and tumor lysis by the tyrosinase-specific
CD8+ CTL clone LAU 156/34. TIL Me 336 were obtained from a cell suspension prepared from an
excised melanoma metastasis of patient LAU 156 as detailed in the Materials and Methods section. (A)
The contribution of single amino acid side chains to recognition by the TCR was tested by titrating single
alanine-substituted peptides at a Lymphocyte to target cell ratio (L/T) of 10:1 in a standard CTL assay. (B)
Tumor reactivity of clone LAU 156/34 was tested in a CTL assay as detailed in the Materials and Methods
section. Lysis of the tyrosinase+ (Me 275) and tyrosinase- (NA8-MEL) tumor cell lines was assessed at the
indicated lymphocyte to target (L/T) cell ratio in the absence or presence of exogenously added peptides
Tyro371N and Tyro371D at 1 µg/ml.
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These two peptides have the same affinity for the HLA-A*0201 molecule, but they are
recognized with different efficacy by tyrosinase-specific CTL [82]. The monoclonal
Tyro369-377 specific CTL clone LAU 156/34 was previously isolated in our laboratory by
limiting dilution cloning of TIL from melanoma patient LAU 156. Recognition of both
peptide variants by this clone was assayed in a CTL assay as shown in Figure II.1A. In
agreement with the previous study done with other tyrosinase-specific, melanoma-
reactive CTL clones [180], a concentration of 25 nM of the peptide variant Tyro369-377
YMDGTMSQV (Tyro371D hereafter) was required to achieve 50% maximal lysis. In
contrast, peptide variant Tyro369-377 YMNGTMSQV (Tyro371N hereafter) was recognized
300 times better, since the concentration required to achieve 50% maximal lysis was of
0.075 nM. A panel of peptides with single A substitutions (Ala scan) of all the amino
acids composing the sequence of peptide Tyro371D was available in the laboratory.
Therefore, and in order to get an insight into the fine specificity of Ag recognition, we
tested these the recognition of these Tyro371D analogs by clone LAU 156/34. It should be
noted, however, that the effect observed using these peptides can be considered only
as an approximation of the actual effect due to the preference of this clone for the
Tyro371N peptide. Indeed, a similar analysis with this second peptide would be more
appropriate. Peptide recognition was completely abolished after substitution of residues
Y1, N3, G4 and T5 with A, indicating that these residues are essential for T lymphocyte
antigen recognition. Substitution of residues S7 and Q8 with A did not significantly affect
T lymphocyte recognition. Finally, we observed a slight decrease in peptide recognition
(up to 10 fold) after the substitution of residues M2, M6 and V9 with A. Tumor
recognition by clone LAU 156/34 was assessed in a CTL assay at different lymphocyte
to target cell ratios as shown in Figure II.1B. Clone LAU 156/34 was able to efficiently
kill the melanoma cell line Me 275, expressing the correct HLA restricting molecule and
tyrosinase, both in the presence and absence of exogenously added peptide. In
contrast, the melanoma cell line NA8-MEL, which expresses HLA-A*0201 but not
tyrosinase, was only lysed in the presence of exogenously added tyrosinase peptide.
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Library Representation Code 1 2 3 4 5 6 7 8 9 10
9-PS-SCL-NH2 PCL 97-3
Max %Specific lysisa 33 19 54 72 46 20 25 29 39
aa in most active mixtures Y Q N G T V F L V
M S S W T I
L F P P L
Y V A
I T
S
Q
G
9-PS-SCL-COOH TPI 921
Max %Specific lysisa 84 59 77 85 45 38 32 52 66
aa in most active mixtures Y I N G T W Y P
M G C S P L V
Q V D W Q
M H T S
Y E M I
S L G
L S
V W
H Y
N Q
T D
10-PS-SCL-NH2 DCR 207
Max %Specific lysisa 81 40 100 100 83 84 85 40 36 34
aa in most active mixtures Y Q N G G W W L V W
I M H S T T P W L V
L C N F F F A I I
I Y C P H C I C
Y E W G
C L
H
10-PS-SCL-COOH TPI 1210
Max %Specific lysisa 37 44 26 35 30 14 18 20 31 19
aa in most active mixtures Y Y I C G P M I N
Q L Y N H N F Q I
S E N L Y L G V
P V P S C P M
N N C G Y
R M S I F
F Q V H
M M R
W M
H
I
aMaximal %specific lysis of each position.
Amino acid corresponding to the native peptide Tyro371N YMNGTMSQV.
Lecture of the amino acid corresponding to the native peptide Tyro371N YMNGTMSQV
according to a frame shift of 1 amino acid.
Positions
Table II.1. Summary of the results obtained for the four libraries
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Recognition of PS-SCL by clone LAU 156/34
Four different PS-SCL were selected for this study, two nonapeptide and two
decapeptide libraries with amidated or free C-termini accordingly. They were all tested
for recognition by clone LAU 156/34 in a CTL assay. Table II.1 summarizes the results
obtained for all four libraries.
Figure II.2 describes the results of the analyses performed with the two nonapeptide
PS-SCL. The screening of the C-terminal amidated nonapeptide library (9-PS-SCL-NH2;
PCL 97-3), is shown in Figure II.2A. Remarkably, the mixtures defined with the native
amino acid in several positions (Y1, N3, G4, T5 and V9) elicited the highest responses.
It is of note that the high levels of specific lysis observed at position 3 for the peptide
mixture defined with N is in complete agreement with the preference of clone LAU
156/34 for the peptide variant Tyro371N, as previously shown in Figure II.1A. At position
2, the most active mixtures were defined with aliphatic hydrophobic (L, I, V) or neutral
(Q) amino acids, in good agreement with the notion that this position is an anchor
position for HLA-A*0201. The peptide mixture defined with the native amino acid M was
among the ones eliciting good responses, nevertheless, the overall activity for this
position, and for all mixtures was rather low. At positions 6 and 8 the mixtures defined
with hydrophobic amino acids (F, I, L, V) where the most active ones, although lower
levels of lysis were obtained, as compared to other positions, with all the mixtures,
including the ones containing the native amino acids. Position 7 reveals the strongest
responses with the aromatic amino acids F and W, besides P. In position 9 again, we
find the highest responses with mixtures defined with aliphatic amino acids known as
anchors for HLA-A*0201, namely I, L and the native amino acid V.
The screening of the free C-terminal nonapeptide library (9-PS-SCL-COOH; TPI 921),
shown in Figure II.2B, revealed that significantly higher levels of specific lysis were
obtained in all positions, suggesting that there is a much higher number of active
sequences in this PS-SCL as compared to 9-PS-SCL-NH2.
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Figure II.2. Recognition of 9-PS-SCL by clone LAU 156/34. Recognition of two 9-PS-SCL [(A) C-terminal amide (PCL 97-3) and (B) C-
terminal free (TPI 921)] was assessed in a CTL assay as detailed in the Materials and Methods section. For each panel, the Y axes represent
the level of specific lysis obtained in the presence of individual peptide mixtures, and the X axes represent one of the 20 natural amino acids
defined at the given position. Amino acids are named according to the single-letter code. Open bars in panels represent amino acids
corresponding to the Tyro369-377 sequence.
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Figure II.3. Recognition of 10-PS-SCL by clone LAU 156/34. Recognition of two 10-PS-SCL [(A) C-terminal amide (DCR 207) and (B) C-
terminal free (TPI 1210)] was assessed as in Figure II.2. Open bars in panels represent amino acids corresponding to the Tyro369-377 sequence.
Striped bars in panels represent amino acids corresponding to the Tyro369-377 sequence read in the next adjacent position.
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The only native amino acids that could be identified as the mixtures eliciting the
strongest responses in this case were Y1 and G4, although M2, N3, T5 and V9 were
found among the most active defined mixtures at the corresponding positions. In Figure
II.3 we summarize the screening results of the two decapeptide PS-SCL by clone LAU
156/34. In the case of the amidated C-terminal decapeptide (10-PS-SCL-NH2; DCR 207,
Figure II.3A). This screening profile was very similar to the one obtained with 9-PS-
SCL-NH2 (Figure II.2A). The native amino acids Y1, N3 and G4 were identified at these
positions with the corresponding defined mixtures giving the strongest response. Here
again, hydrophobic aliphatic amino acids were among the most active mixtures in the
anchor positions 2 and 9. In position 5, the mixtures defined with G and with the native
amino acid T were the most active ones. The main difference between these results and
the screening profile of 9-PS-SCL-NH2 is that the mixtures defined with W at positions 6
and 7 elicited high levels of specific lysis. In this screening, some of the active defined
mixtures comprising the native Tyro369-377 sequence were also found to elicit a response
in the next adjacent position. This phenomenon has already been described in studies
done with CD4+ T lymphocytes specific for the myelin basic protein (MBP) peptide
[36,37]. The proposed explanation for this phenomenon was the so-called “sliding
effect”, where peptides bind to the MHC molecules in different registers influencing
therefore the way these peptides are recognized by the TCR.
Lastly, we screened a free C-terminal decapeptide library (10-PS-SCL-COOH, TPI
1210) as shown in Figure II.3B. Here again, and as observed for 9-PS-SCL-COOH
versus 9-PS-SCL-NH2 (Figure II.2B), higher levels of specific lysis were obtained in
general as compared to 10-PS-SCL-NH2 for all the mixtures. In the first reading frame
(positions 1 to 9), only Y1 was detected as the most active defined mixture. In the
second reading frame (positions 2 to 10), in contrast, the defined mixtures giving the
strongest activities in positions 2 (Y), 4 (N) and 5 (G), corresponded to the native
tyrosinase sequence. We could not establish a particular amino acid “pattern” for
positions 6 to 8. Indeed, there was no marked preference for a particular group of amino
acids (i. e. hydrophobic, charged or hydrophilic amino acids) at these positions. At
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positions 9 and 10 we found some anchor amino acids (I9, the native V9, I10, M10, T10
and V10) among the mixtures eliciting the highest levels of specific lysis.
Despite the differences in specific lysis levels observed between the four PS-SCL used,
a good correlation can be seen between the results obtained from the Ala scan and the
PS-SCL screenings summarized in Table II.1. Indeed, the amino acids whose
substitution with A completely abolished peptide recognition, namely Y1, N(D)3, G4 and
T5, were generally found to be among the most active peptide mixtures of all PS-SCL
analyzed.
PS-SCL-based biometric database analysis for the results of clone LAU 156/34
We used the PS-SCL-based biometric database analysis detailed in chapter I to analyze
the screening results of the four different libraries with clone LAU 156/34 [162]. The
ranking of peptide Tyro369-377 obtained from this analysis with the different PS-SCL is
summarized in Figure II.4A. The examples in Figures II.4B and C represent the score
distribution of more than 100 million peptides within the human GenPept database that
were scored based on the screening results of 9-PS-SCL-NH2 and 10-PS-SCL-NH2
respectively. It is of note with this score distribution that there is a relative small number
of retrieved peptides having the highest scores (between 10,000 and 60,000), and that
the native Tyro369-377 peptide was found among this group of peptides in all cases.
Indeed, when the PS-SCL-based biometric database analysis was performed with the
data of 9-PS-SCL-NH2, the native Tyro369-377 peptide was identified as the best ranking
sequence. In contrast, when the data of 10-PS-SCL-NH2 was used, Tyro369-377 ranked
only 29th. The ranking of the native Tyro369-377 peptide was lower, as compared to
amidated C-terminal libraries, when the PS-SCL-based biometric database analysis was
performed with the data obtained for the free C-terminal libraries. Indeed, Tyro369-377
ranked 10th when the data of 9-PS-SCL-COOH was used, and in the case of 10-PS-
SCL-COOH, we retrieved over 2000 sequences that had a higher score than the Tyro369-
377 peptide (Figure II.4A).
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Figure II.4. Score distribution and ranking of the native Tyro371D peptide in the human and TAA
databases. (A) Summary of the ranking obtained for the native Tyro371D peptide with the four PS-SCL
used. Score distribution of more than 100 million peptides within the human GenPept database scored
based on the results of the screening of (B) 9-PS-SCL-NH2 and (C) 10-PS-SCL-NH2.
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The main conclusion that can be thrown from these analyses is that the accuracy of the
scores attributed to the naturally occurring peptides on databases will depend on the
profile of the PS-SCL screening. In other words, profiles with a marked differentiation
between active and non-active mixtures will generate accurate matrices. Indeed, the
best profile in our case was obtained with 9-PS-SCL-NH2 (Figure II.2A), where active
amino acids are clearly separated in most of the diversity positions, and consequently,
the matrix generated with this data allowed the identification of tyrosinase as the highest
ranking protein.
Identification of a decapeptide analog that fully cross-reacts with the peptide
variant Tyrosinase371N
We investigated the length requirements for tyrosinase peptide recognition by clone LAU
156/34 in a CTL assay using the native Tyro369-377 peptide and a decapeptide analogue
to which an amino acid was added at the C-terminus according to the tyrosinase coding
sequence (Tyro369-378/371N, YMNGTMSQVQ). The experiment illustrated in Figure II.5
demonstrates that the decapeptide Tyro369-378/371N was recognized by the CTL clone, but
this recognition was one hundred times less efficient when compared to the recognition
of the native Tyro369-377 peptide. Therefore, and considering that the native decapeptide
is present within the mixtures only at subfemtomolar concentrations, it is not very clear
why clone LAU 156/34 was able to recognize the 10-PS-SCL. There are two possible
explanations to this: i) the presence of sequences that fully cross-react with the native
Tyro369-377 peptide within the decapeptide mixtures, or ii) the presence of nonapeptides
within the decapeptide mixtures derived by cleavage of COOH-terminal residues of
decapeptides in the PS-SCL by proteases present in the culture medium (serum
proteases) during the experimental period [181]. Nevertheless, and taking into
consideration that peptides are supposed to be protected from trimming by the C-
terminal amidation, the second proposal would be applicable only to the 10-PS-SCL-
COOH, and not to the 10-PS-SCL-NH2. Therefore, the most suitable explanation for the
recognition of PS-SCL seems to be the presence of cross-reactive decapeptides. Based
on the results obtained from the screening of 10-PS-SCL-NH2, we synthesized and
tested nona- and decapeptide analogs containing W at positions 6 and 7. The
nonapeptide analog Tyro371N M374W, S375W was recognized 10 times more efficiently
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than nonapeptide Tyro371N. The most striking results were obtained with the decapeptide
analog Tyro369-378/371N M374W, S375W, which not only exhibited an improved
recognition as compared to the native decapeptide Tyro369-378/371N, but was also
recognized as efficiently as the native nonapeptide Tyro371N. It is important to note that
the hierarchy in peptide recognition was not altered when amidated C-terminal or free C-
terminal peptides were used, and that in general free C-terminal peptides were more
efficiently recognized than their amidated C-terminal counterparts (at least ten times
better). These results confirm the presence of cross-reactive peptides within the 10-PS-
SCL including the analog Tyro369-378/371N.
Figure II.5. Recognition of a cross-reactive decapeptide analog by clone LAU 156/34. The
recognition of Tyro369-377, Tyro369-378 and their analogs including W at positions 6 and 7 by clone LAU
156/34 was tested in a CTL assay as detailed in the Materials and Methods section. (A) Lysis of T2 cells
was assessed at a lymphocyte to target cell ratio (L/T) of 10:1 in the presence of serial dilutions of the
indicated C-terminally amidated peptides. (B) Lysis of T2 cells was assessed as in (A) in the presence of
serial dilutions of the indicated C-terminal free peptides.
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Conclusions to chapter II
The screening of different PS-SCL of varying length and having different C-terminus with
the same CTL clone and the subsequent PS-SCL-based biometric database analysis
enabled us to compare the results obtained so as to evaluate the potential of this
approach. Our results speak again in favor of the high predictive value of the positional
scanning approach in conjunction with the mathematical algorithm used. Indeed, by
combining these two methodologies, Tyro369-377 was retrieved as the stimulatory peptide
having the highest score when the matrix generated with the screening results of 9-PS-
SCL-NH2 was used. In contrast, when the matrix incorporating the results obtained with
10-PS-SCL-COOH was used, more than 2000 peptides were predicted to be better
stimulators than the native peptide Tyro369-377. Therefore, these results also clearly
indicate that the quality of the data generated for the identification of the peptide ligand
significantly varies for different PS-SCL and CTL clones.
The peptides contained in two of the libraries used had amidated C-termini. [146] The
overall effect of carboxyl-terminal amidation on the recognition of PS-SCL is difficult to
evaluate. Indeed, Brinckerhoff et al. [181] recently demonstrated that C-terminal
amidation of the Melan-A peptide protects it from enzymatic degradation and
significantly increases the peptide half-life in a serum-containing milieu. It seems evident
that for the single peptides present at subfemtomolar concentration in the PS-SCL
mixtures, protection from enzymatic degradation could be critical to ensure their
recognition. They also described that the C-terminally amidated Melan-A peptide has a
decreased MHC-binding capacity. This could explain the reduced number of active
peptides in the PS-SCL mixtures tested, and this is also in agreement with the fact that
free C-terminal PS-SCL where more active than PS-SCL with amidated C-termini. These
observations may partially explain the fact that a higher number of mixtures were found
to be clearly active when free C-terminal PS-SCL were used. In addition, the presence
of serum proteases in the milieu used during the experimental procedures could have
produced a significant trimming of deca- to nonapeptides. This would support the high
responses observed for one same amino acids at two adjacent positions because of the
peptide binding to the HLA molecule in two different registers [36,37]. Indeed, this
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“sliding effect” was more pronounced in the case of 10-PS-SCL-COOH than of 10-PS-
SCL-NH2.
Nevertheless, the recognition of 10-PS-SCL by the tumor-reactive clone used could not
be solely explained by this trimming of peptides during the experiment. In fact, the
presence in the decapeptide PS-SCL of individual decapeptide analogs that are fully
cross-reactive with the native nonapeptide sequence was demonstrated with the analog
incorporating W at positions 6 and 7.
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Chapter III: Recognition of PS-SCL by the tumor-reactive, TILN-derived
clone of unknown specificity LAU 156/4D7
In the preceding two chapters, the recognition of PS-SCL by CTL clones specific for two
different melanocyte-differentiation Ags was analyzed and in both cases we were able to
ascertain the identity of the native epitopes in the PS-SCL screening profile. The next
step towards the validation of this approach for the identification of new TAA recognized
by T lymphocytes was to test PS-SCL by CTL clones of unknown specificity. TILN are
an excellent source of tumor-reactive CTL, therefore, we used a CD8+ CTL clone (clone
LAU 50/4D7) derived by limiting dilution cloning from TILN of melanoma patient LAU 50
and for which the specificity could not be determined under other conditions. Indeed, we
performed a CTL assay and an ELISPOT assay and clone LAU 50/4D7 failed to
recognize the 12 HLA-A*0201 restricted epitopes selected which are known to be
recognized by melanoma specific CTL. (Melan-A26-35 and 27-35, Tyro1-9, Tyro369-377,
gp100.1154-162, gp100.2209-217, gp100.3280-288, gp100.4457-466, gp100.5476-485, NY-ESO-1157-
165, CAMEL1-11, MAGE-A10256-264, MAGE-A4230-239, Figure III.1A). The TILN of this
melanoma patient LAU 50 have previously been used in our laboratory to derive CTL
clones specific for the TAA NY-ESO-1157-165 [182] and Camel1-11 [183]. The clonality of
this population was tested by flow cytometry using a panel of mAb directed against the β
chain variable region (Vβ) and the results in Figure III.1B demonstrate that it expresses
Vβ7. Clone LAU 50/4D7 was able to specifically lyse the autologous melanoma cell line
Me 275 (Figure III.2A), but it failed to lyse the T2 cell line. The observed tumor-specific
lysis was proven to be HLA-A*0201 restricted, since as shown in Figure III.2B, an anti
HLA-A*0201 mAb completely inhibited this recognition in a dose-dependent manner.
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Figure III.1 Testing clone LAU 50/4D7 for recognition of known TAA and for clonality. (A)
Recognition of a panel of 12 HLA-A*0201 restricted epitopes known to be recognized by melanoma
specific CTL by clone LAU 50/4D7 was assayed in a functional CTL assay as detailed in the Materials and
Methods section at a lymphocyte to target cell ratio (L/T) of 10:1. Synthetic peptides were used at a
concentration of 1 µM. (B) Clonality of the tumor-reactive population was confirmed by flow cytometry
using mAb against several Vβ regions.
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Figure III.2. CTL clone LAU 50/4D7 specifically lyses the autologous melanoma cell line Me 275
in an HLA-A*0201 restricted manner. (A) Clone LAU 50/4D7 was tested for tumor recognition in a CTL
assay as detailed in the Materials and Methods section at the indicated lymphocyte to target cell ratios.
(B) Specific lysis was assessed at a lymphocyte to target cell ratio (L/T) of 10:1 on Me 275 cells alone or
in the presence of different dilutions of the anti-HLA-A*0201 mAb CR11-351.
Recognition of PS-SCL and deduced ligands by CTL clone LAU 50/4D7
The broad analysis done in chapter II with several PS-SCL demonstrated that more
straightforward results could be obtained from the screening of 9-PS-SCL. We also
observed that PS-SCL bearing free C-terminal peptides seem to allow the identification
of a higher number of active mixtures at most of the positions. Therefore, and
considering that most of the peptides that are optimally recognized by CTL are
nonapeptides, we decided to test the recognition of a 9-PS-SCL-COOH (TPI 921) by
clone LAU 50/4D7 (Figure III.3) [151]. We obtained a very clear pattern of activity from
this screening. There was no marked preference for any particular amino acid in
positions 1, 3 and 9. However for P3, and despite the rather low levels of specific lysis
obtained with mixtures defined with polar or small amino acids (i.e. S, G and D), they still
elicited higher responses when compared to the remaining defined mixtures.
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Figure III.3. Recognition of a nonapeptide PS-SCL by clone LAU 50/4D7. Recognition of the C-
terminal PS-SCL was assayed in a CTL assay as detailed in the Materials and Methods section. Several
experiments were performed to determine the reproducibility, results obtained for a representative
experiment are shown. Each panel represents the level of specific lysis (Y-axes) obtained in the presence
of individual mixtures, each containing one of the 20 natural amino acids at the defined position (X-axes).
The amino acids are designated by single letter code. Data represent the mean of two independent
experiments giving comparable results.
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The mixture defined with the hydrophobic amino acid A gave the strongest response in
position 2. Three mixtures showed clear activity in position 4. The one defined with P
was the most active one, followed by the ones defined with G and E. A clear peak of
activity was obtained in position 5 with the peptide mixture defined with K. The mixtures
defined with I and V, both aliphatic and hydrophobic amino acids, were the ones eliciting
the strongest activities in position 6. In positions 7 and 8, strong activities were obtained
only with the mixtures defined with F and Y, respectively, although in this case the level
of specific lysis was not as high as in position 5.
Figure III.4A shows a compilation of these results. Based on them, a set of individual
peptides was designed according to the criteria also detailed in Figure III.4A. Shortly,
the deduced peptides are composed of the amino acids defined in all mixtures eliciting
the strongest responses in the functional assay, but only those amino acids eliciting a
specific lysis higher than 10% were taken in consideration. In positions 1, 3 and 9,
where all mixtures induced responses producing less than 10% specific lysis, a small
and neutral amino acid (A) was selected. For positions 2, 5, 7 and 8 the selection was
rather easy since in all of them only one defined peptide mixture induced responses with
specific lysis higher than 10%, namely A2, K5, F7 and Y8. In some cases, however,
amino acids giving % specific lysis higher than the average lysis of all mixtures plus one
or two times the standard deviation (SD) were also selected (A1, D and G3, G and E4
and V6). A list of the deduced peptides is given in Figure III.4D. Recognition of these
peptides by clone LAU 50/4D7 was tested in a titration experiment. The results obtained
for some of the deduced peptides are shown in Figure III.4B, yet in general there was
an efficient recognition of all peptides tested by the CTL clone. The most active peptide
was AAAPKIFYA (apparent avidity of ~ 1pM), and therefore we decided to compare the
antigenicity of the other deduced peptides relative to this optimal sequence by
calculating the EC50 of peptide AAAPKIFYA and dividing it by the EC50 of the additional
test peptides. The deduced peptides were all recognized less efficiently than the optimal
peptide AAAPKIFYA, but the recognition of the deduced peptides remained a “high
avidity” recognition, since clone LAU50/4D7 recognized these peptides with apparent
avidities ranging from 10 to 100 pM.
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Figure III.4. Recognition of PS-SCL deduced peptides by clone LAU 50/4D7. (A) Compilation of the
data obtained from the screening in Figure III.2. Selected amino acids and their corresponding thresholds
are shown. (B) Relative antigenic activity of a selected panel of PS-SCL deduced peptides (to be
identified with the symbols in (D)) was assessed a CTL assay at a lymphocyte to target cell ratio (L/T) of
10:1 in the presence of serial dilutions of each peptide. (C) Relative peptide binding to HLA-A*0201 of the
selected deduced peptides was assessed in a functional competition assay as detailed in the Materials
and Methods section. (D) Compilation of the data obtained for all deduced peptides. Relative antigenic
activity is expressed as compared to the peptide most efficiently recognized (AAAPKIFYA, 50% maximal
lysis at 20 pM). Competitor activity (relative binding) is expressed relative to peptide AAAPKIFYA (50%
inhibition at 20 nM). The competitor activity of this peptide was similar to that of peptide FluMA58-66
which has been shown to bind to HLA-A*0201 with high affinity (50% inhibition at 30 nM).
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We then determined the relative ability (again, relative to the optimal peptide
AAAPKIFYA) of the deduced peptides to bind to HLA-A*0201 in a competition assay as
shown in Figure III.4C and summarized in Figure III.4D. All of the deduced peptides,
including the optimal sequence, were able to bind efficiently to the HLA molecule. In
order to determine the contribution of individual amino acids in the deduced peptides to
recognition by clone LAU 50/4D7 and binding to HLA-A*0201, five additional peptides
were synthesized where the amino acids (other than A) were replaced with A (Ala scan).
Regarding the HLA-A*0201 binding capacity, none of the substitutions showed a drastic
reduction in peptide binding, all of them bound to HLA-A*0201 as efficiently as
AAAPKIFYA, or around ten times less efficiently. Peptide recognition by clone LAU
50/4D7, in contrast, was rather sensitive to these modifications. We observed a
moderate reduction in recognition when amino acids at positions 4 and 6 (P4 and I6)
were substituted with A, whereas substitution of K5, F7 and Y8 strongly diminished or
even abolished peptide recognition (Figure III.4B). It is important to note that the
introduction of anchor residues at positions 2 and 9 (i.e. amino acids L, M and V) did not
significantly alter either peptide binding to HLA-A*0201 or recognition by clone LAU
50/4D7.
Identification of a shared antigen as the native epitope
The PS-SCL screening allowed the identification of several peptides that were very
efficiently recognized by clone LAU 50/4D7. When only the level of specific lysis
obtained from the screening was considered, these peptides had a “core” motif
(XAXPKIFYA). This motif turned out to be very similar to the SSX-241-49 (KASEKIFYV)
epitope recently identified in our laboratory using an approach that combines an in vitro
proteasomal degradation assay with the prediction of putative HLA-A*0201 binding
sequences [119]. Indeed, five amino acids of the most active mixtures (A2, K5, I6, F7,
and Y8) corresponded entirely to the SSX-241-49 sequence. It is of note, however, that
the defined amino acid of the most active mixture at position 4 was P, followed by G and
the native E. This observation was compatible with our previous data showing that not
all the amino acids eliciting the strongest responses at a defined position of a mixture
correspond to the amino acid present at that position in the native sequence
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[37,152,161]. Recognition of peptide SSX-241-49 by clone LAU 50/4D7 was confirmed in
a CTL assay (Figure III.5A). Remarkably, the efficiency of recognition of the native
sequence was in the same range of that of the optimal sequence identified by PS-SCL.
The TAA synovial sarcoma X (SSX)-2 was identified as HOM-MEL-40 in 1995 by Sahin
et al. [109] using the SEREX (serological identification of Ags by recombinant
expression cloning) approach. The sequence of this Ag was identical to the sequence of
the gene SSX-2 [143], which maps to the chromosome X and is involved in the
chromosomal translocation t(X;18)(p11.2;q11.2) found in 70% of synovial sarcomas
[184]. Expression analysis performed by Northern blot and real time polymerase chain
reaction (RT-PCR) demonstrated the presence of HOM-MEL-40 transcripts in a
significant proportion of human melanomas (50%), hepatocarcinomas (30%), breast
carcinomas (20%) colorectal cancers (27%), head and neck cancers (75%) and
lymphomas (36%) among other tumor types [143,185]. In addition, Tüerci et al. [143]
also demonstrated that, in contrast to healthy individuals, 10% of the melanoma patients
studied had high-titer antibodies to SSX-2. As this Ag is expressed by several tumors of
different histological types but not by normal tissues, except for the testis, it has been
classified in the group of shared or cancer-testis (CT) Ags. CTL specific responses to
this kind of Ags can be considered tumor specific since the only tissue that expresses
SSX-2, the testis, is an immunoprivileged site that does not express surface HLA
molecules.
Considering the points addressed above, it is clear that SSX-2 is an interesting
candidate for the development of a peptide-based tumor vaccine. SSX-2 belongs to a
gene family consisting of at least 5 genes sharing strong sequence homology, with
nucleotide homology ranging from 89 to 95% and amino acid homology ranging from 77
to 91%. Highest homology was seen between SSX-2 and SSX-3, and SSX-1 appeared
to be the most different from the family members. The five SSX genes identified showed
testicular expression, and all but SSX-3 were found to be expressed in tumors too
[185,186].
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Figure III.5. Score distribution and ranking of retrieved peptides in human and tumor associated antigen (TAA) protein databases.
(A) Relative antigenicity of SSX-241-49 native sequence and analogs (symbols are given in (B)) was assessed on 51Cr labeled T2 cells at
a lymphocyte to target cell ratio of 10:1 in the presence of serial dilutions of each peptide. (B) Compilation of the data obtained for the SSX-
241-49 homologous regions including score, rank and relative activity (relative to the optimal peptide AAAPKIFYA).  (C) Specific lysis of four
melanoma cell lines was assessed in a CTL assay at a lymphocyte to target cell ratio of 10:1. HLA-A*0201 expression was assessed by
flow cytometry analysis using anti-HLA-A*0201 mAb. SSX-2 expression was assessed by RT-PCR (Ayyoub, M. et al. 2002). (D) Data from
PS-SCL screening were used to generate a matrix (as detailed in the Materials and Methods section) that was used to score all overlapping
9-mers in the GenPept database restricted to either human or tumor associated antigen (TAA) sequences. The X-axis represents the score
and the Y-axis represents the number of peptides.
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Because of the high homology of the SSX family members, we decided to investigate
the potential cross-reactivity of SSX-2, the optimal peptide recognized by clone LAU
50/4D7 and the SSX-1, SSX-3, SSX-4 and SSX-5 nonapeptides corresponding to the
SSX-241-49 homologous region. As shown in Figures III.5A and B, and in spite of the
high sequence homology, none of the SSX-2 homologous sequences was efficiently
recognized by clone LAU 50/4D7. The lack of recognition of the SSX-241-49 homologous
regions can be explained by the amino acid substitution at position 7. In fact, this
position has previously been proven to be essential for peptide recognition by clone LAU
50/4D7 since the substitution of F with A completely abolished it (Figure III.4D). Indeed,
the aromatic and hydrophobic amino acid F is replaced by the small and hydrophilic
amino acid S in SSX-1. In SSX-3, SSX-4 and SSX-5 we find the aliphatic amino acids V
and I at this position. Because of this lack of recognition, efforts should be made to find
other CTL epitopes that could be used in cancer therapy for SSX-1, SSX-4 and SSX-5,
which are expressed in a number of tumors of different histological types as SSX-2
[185].
SSX-2 expression of a panel of melanoma cell lines was previously determined in our
laboratory by RT-PCR [119]. Based on these results, on the recognition of SSX-241-49 by
clone LAU 50/4D7 and on the similarity of the deduced optimal sequence to the SSX-
241-49 epitope, we expanded our analysis on tumor recognition by this clone with
additional melanoma cell lines that expressed either SSX-2, HLA-A*0201, or both as
illustrated in Figure III.5C. As expected, besides the autologous melanoma cell line Me
275 previously shown to be lysed by this clone (Figure III.2A), the SSX-2+ HLA-A*0201+
melanoma cell line SK-MEL-37 was also efficiently lysed. In contrast, no significant lysis
was obtained when the melanoma cell lines Me 260, which expresses SSX-2 but not
HLA-A*0201, or SK-MEL-23, which is HLA-A*0201+ but SSX-2-, were used as target
cells.
PS-SCL-based biometric database analysis and search in protein databases
We generated a scoring matrix with the data obtained from the screening of 9-PS-SCL-
COOH with clone LAU 50/4D7 and performed the PS-SCL-based biometric database
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analysis previously described (chapter I and [163]) to search for stimulatory peptides in
the human database GenPept. Figure III.5D shows the scoring distribution of the
retrieved peptides, which were ranked according to their potential stimulatory score. By
the time the PS-SCL-based biometric database analysis was performed, 49,765 human
proteins were annotated in this database, which represents close to 16 million
nonapeptides, and the sequence corresponding to SSX-241-49 ranked 27
th. The search
within the GenPept database was then restricted to known proteins associated with
human tumors. Thus, a “TAA-database”, which included 1397 cancer-related proteins,
was used to search again for stimulatory peptides. This analysis resulted in the retrieval
of 400,271 nonapeptides, from which SSX-241-49 was the nonapeptide with the second
highest score. The scores of the SSX-241-49 peptide and the other SSX-241-49
homologous regions are shown in Figure III.5B. Interestingly, and in agreement with the
lack of recognition of these sequences by clone LAU 50/4D7, the SSX-241-49
homologous regions had only very poor stimulatory scores. These results emphasize
the importance of the PS-SCL-based biometric database analysis presented here, which
is based on experimental data gathered from functional assays and which takes into
consideration the independent contribution of each amino acid to the overall peptide
recognition. This is still stressed by the fact that SSX-5, which is the only SSX-241-49
homologous region that was recognized by clone LAU 50/4D7, although poorly as
compared to the optimal peptide and the native SSX-241-49 sequence, had the highest
score of all the SSX-241-49 homologous regions. Therefore, we can assert that peptides
sharing sequence homology, but which obtain a low score based on their amino acid
composition, are not necessarily cross-reactive. In contrast, peptides with no apparent
sequence homology, but with equal stimulatory scores, have good chances of being
cross-reactive sequences.
Conclusions to chapter III
In this third chapter, the screening of PS-SCL allowed the identification of the antigen
recognized by a human tumor-reactive clone of unknown specificity, clone LAU 50/4D7.
After a deconvolution step, a limited number of peptides incorporating the building
blocks of the most active mixtures at each diversity position were synthesized and
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tested in a CTL assay. We were able to identity several peptide ligands recognized by
the CTL clone with high efficiency (EC50 in the picomolar range). Furthermore, the use of
a recently developed PS-SCL-based biometric database analysis enabled us to retrieve
the native antigenic peptide in public protein databases. The SSX-241-49 peptide, whose
sequence is highly reminiscent to that of the deduced peptides from the PS-SCL
screening, was among the peptides with the highest stimulatory scores.
The peptide that was identified as the optimal sequence recognized by clone LAU
50/4D7 (AAAPKIFYA) had 5 amino acids (A2, K5, I6, F7, Y8) that were also found in the
native SSX-241-49 peptide (KASEKIFYV) at the corresponding positions. Consistently
with this finding, substitution of K1, S3 or V9 with A in the native sequence did not
significantly affect peptide recognition (data not shown). The 5 amino acids mentioned
above were shown to be essential for recognition of both the AAAPKIFYA and
KASEKIFYV peptides, suggesting that they are the amino acids implicated in the
interaction with the TCR at the contact interface. Indeed, their substitution with A
affected peptide recognition, and in some of the cases even dramatically. P4, whose
substitution with A provoked only a 10 fold decrease in peptide recognition, was an
exception. For this diversity position, the amino acid defined in the most active mixture
was very different from the one present in the native sequence at the corresponding
position (E, which was the third most active mixture). In agreement with these results,
the substitution P44E in the native sequence did not affect peptide recognition (data not
shown). This observation supports previous findings indicating that not all the amino
acids defined at the most active mixtures for a given position correspond to the amino
acid present at that same position in the native sequence [37,152,161].
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Discussion
In the last few years, one of the major challenges for cancer immunologists has been
the identification and characterization of tumor-derived Ags recognized by tumor-
reactive CTL that could represent relevant targets for the development of tumor
vaccines. Several strategies have been developed so far, but they are not easily
applicable, mostly time consuming and labor intense. The genetic approach implies the
generation first of a cDNA library from tumor cells, which are rather difficult to grow in
vitro, for the identification of genes encoding for relevant proteins. These proteins have
then to be fragmented to find the epitopes, requiring several laborious experimental
steps. The strategy based on the purification of peptides eluted from MHC molecules of
tumor cells requires even larger amounts of tumor cells. In addition, this approach can
only be applied in specialized laboratories that have the expensive and highly technical
equipment necessary to perform the purification steps and the sequencing of the eluted
peptides. This technique, however, has been proven to be very attractive for the
determination and characterization of immunodominant epitopes. Indeed, Skipper et al.
[82] showed that the peptide Tyro369-377, eluted from tumor cells, differed from the
predicted sequence due to a posttranslational modification at residue 371. They also
demonstrated [187] that the Melan-A27-35 nonapeptide was naturally processed by tumor
cells and presented in association to HLA-A*0201. The identification of peptides
recognized by T lymphocytes based on the development of MHC-peptide binding
models [50,188-191] is only applicable if the protein from which the predicted peptide is
derived is previously known. In addition, it has been described that the native sequences
recognized by “self-reactive” T lymphocytes are often weak binders to the MHC-
restricting molecules [21,172,192,193] which reduces the chances of identifying them
with this strategy. Moreover, Andersen et al. [194] found a poor correspondence
between predicted and experimental binding of peptides to MHC class I molecules using
predictive computer algorithms. The SEREX approach enables the identification of
proteins potentially bearing T lymphocyte epitopes, but this technique is limited by the
fact that Ab directed against the relevant proteins have to be produced by the patients.
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All these observations support the need to explore new approaches that are easily
applicable and accessible for the identification and/or characterization of TAA.
Validation of the use of PS-SCL as a novel approach for the identification of
epitopes
The use of PS-SCL has recently emerged as a practical and easily applicable approach
for the identification of peptides recognized by T lymphocytes and for the study of
degeneracy in antigen recognition. This approach, when compared to the numerous
methodologies developed so far, has the advantage of not requiring previous knowledge
of the protein from which the relevant peptide is derived. In addition, this approach can
be applied to all histological types of tumors if CTL reactive to that particular type of
tumor are available, and this regardless of the haplotype of the patients because
autologous cells (i.e. monocyte-derived DC) could be used as APC during the
experimental procedure. The only limitation to this technique is the amount of tumor-
reactive CTL needed for the screening of PS-SCL. It is important to note that T
lymphocyte populations bearing a unique TCR should be used when applying this
methodology (i.e. CTL clones). The use of cells bearing multiple receptors displaying
different fine specificities for the same antigen would render the interpretation of the data
generated from the PS-SCL screening extremely difficult.
The PS-SCL approach is based on the simultaneous screening of billions of peptides
contained in complex peptide mixtures that are in turn arranged in a positional scanning
format. As mentioned before, there is increasing evidence showing that recognition of
pMHC complexes by T lymphocytes is highly degenerate. Because of this, and because
of the fact that the concentration of individual peptides in the diversity mixtures
composing the PS-SCL is extremely low (between 10-15 and 10-16 M), it seems likely that
the activity detected in the PS-SCL screening is due to the simultaneous recognition of
several peptides in the mixture having in common only the amino acid at the defined
position. Consequently, the individual contribution of amino acids within a peptide to its
recognition can be analyzed by the screening of such libraries. The methodology also
allows dissecting the interaction of a particular TCR with the entire spectrum of potential
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peptides if the 20 natural amino acids are used for the synthesis of the PS-SCL. In order
to fully exploit the information obtained using this methodology to study and characterize
tumor-reactive CTL, we considered capital to explore its use with well-defined antigenic
systems. In this regard, and as a first step, we used three tumor-reactive CTL clones
specific for the melanocyte differentiation Ag Melan-A to screen two different (a nona-
and a decapeptide) PS-SCL. This analysis enabled us to identify most of the amino
acids composing the native Melan-A26-35 sequence among the most active peptide
mixtures of the 10-PS-SCL tested with clones LAU 203/1.5 and LAU 203/17. In contrast,
the screening of the 9-PS-SCL did not permit the identification of the native sequence
with none of the clones tested. This was especially intriguing for clone LAU 203/17,
considering that this clone was shown to recognize the nonapeptide Melan-A27-35 and
the decapeptide Melan-A26-35 with similar efficacy in a functional CTL assay (Figure
I.1A). Two sequences have been described for the TAA Melan-A as the native epitopes,
the nonapeptide Melan-A27-35, and the decapeptide Melan-A26-35. A study done by
Skipper et al. [187] demonstrated that the nonapeptide Melan-A27-35 is apparently the
only naturally processed and presented epitope, since it was the only one present
among the peptides eluted from HLA-A*0201 molecules of human melanoma cells.
Nevertheless, the decapeptide Melan-A26-35 has also been shown to be more
immunogenic than the nonapeptide [93] and the great majority of monospecific
polyclonal populations and CTL clones tested in our laboratory recognize the
decapeptide with increased avidity. This increased avidity may be the reason why we
were able to identify the native sequence using the 10-PS-SCL and not the 9-PS-SCL. It
should be noted that there was no significant recognition of either PS-SCL tested with
clone LAU 203/1.3. This may be due to the fact that both the native Melan-A nona- and
decapeptides were recognized with very low avidity by this CTL clone and that the
amidated counterparts were not recognized at all.
Because of the important differences in recognition of PS-SCL observed before, and to
further discern the use of this method, we then analyzed the recognition of four distinct
PS-SCL differing in length and C-terminus by a single tumor-reactive CTL clone specific
for the melanocyte differentiation Ag tyrosinase. We obtained significant levels of
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specific lysis with all the PS-SCL analyzed. However, we also observed that this
approach might not lead to the identification of tumor-derived antigenic sequences with
every CTL clone used. Indeed, we screened a PS-SCL with two other tyrosinase
specific CTL clones previously shown to recognize peptide Tyro371D with the same
apparent avidity [180] and data not shown), but they failed to show any significant
recognition of the PS-SCL (not more than 20% maximal lysis).
The results obtained from these analyses confirmed previous observations regarding the
recognition of PS-SCL by CD4+ T lymphocytes that could be extrapolated to CD8+ T
lymphocytes. Indeed, Hemmer et al. [36,37] documented the efficient recognition of a
given amino acid in a defined mixture in several adjacent positions and called this
phenomenon the sliding effect. They proposed that the active peptides bind in different
registers to the MHC molecule, resulting in the activity of adjacent peptide mixtures
defined with the same amino acid. Although the peptide binding grooves in MHC class I
molecules are less flexible, peptides could fit differently inside the MHC molecules under
our test conditions. This is particularly important considering that some of the libraries
tested were composed of free C-terminal peptides. Taking into consideration what has
recently been described by Brinckerhoff et al. [181] (i.e. the half-life of the Melan-A
peptide is significantly increased and the peptide itself is protected from enzymatic
degradation by C-terminal amidation), we could assume that the peptide mixtures of the
free C-terminal PS-SCL are composed of peptides of different lengths generated by
enzymatic degradation by the serum proteases during experimental procedure. In fact,
and speaking in favor of this peptide protection, we observed a more marked sliding
effect with the 10-PS-SCL-COOH than with the 10-PS-SCL-NH2.
Our data clearly indicates that the quality of the data generated for the identification of
the peptide ligand can significantly vary for different PS-PCL, most certainly because of
the particular degree of degeneracy of each CTL clone. Therefore, and based on the
results of this study, we suggest that 10- or 11-PS-SCL should be used only in cases
where no activity is detected wit 9-PS-SCL. If the screening reveals high levels of
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specific lysis with a large number of peptide mixtures, PS-SCL-NH2 should be preferred
to PS-SCL-COOH, since they seem to be less active.
Identification of active peptides within PS-SCL: deconvolution strategy
We have demonstrated that functional T lymphocyte responses can be elicited from CTL
specific for different melanocyte differentiation Ags with PS-SCL and that peptide
analogs can be designed based on the results obtained from the screening of such
libraries. For the deconvolution, the screening results are analyzed by rank ordering
each position by activity and the peptides resulting from all combinations of the defined
amino acids in the most active mixtures are synthesized. Several specificity studies
describe the efficient identification of mimic peptides through the systematic
deconvolution of the data obtained from PS-SCL. One of the first studies was performed
by Udaka et al. [35]. They identified peptides recognized by the alloreactive CTL clone
2C using a biased octapeptide PS-SCL where the known H-2Kb anchor residues were
defined. Given that this deconvolution strategy was based on known H-2Kb primary
anchors, an important number of active peptides that did not contain the allele-specific
motif were very probably missed. Another study led to the identification of peptides
recognized by a CD8+ CTL clone of unknown specificity generated by repeated
stimulation with a tumor cell line [195]. The combination of the amino acids at the few
positions defined with mixtures giving clear activities, together with the definition of
canonical anchors for HLA-A1 and HLA-A8, resulted in the identification of potential
epitopes. Three of these peptides were recognized by the CTL clone used for the PS-
SCL screening in the context of HLA-A8. However, comparison of the retrieved
sequences with proteins in databases failed to identify potential source proteins. This
was possibly due to the assumption that the selected active mixtures contained the
canonical MHC motif, which is probably not the case. Indeed, it could be hypothesized
that an important number of highly stimulatory sequences contained within the active
mixtures could have different residues at the MHC anchor positions. Judkowsky et al.
[155] applied a similar approach, in which no biased assumptions were made, to identify
and characterize mimics to the autoantigens involved in the development of diabetes in
mice. For this purpose, they designed less complex libraries where the defined amino
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acids were selected based on the screening of a complete PS-SCL where active
mixtures could be identified only in two positions. The resulting less complex peptide
mixtures, where each position was composed only of the amino acids defined in the
most active mixtures, showed an increase activity relative to the original mixtures from
the PS-SCL. In this way, several peptides able to cause diabetes in mice were identified.
The study done by Wilson et al. [159] with a pigeon cytochrome c (PCC)-specific CD4+
T lymphocyte clone and a 10-PS-SCL showed that several of the native amino acids
were within the most active mixtures at the corresponding positions in the 10 C-terminal
amino acids of the 17-mer PCC peptide, giving already an insight into the predictive
value of the PS-SCL approach. Here, the deconvolution strategy permitted the
identification of superagonist peptide epitopes able to induce an immunogenic response
in vivo against the native epitope.
We performed a systematic deconvolution strategy for the results obtained from the
screening of PS-SCL with two Melan-A-reactive CTL clones. The improved recognition
observed in some cases for several deduced single or multisubstituted peptides (i.e.
N88-56: RVAGIGILTV, N88-74: EVTGIGILTV, N88-77: EVAGIGILPV and N88-100:
ALWGIWWLTV, Figures I.3 and I.4) could be partially explained by an improved binding
to the restricting molecule HLA-A*0201 due to the introduction of the anchor residues V
and L at position 2. It is important to note that in our case, the anchor amino acids were
defined at the corresponding positions of the most active mixtures and not arbitrarily
introduced to improve peptide binding. Nevertheless, this improved binding may not be
the sole explanation to the enhanced recognition since other peptides having anchor
amino acids at position 2 were poorly or not recognized at all (i.e. N88-93:
ALTGWGILTV). In agreement with previous observations [37,152,161], we demonstrate
that not all the defined amino acids in the most active mixtures for a given position
correspond to the amino acids present at the same positions in the native sequence.
Generally speaking, this observation is also in agreement with previous studies showing
that native sequences are often suboptimally recognized by tumor-specific T
lymphocytes [36,172,192] and that they represent therefore suboptimal ligands. This
observation is encouraging for the identification of agonistic peptides of native
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sequences displaying increased antigenicity and immunogenicity with the PS-SCL
approach. Indeed, the “optimal” amino acids for each position of the enhanced antigenic
peptides for a given TCR can be identified by the response of the CTL bearing that
particular TCR to the sublibraries composing the PS-SCL. In addition, and importantly,
the negative impact on antigen recognition of amino acids that are not optimal at certain
positions is counterbalanced with the positive effect of optimal amino acids in other
positions, increasing in this way the number of possible stimulatory peptides for the
given TCR. Nevertheless, the fact that most active defined mixtures are not necessarily
the ones corresponding to the amino acids in the native epitopes has to be taken into
consideration when analyzing the data generated with PS-SCL.
Identification of cross-reactive peptides from various origins: PS-SCL-based
biometric database analysis
For the analysis of the complex data generated from PS-SCL screening, and in order to
search for potential stimulatory peptides within public protein databases, we used a
recently developed algorithm (PS-SCL-based biometric database analysis) [163]. This
methodology consists in the transformation of experimental lytic results into a scoring
matrix that represents the stimulatory potency of each amino acid at each position of a
putative peptide. The matrix is used to attribute a value to all amino acids composing
antigenic peptides based on the percentage of specific lysis values experimentally
obtained with the PS-SCL. In this way, the score of a candidate peptide is determined by
the sum of the values for all amino acids at each position. Similar studies based on motif
searches, where the amino acids are derived from single substitution analog studies
[196] or from the most active mixtures of a PS-SCL [36], have allowed the retrieval of a
limited number of peptides from databases. In contrast to these search tools based on
binding motifs, the PS-SCL-based biometric database analysis strategy utilizes the
information generated by screening one specific TCR with PS-SCL, allowing the
retrieval of an infinite number of potential stimulatory sequences. Another advantage of
this strategy is that retrieved sequences can be ranked according to the obtained score,
which is of great practical value when analyzing a large number of sequences, and
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especially considering that a single TCR can potentially recognize as many as 105 to 106
different peptides [26].
Using the screening data generated with a 10-PS-SCL and a CD4+ T lymphocyte clone
isolated from cerebrospinal fluid of a patient with chronic Lyme disease in combination
with the PS-SCL-based biometric database analysis, Hemmer et al. [169] identified
several potential relevant epitopes derived from Borrelia burgdorfei (the agent causing
Lyme disease) and human proteins. In this regard, and further supporting the highly
predictive value of the PS-SCL-based biometric database analysis, the self-Ag Melan-A
scored 22nd and 4th when this analysis was performed with the matrices generated using
the results from the screening of 10-PS-SCL-NH2 with clones LAU 203/1.5 and LAU
203/17, respectively (Table I.2). As a next obvious step, we performed the same
analysis to the results obtained for the second TAA studied. The sequence originally
identified for tyrosinase and recognized by clone LAU 156/34 is a nonapeptide [85]. As
we have shown in Figure II.5, the decapeptide analogue to which an amino acid was
added at the C-terminus according to the tyrosinase coding sequence (YMNGTMSQVQ)
was recognized, although less efficiently than the nonapeptide Tyro369-377. Therefore, we
performed the PS-SCL-based biometric database analysis with the data obtained from
the screening of 9-PS-SCL-NH2. The application of this methodology allowed the
identification of the native ligand tyrosinase as the sequence with the highest score
among billions of self-derived nonapeptides within the GenPept database (Figure II.4C).
Based on these results, and taking into account that the majority of the peptides
optimally recognized by CTL are nine amino acids long, we decided to screen a 9-PS-
SCL with the clone of unknown specificity LAU 50/4D7. We obtained a very clear
screening pattern that, in combination with the PS-SCL-based biometric database
analysis, allowed the identification of SSX-241-49 as the native sequence and its ranking
as the 27th most active nonapeptide within the GenPept database. In addition, by
restricting the search to known tumor associated proteins, SSX-241-49 scored 2
nd of
400,271 nonapeptides (Figure III.5B). The application of these combined methodologies
has demonstrated that a large number of stimulatory peptides (with various stimulatory
scores) exist for each TCR. In contrast to the PS-SCL-based biometric database
Discussion Rubio-Godoy
111
analysis described here, all of the previously developed mathematical approaches
aimed at describing TCR/pMHC interactions failed to give a quantitative aspect. This
point seems extremely important especially in cases where several highly homologous
sequences are available. For instance, we demonstrated that the SSX-241-49
homologous sequences, although very similar in sequence, had in general low scores
and were not recognized in the functional CTL assay by the SSX-241-49-specific clone
LAU 50/4D7 (Figure III.5A). The lack of recognition of these sequences by this
particular CTL clone, however, does not necessarily speak against their potential as
TAA-bearing proteins, and this is especially interesting in the case of SSX-1, SSX-4 and
SSX-5, which, like SSX-2, are expressed in a variety of tumors.
The two strategies described previously for the analysis of the results obtained from the
screening of PS-SCL end up with the identification of stimulatory peptides, the main
difference being that the sequences obtained using the PS-SCL-based biometric
analysis are contained in proteins, and represent therefore potential natural epitopes.
Thus, we could propose to use the PS-SCL-based biometric analysis as a first step for
the identification of T lymphocyte ligands for clones of unknown specificity and the
deconvolution strategy for the optimization thereof. If the specificity of the T lymphocytes
used is known, the biometric analysis can be used to search for cross-reactive or mimic
sequences within several databases (i.e. containing human, viral, fungal or bacterial
proteins) and the deconvolution strategy again for the optimization of an already known
epitope. An important aspect should be though considered for the possible use of the
peptides identified either using the deconvolution strategy or the PS-SCL-based
biometric database analysis as vaccine components. Indeed, a phenomenon known as
“original antigenic sin”, originally described for antibody responses and where
stimulation with a new but serologically related influenza strain elicited a response
directed predominantly against the first strain encountered, was shown to be extended
to some CTL responses by Klenerman et al [197]. Using a murine LCMV model, they
showed that CTL from mice immunized with a wild type CTL epitope were able to
recognize a mutant peptide. Surprisingly, challenging the mice with the mutated peptide
also led to CTL being primarily specific for the priming epitope, rather than the
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challenging one. On the contrary, if mice were primed with the mutant peptide, CTL
were able to recognize both wild type and mutant epitopes after challenging with either
peptide. They concluded that the CTL responses were determined by the original
peptide presented, and that cross-reactivity is asymmetrical and its outcome determined
by the order of epitopes. More recently, Anderson et al. [198] proposed that original
antigenic sin could be circumvented by immunizing with multiple peptide variants.
Therefore, active peptides identified by PS-SCL could be potentially used in order to
avoid immune escape of mutant proteins (i.e. in some cancer types) and viruses (i.e.
Human immunodeficiency virus (HIV), Hepatitis C virus (HCV), EBV), and/or
autoimmune diseases.
Degeneracy in antigen recognition by tumor-reactive CTL
As a first approach to study the degenerate recognition of T lymphocytes with PS-SCL,
Hemmer et al. [160] performed a study to determine the number of modifications within
antigenic peptides that could be tolerated by a TCR. They tested the recognition of
single and multisubstituted peptides by three CD4+ T cell clones and identified several
analogs with no sequence homology. To explain the promiscuous recognition of
unrelated peptides observed in this and other studies [159], they proposed a
degeneracy of CD4+ T lymphocytes that is several orders of magnitude higher than for
CD8+ T lymphocytes because of the restricted expression of MHC class II molecules. In
our study, we identified several CD8+ T lymphocyte stimulating peptides, which were
designed by combining the building blocks of the most active mixtures in all diversity
positions. Among the deduced peptides, enhanced analogs as well as agonists sharing
very little sequence homology were found. Whether the degeneracy for CD4+  T
lymphocytes is indeed higher than for CD8+ T lymphocytes still remains to be
determined.
A high degree of degeneracy has already been described for Melan-A-specific
lymphocytes by Loftus et al. [196]. They proposed a mechanism for the induction of
autoreactive Melan-A-specific T lymphocytes due to epitope mimicry, where the CTL
would encounter mimic peptides of the Melan-A epitope derived from non-tumor sources
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(i.e. other self-antigens or pathogen-derived antigens) resulting in an augmented
population of CTL potentially specific for Melan-A. In this way, and providing that there is
a certain degree of cross-reactivity between the two epitopes in question, CTL triggered
by a foreign antigen or by a high avidity self-antigen might in turn react with a previously
ignored self-antigen. In a second study, Loftus et al. [199] showed that peptides derived
from self-proteins had an antagonistic effect on Melan-A-specific cells in the periphery.
They proposed that these peptides, rather than pathogen-derived peptides as suggested
in the precedent work, would be responsible for the maintenance of the Melan-A-specific
cells in the periphery. In other words, with these two studies Loftus et al. demonstrated
that Melan-A-specific lymphocytes are able to recognize a high number of cross-reactive
peptides, but this has not been observed to occur in vivo. Thus, these peptides rather
than being implicated in the peripheral maintenance, as they propose, could be more
implicated in the thymic selection of such a large repertoire. Indeed, Zippelius et al.
[200] provided direct evidence that the predominant mechanism shaping the Melan-A-
specific T lymphocyte preimmune repertoire was a high frequency of thymic precursors
by determining the presence of TCR excision circles (TREC) and the telomere length in
Ag-specific CD8+ T lymphocytes ex vivo. This study also suggest that recognition of
Melan-A-cross-reactive ligands may play an important role in positive thymic selection
by generating a large naive T lymphocyte pool. Our results indicate that a large number
of cross-reactive peptides are to be found among both self- and pathogen proteins.
Indeed, 39% of the 72 MSI 44 peptides (Figure I.8) retrieved from human, viral and
bacterial protein databases having scores higher than the native Melan-A26-35 peptide
were significantly recognized by the clone that was used to screen the PS-SCL and
subsequently generate the scoring matrix (i.e. clone LAU 203/1.5). More importantly,
this cross-recognition was not exclusive of clone LAU 203/1.5 since a panel of Melan-A-
monospecific CTL lines and clones was also shown to cross-recognize, to different
extents, some of the MSI 44 peptides (Tables I.4, I.5 and I.6).
The use of PS-SCL may allow getting an insight into the interactions ruling T lymphocyte
activation. Indeed, based on crystal structures of TCR interacting with pMHC
complexes, it has been proposed that the interaction between MHC and TCR
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contributes greatly to the overall affinity of the trimolecular complex [7,43,51], and that
the antigenic peptides modulate only this pre-existing affinity. If the contribution of the
MHC is low, only a few peptides will be able to increase the overall affinity beyond the
threshold required for T lymphocyte activation, rendering recognition by the TCR rather
inflexible. If on the contrary, this pre-existing affinity is elevated, the threshold for T
lymphocyte activation would be easily achieved by a high number of peptides, resulting
in an extremely degenerate peptide recognition [25]. Therefore, the degree of
degeneracy of individual TCR would be the consequence of its affinity for the MHC
molecule. The peptides within the PS-SCL are present at a concentration that ranges
from10-15 to 10-16. Given the minimal concentration of the native epitopes studied
required to induce 50% maximal lysis (Melan-A26-35 EC50: 0.1 nM; Tyro371N EC50: 0.075
nM; SSX-241-49 EC50: 0.003 nM) obtained in titration experiments, it is likely that a high
number of different ligands are being recognized simultaneously and are stimulatory for
the CTL clones studied. These observations, added to the differential ability of the CTL
clones here studied to recognize complex peptide mixtures, provide an estimate of the
degree of degeneracy in peptide recognition by these TCR. In fact, and based on
positional analyses of various amino-acid substitutions at the residues of a peptide that
are accessible to TCR, it has been estimated that a given TCR is capable of recognizing
a million different peptide-MHC combinations [26]. Based on these observations, we
could hypothesize that for T lymphocyte activation, poorly degenerate TCR would
require large amounts of the same stimulatory peptide, whereas highly degenerate TCR
would require large amounts of different stimulatory peptides. In this context, the use of
PS-SCL should allow the identification and/or retrieval from databases of virtually all
peptides capable of increasing the TCR/MHC affinity above the particular threshold of
each TCR, providing in this way information about degeneracy of peptide recognition.
Another explanation for the high level of cross-reactivity observed for the Melan-A-
specific CTL monospecific lines and clones here studied comes from the work of Willcox
et al. [58] and Boniface et al. [57]. They performed kinetic and thermodynamic analyses
to study the changes induced on TCR and/or pMHC complexes after binding. Their
results suggest that TCR and/or pMHC have flexible binding surfaces that are stabilized
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upon binding by a large number of contacts, and that these conformational adjustments
at the binding interface contribute to the cross-reactivity characteristic of TCR/pMHC
interactions. In agreement with this, the crystal structures of unligated TCR, of their
cognate pMHC complex, and of the TCR/pMHC complexes [7,43] reveal poor surface
complementarity. Upon binding, important conformational changes were observed in
some of the Ag-binding hypervariable CDR loops. Interestingly, these changes have
been reported to be of a particular magnitude for the CDR3β loop [201]. This structural
plasticity or induced fit suggests that a single TCR may accommodate different pMHC.
In addition, the remarkable flexibility at the TCR binding site could also explain the
relatively low affinity (Kd 1-90 mM [202]) as well as the slow association and fast
dissociation kinetics of TCR/pMHC interactions. In the case of Melan-A-specific TCR,
the study of the changes induced on a given TCR (derived i.e. from clone LAU 203/1.5)
upon binding to an HLA-A*0201 molecule complexed to several of the peptides retrieved
from the PS-SCL-based biometric database analysis would give an insight into the
conformational flexibility of that particular TCR.
Mason raised the question whether cross-recognition of peptides by T lymphocytes is
focused or unfocused [26]. With this question, he intended to establish whether different
CTL clones that are specific for a particular epitope would recognize the same set of
cross-reactive peptides, or whether in contrast, they would each recognize different
peptides. The results that we obtained from the screening of self- and pathogen-derived
peptides cross-reactive with Melan-A would speak in favor of a, at least to some degree,
focused cross-recognition. In fact, although certain MSI 44 peptides tested were only
recognized by some CTL clones or lines, other peptides, like MSI 44-10 (PT178-187), MSI
44-25 (PV454-463) or MSI 44-56 (CT51-60), were recognized by most of the Melan-A-
monospecific populations used (Table I.6 and [175]).
Perspectives
To further analyze the degeneracy of antigen recognition by tumor-specific CTL, it would
be essential to perform PS-SCL-based biometric database analyses on databases
containing proteins from non-human origin with several matrices generated using the
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results of PS-SCL screenings with different tumor-reactive CTL clones. A particular
feature of the TAA Melan-A-specific repertoire, in contrast to tyrosinase- and SSX-2-
specific repertoires, is that it represents the only known naive repertoire present in high
frequencies in both melanoma patients and healthy individuals [200]. In this way, and in
order to measure the degeneracy of tyro- and SSX-2-specific CTL clones, an analysis
similar to the one performed for the Melan-A (i.e. searching databases containing viral
and/or bacterial proteins, [176]) could be performed with the other two TAA-specific
clones used in this study, namely the tyrosinase-specific clone LAU 156/34 and the
SSX-241-49-specific clone LAU 50/4D7. Such an analysis would allow to determine is the
presence of such an important repertoire is the consequence of a high degree of
degenerate recognition of the Melan-A epitope. The synthesis of the so retrieved
potentially cross-reactive sequences would allow to determine whether those clones are
capable of cross-recognizing as many peptides as the Melan-A-monospecific CTL lines
and clones tested, and to get a deeper understanding of the issue of focused versus
unfocused cross-recognition. Also in this context, peptide analogs were designed using
the deconvolution strategy described in chapter I, which consists in combining the
building blocks of the most active mixtures from the screenings of 9-PS-SCL-COOH with
clone LAU 50/4D7. Preliminary results indicate that a significant proportion of the 29
deduced SSX-2 analog peptides are efficiently cross-recognized, as assessed in a CTL
assay at a single peptide dose (1 µM, 15 peptides elicited ≥50% specific lysis, data not
shown).
In the present study we analyzed the degree of cross-recognition of an anti-self system,
in particular of the TAA Melan-A. One important question that remains to be answered is
whether such a high degree of cross-recognition would also be observed in a non anti-
self system. To address this, PS-SCL could be screened with a clone specific for a
pathogen-derived epitope (i.e. Influenza virus) and the subsequent PS-SCL-based
biometric database analysis would allow determining the number of potential stimulatory
peptides for that particular clone. The posterior synthesis of the best ranking sequences
retrieved could enable us to determine if CTL specific for foreign epitopes present in the
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individuals as a part of the CTL repertoire are as cross-reactive as the anti-self (Melan-
A) CTL.
High resolution crystal structures of two modified Melan-A peptides (ELAGIGILTV and
ALGIGILTV) complexed to HLA-A*0201 were recently resolved [203]. Complexes with
the native Melan-A nona- and decapeptides were not done because they were too
unstable to be purified and crystallized. This study provides one of the first insights into
the structural properties of TAA, revealing that, although all the atoms that both modified
peptides have in common are in the same position in both structures, the central region
is extremely different in the two complexes. They propose that the centrally located
difference observed could account for the differences in T lymphocyte recognition of
these peptides (the modified decapeptide showed an improved recognition as compared
to the native decapeptide, whereas the modified nonapeptide showed a strong reduction
in peptide recognition). The central region difference observed between the two modified
peptides is most probably the consequence of the A28L substitution in the nonapeptide
(e.g. the nonapeptide is “stretched” to accommodate the anchor residue L in the first
binding pocket of the MHC molecule). Based on this, they propose that both natural
nona- and decapeptides bind similarly to the MHC molecule in such a way that the P1
pocket would be filled with a peptide amino acid in the decamer complexes, but empty
or more likely water filled in the nonamer complex. This kind of studies could lead to the
development of more efficient modified peptides and eventually for their use as vaccines
for the treatment of cancer. Such an approach could also be envisaged to determine
how the MSI 44 Melan-A cross-reactive peptides that we identified are buried within the
MHC class I binding cleft, and which amino acid side chains are accessible to TCR. In
this way, we could try to explain the cross-recognition observed in this study from a
structural point of view.
Since some of the MSI 44 peptides were recognized more efficiently than the native
Melan-A epitope, they could be considered as potential candidates for the development
of novel therapies. Besides, our results suggest that the recognition of the cross-reactive
MSI 44 peptides is focused, which would allow to generalize the results obtained from a
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single clone to speculate that these peptides will be cross-recognized by Melan-A-
specific precursors when injected to melanoma patients. One important issue that
remains to be studied is the natural processing of the sequences identified in order to be
presented to CTL in association to MHC class I molecules. We used a proteasome
processing prediction programb to determine how many of the MSI 44 peptides would
virtually be properly generated and found that 33% of them had the correct cleavage site
at the C-terminus (not shown). In order to confirm these observations, plasmid
constructs could be designed to express fragments of the relevant proteins comprising
the sequences of interest. Proteasomal processing of the peptides could be assessed in
a cytokine production assay using cells previously transfected with the plasmids as
APC.
Among the peptides most frequently cross-recognized by Melan-A-monospecific CTL
analyzed in this study are peptides from viral (MSI 44-25; PV454-463) or bacterial (MSI 44-
56; CT51-60) origin. Another peptide from bacterial origin (Mycobacterium tuberculosis;
VVAGIGILAI; MT126-135) not included in the analysis was also recognized by most of the
Melan-A-monospecific CTL lines and clones tested (not shown). It would be of relevant
interest to determine if Chlamydia trichomatis- or Mycobacterium tuberculosis-specific
CTL derived from patients infected with those parasites, or with viruses encoding for
proteins containing Melan-A cross-reactive sequences, would in turn recognize the
native Melan-A epitopes.
                                                 
b Internet address: http://www.paproc.de/
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